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1.1 Epidemiology 
Each year, more than 3 million cancer cases are diagnosed in Europe, with over 1.5 
million patients dying from this disease. The major cause of cancer death is lung 
carcinoma, accounting for almost 20% of all deaths due to cancer in 2008 1. It is the 
third common malignancy in Europe, after colorectal and breast cancer, accounting 
for more than 12% of all new cancer cases. 
In the Netherlands, the age-standardised incidence of lung carcinoma is decreasing 
in men, but still increasing in women. These trends largely reflect the changes in the 
prevalence of smoking, which is the major cause of this disease 2. Since 2006, more 
than 10,000 patients a year are diagnosed with lung carcinoma. Given the ageing of 
the population, lung cancer will remain an important health problem. The prognosis 
of the disease is poor, with a 1 year overall survival of 40% and a 5 year overall sur-
vival of only 14% 3. 
 
Lung cancer is broadly divided in two main categories on basis of its histology: non-
small cell lung cancer (NSCLC), accounting for 80-85% of cases, and small cell lung 
cancer (SCLC), accounting for 15-20% of cases. Approximately 40% of NSCLC and 
more than 70% of SCLC patients have distant metastases at initial presentation 4. 
Most of these patients are treated with palliative systemic treatment, together with 
analgesics and palliative radiotherapy to relieve symptoms. The remaining patients 
present with disease confined to the thorax. Those patients are generally offered 
curative intent therapy.  
Non-small cell lung cancer (NSCLC) 
NSCLC is divided in four different stages on basis of the anatomical extent of dis-
ease, which is classified according to the TNM classification. The TNM classification 
is used to define the extent of disease with respect to the primary tumour (T), in-
volvement of regional lymph nodes (N) and the presence of distant metastases (M). 
Recently, the 7th edition of the TNM classification system has been introduced 5. 
With respect to NSCLC, this edition includes some changes in the T and M descrip-
tors, as well as in the assigned stages on basis of the TNM 6.  
 
The assigned stage is prognostic for survival, and it forms the basis for selection of 
the most appropriate treatment regimen (Figure 1.1). Of all patients with NSCLC, 
only 25% is diagnosed with stage I & II disease, which is considered as resectable. 
Early stage patients who are medically inoperable are commonly treated with radio-
therapy. In particular, stereotactic radiotherapy has become an attractive treatment 
modality for this patient category, with a 3 year local control rate of more than 90% 
and a 3 year overall survival of 60% 7. Thirty-five percent of patients have locally 
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advanced (stage III) disease, for whom surgery is mostly not an option 4. For these 
patients, the current standard treatment consists of radiotherapy in combination 
with chemotherapy. 
 
T N M Stage
1 0 0 IA
2a 0 0 IB
1 1 0 IIA
2a 1 0 IIA
2b 0 0 IIA
2b 1 0 IIB
3 0 0 IIB
1 2 0 IIIA
2 2 0 IIIA
3 1 or 2 0 IIIA
4 0 or 1 0 IIIA
any 3 0 IIIB
4 2 or 3 0 IIIB
any any 1 IV
First choice treatment*
Surgery
Surgery + 
chemotherapy
Concurrent 
chemoradiotherapy
Chemotherapy**  
Figure 1.1 TNM staging (7th edition) for NSCLC and treatment of choice per assigned stage 
* According to the American College of Chest Physicians (ACCP) guidelines 
** In selected patients with oligometastasis: chemotherapy, high dose radiotherapy, surgery 
Small cell lung cancer (SCLC) 
SCLC is characterized by a rapid growth rate and early dissemination to lymph nodes 
and distant organs. SCLC patients are classically divided into limited and extensive 
stage disease 8, 9. Recently, however, the use of the TNM staging system has been 
recommended for SCLC as well 10, 11. Approximately 25% of SCLC patients present 
with stage I-III disease 4. Even in this patient group without distant metastases, 
surgery is rarely an option because of the advanced stage of locoregional disease. 
Furthermore, its benefit in the rare stage I patient is controversial 12, 13. Therefore, 
combined chemo-radiotherapy is the first choice treatment for patients with stage I-
III SCLC.  
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1.2 Imaging modalities for patient selection and evaluation of 
treatment 
Traditionally, anatomical imaging modalities are applied for the diagnosis and stag-
ing, as well as in the follow-up of lung cancer patients. These modalities are based 
on contrast differences between normal and cancerous tissue. More recently, mo-
lecular imaging techniques have been developed, which allow the visualization of 
molecular processes inside tumour and normal tissues in a non-invasive manner. 
Anatomical imaging 
Chest X-ray and computed tomography (CT) are the most widely used anatomical 
imaging modalities in lung cancer. A chest X-ray is useful as a first-line tool to assess 
the indication for further imaging. The chest CT scan allows cross-sectional imaging 
of the body through rotational x-ray imaging. Modern CT scanners have a resolution 
down to less than 1 mm. For lung cancer, it is the imaging modality that provides 
best anatomic detail. It has a high sensitivity for the detection of the primary tu-
mour, enabling its exact localization. The contrast between adjacent tissues can be 
further improved by the administration of intravenous contrast agents. 
 
While CT is the most accurate imaging modality with respect to anatomical informa-
tion in lung cancer, its limited potential to distinguish between vital tumour and 
non-malignant tissue prevents the use in certain areas of the TNM classification. 
Anatomic imaging modalities are compromised in their ability to define the exact 
tumour border in certain circumstances, such as in patients with atelectasis or tu-
mours near the thoracic wall 14. Furthermore, the accuracy to differentiate between 
malignant and benign lymph nodes is lower, with a sensitivity and specificity of CT 
for identifying mediastinal lymph node involvement of 51% and 85%, respectively 15. 
Finally, the assessment of changes early during or after treatment with conventional 
chest X-ray and CT is limited by their poor discriminating capacity between residual 
tumour and treatment induced changes 16, 17. 
 
With respect to these issues, molecular imaging with positron emission tomography 
(PET), providing information on specific biochemical pathways, has additional value.  
Molecular imaging with positron emission tomography (PET) 
The principle of PET lies in the detection of positrons emitted by a radioactive 
tracer. In this way, three dimensional images can be obtained which show the dis-
tribution of the tracer throughout the body. Different radiopharmaceuticals have 
been evaluated for the imaging of malignant tumours, of which 18F-fluorode-
Chapter1
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oxyglucose (FDG) is by far most commonly used. Like glucose, FDG is transported 
into the cell and subsequently phosphorylated by hexokinase. The fluorine atom of 
FDG, however, prevents it further metabolization, and hereby, FDG is metabolically 
trapped inside the cell. FDG-PET scanning utilizes the difference in accumulation of 
FDG between normal and cancerous tissues, based on an enhanced glucose me-
tabolism in cancer cells owing to increased expression of the glucose transporter 
enzyme Glut-1. In this way, tumours can be imaged as focal accumulations of FDG. 
This makes FDG-PET scanning a sensitive method for the detection and visualization 
of tumour bearing areas, as well as for monitoring response to treatment.  
 
The added value of FDG-PET in the staging of locally advanced lung cancer is beyond 
doubt, as it results in stage migration for up to 30% of stage III NSCLC and 6-33% of 
limited disease (LD) SCLC patients, which are diagnosed with distant metastases 18-
30. This upstaging withholds toxic radical therapy in these patients who will not 
benefit from it. FDG-PET is more accurate than CT with respect to mediastinal lymph 
node staging as well, with a sensitivity and specificity of 74% and 85%, respectively 
15. At present, performing an FDG-PET scan is recommended as a routine clinical 
staging tool for assumed stage IB-IIIB NSCLC 15. 
 
There are certain limitations, however, to the use of FDG as a cancer imaging agent. 
One important limitation is the increased uptake in non-malignant areas with en-
hanced glucose metabolism, such as inflammatory regions 31. These limitations have 
driven the search for tracers other than FDG that specifically visualize certain mo-
lecular characteristics. These include proliferation markers, such as 11C-methionine, 
11C-choline and 18F-fluorothymidine and markers of hypoxia, of which 18F-FMISO is 
most commonly applied. Furthermore, tracers are being developed that visualize 
the expression of specific receptors at the surface of tumour cells. 
Thus, molecular imaging with PET shows many advantages over anatomical imaging 
alone in the combined modality treatment of lung cancer. Especially the use of inte-
grated PET-CT, combining anatomical information with functional information of the 
PET scan has great clinical potential.  
1.3 Combined modality treatment for inoperable lung cancer 
Radiotherapy (RT) in combination with chemotherapy is the treatment of choice for 
the approximately 35% of NSCLC patients presenting with locally advanced (stage 
III) disease, for whom surgery is mostly not an option 4. It is also the first choice 
treatment for the approximately 25% of SCLC patients presenting with stage I-III 
disease.  
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Chemotherapy can be given either before the start of RT (sequential chemo-
radiotherapy) or simultaneously with RT (concurrent chemo-radiotherapy). In 
NSCLC, concurrent treatment demonstrated superior outcome compared to se-
quential chemo-radiation with a 3 year survival of 24% with concurrent treatment, 
vs. approximately 18% with sequential therapy 32. The same holds true for SCLC, in 
which a clear benefit of concurrent over sequential chemo-radiotherapy has been 
demonstrated 33. 
1.4 Purpose and outline of the thesis 
Although the survival of locally advanced NSCLC and stage I-III SCLC has significantly 
improved with combined chemo-radiotherapy, the majority of patients still show 
disease progression shortly after the completion of treatment. About one third of 
patients experience local tumour progression as their first site of relapse 34-38. Fur-
thermore, these combined treatment strategies are associated with higher toxicity 
rates than treatment with RT alone. Theoretically, locoregional tumour control 
could be improved by increasing the radiotherapy dose or intensification of the 
chemotherapy regimen. Because dose limiting toxicity already occurs with the pres-
ently applied combined treatment schedules, this is not straightforward, as further 
intensifying therapy would result in unacceptable toxicity. 
 
Recently, more conformal radiotherapy techniques such as stereotactic body RT 
(SBRT), intensity modulated RT (IMRT) or proton therapy have been introduced, as 
well as targeted systemic agents, which increasingly allow for specific antitumour 
therapy. This provides opportunities to improve locoregional control without en-
hancing toxicity. The introduction of these techniques, however, emphasizes the 
need for imaging techniques enabling accurate definition of the presence and ex-
tent of tumour. 
Another approach to optimize the treatment benefit in each individual patient can 
be found in strategies directed at an early adaptation of therapy dependent on the 
treatment response. Finally, the outcome after completion of curative treatment 
could potentially be improved by an early detection of local progression, increasing 
the opportunity to be offered salvage therapy. In view of the limited ability of ana-
tomical imaging techniques to discriminate between active tumour and post-
treatment changes, molecular imaging could play an important role in this respect. 
 
The aim of this thesis is to assess the potential of molecular imaging with PET to 
optimize the combined modality treatment of lung cancer.  
Chapter1
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In regard to this aim the following aspects are addressed: 
 
• FDG-PET-CT based target volume definition to optimize radiotherapy for locally 
advanced lung cancer 
• The value of FDG-PET-CT in the follow-up of locally advanced NSCLC patients 
• Development of novel PET tracers for the non invasive imaging of specific tu-
mour characteristics 
Part I: FDG-PET-CT based target volume definition to optimize radiotherapy for 
locally advanced lung cancer 
No imaging technique allows a direct evaluation of the presence and extent of mi-
croscopic disease extension around the tumour visible on PET and CT. Therefore, in 
RT planning, a margin of tissue surrounding the macroscopic tumour (Gross tumour 
volume, GTV) is added in all patients to ensure that the area with potential micro-
scopic spread is covered by the radiation field 39. The resulting volume is defined as 
the clinical target volume (CTV).  
Microscopic disease spread, however, does not occur in all patients with NSCLC 40, 
41. Hence, the ability to predict the presence of microscopic spread on the basis of 
pre-treatment PET or CT imaging could lead to tumour tailored margins, resulting in 
an optimal sparing of normal tissue in individual patients. In chapter 2, risk factors 
for the presence of microscopic disease spread were identified on pre-treatment 
PET-CT.  
 
Traditionally, both in NSCLC and SCLC, prophylactic irradiation of clinically unin-
volved mediastinal lymph nodes was performed. This resulted in large treatment 
volumes. Routine elective nodal irradiation is no longer recommended in NSCLC 42, 
43, as both PET- and CT-based selective irradiation of involved lymph nodes have 
proven its safety 44-47. The safety of selective nodal irradiation (SNI) in NSCLC, how-
ever, cannot straightforwardly be extrapolated to SCLC. This is illustrated by a study 
showing an unacceptable amount of 11% of isolated nodal failures outside of the 
treatment volume in SCLC with CT-based SNI in SCLC 48. As FDG-PET scanning is 
more accurate than CT in the primary staging of SCLC 29, 49-51, we hypothesized that 
PET based SNI would improve the coverage of involved lymph nodes compared to 
CT-based SNI29, 49-51. Chapter 3 describes the results of a planning study in which the 
influence of selective irradiation of FDG-PET positive mediastinal nodes on radiation 
fields and normal tissue exposure in limited disease (LD) SCLC was investigated. A 
prospective study was subsequently performed to evaluate the safety of PET-based 
SNI in LD-SCLC, of which the results are reported in chapter 4. 
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Part II: The value of FDG-PET-CT in the follow-up of locally advanced NSCLC patients 
Theoretically, early detection of progressive disease after curative intent therapy, at 
a time that radical retreatment is still an option, could improve survival. In NSCLC 
however, there are at present no convincing data supporting that early detection of 
progression with chest X-ray or CT scan results in survival benefit 16, 52-54. A major 
restriction of both modalities is the poor discriminating capacity between residual 
or recurrent tumour and post-treatment changes 16, 17. As repeated imaging is often 
needed to confirm progression, this delay could lead to missing the chance for sal-
vage treatment. In this respect, FDG-PET scanning could have additional value, as 
PET is more accurate than CT in the distinction of tumour from post-radiotherapy 
effects 55-57, and is known to be prognostic for outcome 58-62. In chapter 5, we evalu-
ated whether a PET-CT 3 months after therapy can detect potentially curable pro-
gression in NSCLC patients treated with curative intent with (chemo-)radiation. 
Chapter 6 describes the results of an economic evaluation assessing the cost-
effectiveness of a PET-CT based follow-up strategy. 
Part III: Development of novel PET tracers for the non invasive imaging of specific 
tumour characteristics 
Recent advances in molecular biology have revealed a number of biological charac-
teristics of cancer cells that offer potential targets for imaging. Some of these char-
acteristics, such as hypoxia, cell density and proliferation, are associated with tu-
mour aggressiveness and response to anticancer treatment. These characteristics 
are known to be heterogeneous across the tumour 63-65. Non-invasive imaging of 
those characteristics could have great clinical importance, as it would allow patient 
selection for targeted antitumour therapy as well as the identification of relatively 
treatment resistant areas within the tumour.  
In part III of this thesis, two phase I trials are presented evaluating novel PET tracers. 
In chapter 7 the results of a phase I trial evaluating [18F]HX4, a novel marker of hy-
poxia, are reported. In chapter 8, the safety of Zirconium-89 (89Zr) labelled cetuxi-
mab was evaluated. Cetuximab is a monoclonal antibody against the epidermal 
growth factor receptor (EGFR), a receptor which expression has been correlated 
with tumour aggressiveness and treatment resistance 66. 
Part IV: Discussion 
In part IV, the role of PET in the combined modality therapy of lung cancer is dis-
cussed. A review of the available literature regarding this subject is provided in 
chapter 9. In chapter 10, the major results of this thesis are described in the context 
of the currently existing evidence, and perspectives for future research are high-
lighted.  
Chapter1
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Abstract 
Background and purpose 
One major uncertainty in radiotherapy planning of non-small cell lung cancer 
(NSCLC) concerns the definition of the clinical target volume (CTV), meant to cover 
potential microscopic disease extension (MDE) around the macroscopically visible 
tumour. The primary aim of this study was to establish pre-treatment risk factors for 
the presence of MDE. The secondary aim was to establish the impact of these fac-
tors on the accuracy of PET and CT to assess the total tumour-bearing region at 
pathology (CTVpath).  
Methods and materials 
34 NSCLC patients, who underwent CT and PET prior to lobectomy, were included. 
Specimens were examined microscopically for MDE. The gross tumour volume (GTV) 
on CT and PET was compared with the GTV and the CTV at pathology, taking tissue 
deformations into account. Using multivariate logistic regression, image based risk 
factors for the presence of MDE were identified and a prediction model was devel-
oped based on these factors. 
Results 
MDE was found in 17 of the 34 patients (50%). MDE did not exceed 26 mm in 90% 
of patients. In multivariate analysis, two parameters (mean CT tumour density and 
GTVCT) were significantly associated with MDE. The AUC of the 2 parameter predic-
tion model was 0.86. 13 tumours (38%, 95% CI: 24-55%) were identified as low risk 
for MDE, being potential candidates for reduced intensity therapy around the GTV. 
In the low risk group, the effective diameter of the GTVCT/PET accurately represented 
the CTVpath. In the high risk group, GTVCT/PET underestimated the CTVpath with on 
average 19.2 and 26.7 mm, respectively. 
Conclusions 
CT features have potential to predict the presence of MDE. Tumours identified as 
low risk of MDE show lower rates of disease around the GTV than high risk tumours. 
Both CT and PET accurately visualize the CTVpath in low risk tumours, but underesti-
mate it in high risk tumours. 
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2.1 Introduction 
Radiotherapy (RT) with or without chemotherapy is the current standard treatment 
in locally advanced (stage III) and inoperable stage I/II non-small cell lung cancer 
(NSCLC). Even with concurrent chemoradiotherapy, about one third of patients 
experience local failure as their first site of relapse 1-3. Improving locoregional tu-
mour control by increasing the radiation dose is not straightforward, because dose 
limiting toxicity occurs, such as lung damage and severe esophagitis 4, 5. Technical 
improvements in radiotherapy, like respiration-correlated (RC) imaging, stereotactic 
body RT (SBRT), intensity modulated RT (IMRT) and the use of 18Fluoro-Deoxy-
Glucose (FDG)-PET scans in RT planning have facilitated radiation dose escalation 
with acceptable side effects 6-9. These techniques allow a more precise targeting of 
RT. As a result, accurate target definition becomes increasingly important. PET and 
CT imaging allow definition of the location and extent of the macroscopic tumour 
with growing accuracy 10, 11. However, large inter- and intraobserver variation exists 
in the delineation of the Gross Tumour Volume (GTV) 12. Even more uncertainty 
exists in the definition of the clinical target volume (CTV), which should include the 
GTV with a margin of surrounding tissue covering potential microscopic spread 13. 
Current imaging techniques do not allow direct evaluation of the presence and 
extent of microscopic disease extension (MDE) around the tumour as seen on PET 
and CT. Hence, only population statistics on MDE are available, based on correlation 
of imaging with pathology. These studies report an average MDE from 1.5 mm to 8 
mm 14-17, with more extensive MDE in adenocarcinoma than in squamous cell carci-
noma 15. Considering tissue deformations between in-vivo imaging and ex-vivo pa-
thology, it is likely, however, that these ranges are underestimated. When tissue 
deformations are not taken into account, underestimation of the extent of MDE 
may occur up to a factor 2 18, 19. 
 
MDE, however, does not occur in all patients 15, 18. The ability to predict the pres-
ence of MDE on the basis of pre-treatment imaging could lead to tumour tailored 
CTV margins, resulting in an optimal sparing of normal tissue in individual patients. 
The aim of the current study was two-fold: first, to establish pre-treatment risk 
factors for the presence of MDE at pathology. Secondly, to establish the impact of 
these factors on the accuracy of PET and CT to assess the total tumour-bearing re-
gion at pathology (“CTVpath”) in three dimensions. 
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2.2 Methods and Materials 
Patients 
Patients were included in the following participating hospitals: the Netherlands 
Cancer Institute (Amsterdam, the Netherlands, central approval from the medical 
ethical board), the Onze Lieve Vrouwe Gasthuis (Amsterdam, the Netherlands) and 
the Maastricht University Medical Centre (Maastricht, the Netherlands). All patients 
gave written informed consent. 
Preoperative imaging and tumour delineation 
All patients underwent a chest CT and 18FDG-PET scan within 8 weeks prior to sur-
gery. The CT slice-thickness ranged from 1 to 5 mm, depending on whether the scan 
was made in the diagnostic process or for study purposes. The PET scan was per-
formed during free-breathing with a voxel size of 5 mm, using attenuation correc-
tion based on low dose CT. On the CT scans, the lung lobes and the gross tumour 
volume (GTV) were delineated using lung window level settings (W=1600, L=600) by 
an experienced RT technician (MR) in consensus with a dedicated lung radiation 
oncologist (JK/JB). On the PET scans, the GTV was delineated automatically using a 
42% threshold of the maximum standardized uptake value (SUVmax) as described 
elsewhere 20, 21. PET scanners were calibrated between participating institutes using 
a dedicated phantom 22, 23. 
Pathology processing 
A fixed protocol was used among participating centres to process the resected lung 
lobes 18. In short, the lobe was inflated with 10% formaldehyde injected through the 
bronchial opening. After a minimum of 24 hours the specimen was sectioned into 
0,5 cm slices in a region of 2 cm around the tumour, and of 1 cm thickness through-
out the rest of the lobe. Sectioning was performed perpendicular to the longest axis 
of the lobe, which, in approximation, was parallel to the cranio-caudal axis of the 
patient. Hence, the orientation of the specimen slices was as close as practically 
possible to the orientation of the CT slices. A digital photograph was taken of each 
separate slice. Subsequently, microscopic thin sections covering the tumour and a 2 
cm margin in three dimensions around the tumour were obtained.  
Assessment of GTV and microscopic disease extension at pathology 
All samples were microscopically analyzed by one observer (JvL) in consensus with 
an experienced lung pathologist (RvS). Both the gross tumour based on pathology 
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(GTVpath) and microscopic disease extension were delineated in each microscopic 
section. MDE was defined by the presence of microscopic tumour deposits beyond 
the GTVpath. Thus, the GTVpath did not include MDE.  
The microscopic samples were scanned and loaded into image processing software 
(GNU Image Manipulation Program (GIMP), version 2.0). The volume of the GTVpath 
was calculated by multiplying the area of the index tumour in each microscopic slide 
with the thickness of the corresponding slice. The effective tumour diameter of this 
volume was computed as follows: 
1/3
4π
3V2d ⎟⎠
⎞⎜⎝
⎛
= , where V denotes the GTVpath. 
In addition to the GTVpath, the presence of MDE was recorded for each patient. 
When MDE was found, its shortest distance to the GTVpath was measured in 3-D. 
These distances were corrected for residual deformations between the in-vivo scans 
and the ex-vivo specimen using a previously described method 19. Briefly, the de-
formations around the GTV at pathology are modelled by an ellipse, where the 
deformation factor varies between 0.7 and 3.1, depending on the angle relative to 
the direction of gravity during sectioning. All locations of MDE were corrected for 
deformation using the ellipse parameters for each separate lobe. Subsequently, a 
cumulative histogram of the maximum distances between MDE and the GTVpath 
(MDEmax) was obtained. 
Analysis of risk factors for microscopic disease extension and development of a 
prediction model 
Image, tumour and patient characteristics were evaluated for their potential asso-
ciation with the presence of MDE (Table 2.1).  
 
Table 2.1 Variables tested for their association with the presence of microscopic disease extension 
Variable Description 
GTVCT The gross tumour volume as delineated on the CT scan 
CTmean The mean signal (in water units) observed in the delineated GTV on the 
CT scan 
CT Circularity The circularity of the delineated GTVCT, defined as 
CT
CT
GTVofVolume
diametereffectiveofspherewithinGTVofVolume  
Here, the effective diameter is given by 3
4
3
2
π
CTGTV⋅
⋅  
SUVmax The maximum standardized uptake value as measured on the PET scan 
GTVPET The gross tumour volume on the PET scan (calculated using a 42 % 
threshold of the maximum SUV). 
Tumour type The histology of the tumour (adeno or non-adeno carcinoma) 
Age The age of the patient at surgery 
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The effective diameter of the GTV on CT and PET, the mean CT density of the GTVCT 
and the circularity of the GTVCT were automatically calculated using an adaptation of 
previously employed methods 24. 
All statistical analyses were performed using SPSS version 15.0. The variables were 
tested for their association with the presence of MDE using the independent sam-
ples T-test for scale variables and the Chi-square test for nominal variables. Multi-
variate binary logistic regression was subsequently applied in combination with 
backward feature selection (p-to-entry 0.05 and p-to-remove of 0.1). The perform-
ance of the resulting prediction model was quantified using receiver operating char-
acteristic (ROC) analysis. Based on the output of the model, the patients were cate-
gorized into a group at low risk of presence of MDE and a group at high risk.  
Comparison of the GTV at PET and CT with the GTV and CTV at pathology 
The effective diameter of the GTV at CT and PET was first compared to that of the 
GTVpath (i.e., not including MDE). Secondly, the effective diameters of the GTVCT and 
GTVPET were compared to that of the total tumour-bearing tissue at pathology 
(CTVpath). The latter was defined as the sum of the effective diameter of GTVpath and 
two times the maximum MDE (to convert radius to diameter). Thereafter, the accu-
racy of PET and CT to assess the CTVpath was established separately in the group of 
patients with MDE (MDE+) and without MDE (MDE-). The latter analysis was per-
formed twice; once based on the presence of MDE at pathology, and once based on 
its presence according to the prediction model.  
2.3 Results 
Patient and tumour characteristics 
From September 2006 to December 2008, 34 NSCLC patients (19 male and 15 fe-
male) scheduled for a lobectomy were included. The average age at surgery was 
60.6 years (range: 42-80 years). PET and CT imaging were performed at a median of 
19 days (range: 1-55 days) before surgery. The surgical specimen consisted of the 
left upper lobe (n=11), left lower lobe (n=5), right upper lobe (n=13), right middle 
lobe (n=2) and right lower lobe (n=3). Tumour histology was adenocarcinoma in 
53% (n=18), squamous cell in 18% (n=6), large cell in 12% (n=4), mixed 
adenosquamous in 9% (n=3), bronchioloalveolar in 3% (n=1) and NSCLC, not other-
wise specified in 6% (n=2). 
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Assessment of GTV and microscopic disease extension at pathology 
1311 microscopic sections (median: 38 per patient, range: 17-103) were analyzed. 
MDE outside of the GTVpath was found in 17 of the 34 (50%, 95% CI: 34-66%) pa-
tients. The cumulative distribution of MDEmax, both with and without deformation 
correction, is shown in Figure 2.1. Without deformation correction, a CTV margin of 
14 mm would be needed to cover MDE in 90% of the patients. With deformation 
correction the margin to cover MDE in 90% of the patients increased to 26 mm. The 
distribution of microscopic tumour deposits was found to be isotropic in the trans-
verse plane: MDE medial of the GTVpath was seen in 26%, lateral in 29%, dorsal in 
23% and ventral in 22%. With the current sampling method, no MDE was found in 
the cranial and caudal direction. No association was found between the location of 
the tumour in the lobe and the presence of microscopic tumour deposits. Further-
more, there was no correlation between the time interval between imaging and 
surgery and the extent of overestimation/underestimation with CT and PET. 
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Figure 2.1 Cumulative distribution of the distance of maximum microscopic disease extension (MDEmax) 
to the border of the GTVpath  
Prediction of microscopic disease extension 
The distribution of the potential predictive variables in the subgroups with and 
without MDE is shown in Table 2.2. Two features (CT mean and GTVPET) showed sig-
nificant differences. Multivariate analysis yielded CTmean and GTVCT as significant 
factors in the logistic regression model (Table 2.2). The area under the ROC curve of 
this two-parameter prediction model was 0.86 (95%CI: 0.73-0.98, p=0.001) (Figure 
2.2).  
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Table 2.2 Comparison of variables between the subgroups with and without microscopic disease 
extension (MDE)  
 MDE absent MDE present UVA MVA 
 Mean ± SD Mean ± SD p-value p-value 
GTVCT (cm3) 22.9 ± 11.4 61 ± 21.1 0.14 0.03 
CTmean* 787 ± 22.8 860 ± 24.1 0.04 0.03 
CT Circularity 0.78 ± 0.02 0.71 ± 0.03 0.10 ns 
SUVmax 9.7 ± 4.9 11.7 ± 1.4 0.28 ns 
GTVPET (cm3) 9.8 ± 3.1 24.6 ± 5.7 0.04 ns 
Tumour type** 58 % 35 % 0.18 ns 
Age (years) 58.4 ± 11.4 62.6 ± 11.4 0.29 ns 
SD: standard deviation; UVA: Univariate analysis; MVA: Multivariate logistic regression analysis; Ns: not 
significant 
UVA: p-values ≤ 0,05 indicate a statistically significant difference of the predictor variables between the 
subgroups 
MVA: p-values ≤ 0,05 indicate statistically significant factors resulting from backward logistic regression 
*in water units  
**percentage with adenocarcinoma 
 
 
Figure 2.2 Receiver operating characteristic (ROC) curve of the two parameter prediction model 
Multivariate regression analysis results in CT mean and GTVCT as significant parameters in the prediction 
model. Area under the curve: 0.86  
 
A cut-off value in the model was chosen corresponding to a sensitivity of 90% and a 
specificity of 64%. This operating point corresponds to a probability threshold for 
MDE of 30%. At this operating point, 13/34 patients (38%, 95% CI: 24-55%) were 
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assigned to the low-risk group for MDE. The cumulative distribution of the maxi-
mum distances to the GTV border for these two groups is shown in Figure 2.3.  
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Figure 2.3 Cumulative distribution of the maximum distance of microscopic disease extension  
(MDEmax) to the border of the GTVpath according to the risk of MDE 
MDEmax per patient in the group at low risk of MDE (N=13) and the group at high risk of MDE (N=21), as
predicted by the linear regression model 
 
 
Figure 2.4 Illustration of the difference in overall disease load around the GTV at imaging between
patients at low and at high risk of microscopic disease extension (MDE) 
The difference in overall disease load between high and low risk patients is shown for the GTVCT only to 
provide anatomical information. Colour represents the fraction of patients in whom disease extension
was found at various distances from the GTVCT. Only regions inside the lung are relevant 
A. Illustration in CT scan of a patient at low risk of MDE  
B. Illustration in CT scan of a patient at high risk of MDE 
 
Chapter2
C H A P T E R  2  
 32 
Of the 17 patients with actual presence of MDE, two were at low risk for MDE, ac-
cording to the model, corresponding to a sensitivity of 88%. Of the 17 patients 
without actual MDE, 6 were at high risk of MDE, corresponding to a specificity of 
65%.  
The overall disease load, reflected in the total tumour bearing tissue at pathology, 
around the GTVCT and GTVPET was larger in the subgroup of patients at high risk for 
MDE compared to the subgroup at low risk. This difference in overall disease load 
between patients at low and high risk of MDE is graphically illustrated in Figure 2.4. 
Especially differences in prevalence of microscopic tumour deposits close to the 
GTV at imaging were evident. 
Comparison of the GTV at PET and CT with the GTV and CTV at pathology 
The mean GTVpath was 17.5 cm
3 (range: 0.5 cm3 – 81.9 cm3). Overall, the effective 
diameter of the GTVCT overestimated that of the GTVpath by 6.6 mm (p<0.001). The 
effective diameter of the GTVPET was 0.4 mm larger than that of the GTVpath, which 
was not statistically significant (p=0.63) (Figure 2.5). Conversely, the effective di-
ameter of the CTVpath (deformations included) was underestimated by CT with 13.4 
mm on average, while the PET showed an even larger underestimation of 20.1 mm. 
Both underestimations were significant (p=0.008 and p=0.0003, respectively) (Fig-
ure 2.6). 
Stratified according to MDE at pathology, the CTVpath was underestimated more on 
CT and on PET in the MDE+ subgroup than in the MDE- group (Table 2.3A). The 
underestimation on CT and PET was significant in the MDE+ group (p<0.001), but 
not in the MDE- group. Stratification according to the risk of MDE according to the 
logistic model, demonstrated comparable results (Table 2.3B); both CT and PET 
underestimated the CTVpath in the subgroup at high risk for MDE (p=0.009 and 
p=0.001 for CT and PET, respectively), but the underestimations were not significant 
in the subgroup at low risk. 
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Figure 2.5 Comparison of the effective diameter of the GTVCT and the GTVPET with that of the GTVpath 
Correlation coefficients: GTVCT - GTVpath: 0.95; GTVPET - GTVpath: 0.91 
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Figure 2.6 Comparison of the effective diameter of the GTVCT and the GTVPET with that of the CTVpath  
Correlation coefficients: GTVCT - GTVpath: 0.55; GTVPET - GTVpath: 0.55 
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Table 2.3 Comparison of the effective diameter of the GTV at imaging and the effective diameter of 
the CTV at pathology (CTVpath) 
A) Comparison according to the presence of MDE found at pathology 
CT* Mean ± SD 
(mm) 
p-value PET** Mean ± SD 
(mm) 
p-value 
Overall -13.4 ± 27.9 0.008 Overall -20.1 ± 29.0 0.0003 
MDE+ -30.6 ± 28.8 0.0005 MDE+ -39.9 ± 27.5 0.00002 
MDE- 3.7 ± 39.5 0.229 MDE- -0.3 ± 11.7 0.92 
B) Comparison according to the risk of MDE according to the prediction model 
CT* Mean ± SD 
(mm) 
p-value PET** Mean ± SD 
(mm) 
p-value 
MDE+ -19.2 ± 30.6 0.009 MDE+ -26.7 ± 31.1 0.001 
MDE- -4.1 ± 20.6 0.482 MDE- -9.4 ± 22.3 0.154 
Stratified to patients with and without MDE at pathology (A) and according to the prediction model (B), 
respectively. 
SD = standard deviation 
*Effective diameter of GTVCT minus that of CTVpath 
**Effective diameter of GTVPET minus that of CTVpath 
2.4 Discussion 
To ensure that all tumour bearing tissue is covered by the radiotherapy fields, an 
accurate knowledge of both the gross tumour volume (GTV) and the microscopic 
extension of tumour beyond the visible border on imaging (the margin to be in-
cluded in the clinical target volume (CTV)) is essential. Accurate distinction between 
the location of macroscopic tumour and microscopic disease is of value as tumour 
control probability calculations suggest that the dose required to eradicate micro-
scopic disease (thus, the dose in the CTV margin) is lower than the dose for macro-
scopic tumour 25, 26.  
In the current study, MDE was found in 50% (95% CI: 34-66%) of patients. Mean 
tumour density on CT (CTmean) and tumour volume on CT (GTVCT) were found to be 
significant factors at multivariate analysis associated with the presence of MDE. The 
prediction model on basis of those two parameters had an area under the curve of 
0.86. This model may be used to identify patients with higher overall incidence of 
disease at all distances around the GTV visible on imaging. These findings are en-
couraging as they could ultimately allow to adapt dose painting across the CTV mar-
gin according to subgroups of patients 27, thus optimizing local control while limiting 
toxicity in patients who are at low risk of microscopic disease extension. Therefore, 
validation of the prediction model in a larger patient population is strongly encour-
aged. 
MDE showed an isotropic distribution around the GTVpath. This finding suggests that 
uniform CTV margins may be appropriate. It also supports the use of our CTVpath 
definition, being the GTV with a circumferential margin equal to the maximum ob-
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served MDE. In this study, no MDE was found in cranial and caudal directions. This 
finding is most probably due to the incomplete histological sampling in these direc-
tions compared to the other directions. All pulmonary tissue ventrodorsal and me-
diolateral of the tumour was available for microscopic examination. In the cranio-
caudal directions, histological information was only available from slices taken at 5 
mm distance from each other. In this way, microscopic tumour deposits present in 
between two slices will have been missed.  
Literature comparison  
The current study shows that the GTV delineated on the PET scan using a fixed 
threshold (42% of SUVmax 
20, 21) is better correlated with the GTVpath than the manu-
ally delineated GTVCT. The latter overestimated the diameter of the GTVpath with 6.6 
mm on average. Few reports of other groups are available comparing both PET and 
CT with pathology: With respect to CT, Grills et al. found an overestimation of the 
GTVpath by CT of 5.8 mm 
16, which is comparable to our study. Others, however, 
found a close approximation 15, 17, 29. Yu et al. reported a benefit of PET based de-
lineation over CT mainly in patients with atelectasis 28. As the resolution of both 
imaging techniques is not sufficient to visualize microscopic disease, it may not be 
surprising that both the PET- and CT-based GTV underestimated disease extension 
when MDE is taken into account. In this study, we show however, that the overes-
timation of the GTV at CT and PET does not make up for the lack of coverage of 
microscopic disease. In patients without MDE, all tumour bearing tissue was cov-
ered by the CT- and PET-based GTV. 
The margin of 26 mm found to cover MDE in 90% of patients is much larger than 
what is expected on basis of the literature. The extent of MDE found previously in 
studies correlating imaging with findings at pathology range from 0 to 12 mm 14-16, 
30. It would appear, however, that the microscopic examination of the pathology 
specimen in the present study was more extensive than the methods applied in 
previous investigations. Secondly, deformation of the lung tissue between in-vivo 
and ex-vivo was not taken into account in these studies. Grills et al. concluded that a 
9 mm CTV margin added to the CT-based GTV should cover MDE in 90% of cases. 
Taking into account that CT tends to overestimate the GTVpath by 7 mm on average, 
our results suggest that a CTV margin of 16 mm may still be required to cover 90% 
of MDE. 
Nonetheless, the application of large CTV margins would inevitably lead to a consid-
erable increase in normal tissue exposure. Tumour control probability models, how-
ever, indicate that only 70-80% of the prescription dose to control the macroscopic 
tumour may be needed to eradicate microscopic disease 25, 26. This suggests that 
MDE outside the macroscopic tumour would be largely covered by the beam pe-
numbra of conventional RT fields. New RT technologies, however, are associated 
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with altered penumbra characteristics. Grills et al. investigated to what extent MDE 
would be covered with the use of SBRT 16. Depending on the technique used, ≤ 6-8.5 
mm of MDE would be automatically covered by the 80% isodose line (dose consid-
ered by the authors to be adequate to control microscopic disease). This confirms 
that with the use of more conformal techniques, inadequate CTV margins increase 
the risk of underdosage to tumour-bearing tissue. Our results suggest that this risk 
is higher in patients stratified to the MDE-positive group by the prediction model 
than in patients stratified to the MDE-negative group. 
Prediction model 
Although the prediction model has a relatively high sensitivity, the specificity is 
lower (67%), indicating that only 2 out of 3 patients without MDE are correctly iden-
tified as low risk patients. Nonetheless, the model shows distinct differences in 
disease load around the GTVPET and GTVCT between the two groups, indicating that 
pre-treatment imaging features have the potential to discriminate between the 
presence and absence of microscopic extension. Validation of the prediction model 
in an independent patient cohort is required in order to become a valuable tool in 
clinical practice.  
An explanation as to why higher CT density in the tumour is associated with a larger 
risk for microscopic disease extension is still pending. Theoretically, higher CT den-
sity could be caused by a higher tumour cell density, a higher fraction of necrosis 
and/or a lower fraction of stroma, but these hypotheses are currently unproven and 
subject of further research. Although MDE was present more frequently in 
squamous cell carcinoma than in adenocarcinoma (p=0.18), the histological subtype 
was not significantly associated with MDE in univariate and multivariate analysis. 
GTVPET did not retain significance in multivariate analysis, likely due to its correlation 
with GTVCT.  
Study limitations 
The methods used in the current study for the correlation of imaging with pathology 
have some limitations. Firstly, during PET scanning, no system was used to account 
for respiratory movements of the tumour. Therefore, the exact anatomical localiza-
tion of the tumour is subject to some uncertainty. The role of PET as a predictor for 
the presence of MDE may have been underestimated for this reason. New technol-
ogy, such as 4D-PET-CT scanners may further increase the accuracy of the correla-
tion of the imaging characteristics with pathology. A second limitation is that poten-
tial differences in shape of the GTV at imaging and at pathology have not been 
taken into account. A third limitation originates from the inaccuracy at pathology to 
accurately achieve uniform slice thickness of 5 mm. It is theoretically possible that 
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thinner slicing at pathology would result in a higher detection rate of microscopic 
tumour deposits, but this was technically not feasible. 
2.5 Conclusion 
Multivariate analysis of tumour, patient and PET and CT characteristics shows that 
CT characteristics of NSCLC have the potential to predict the presence of micro-
scopic disease extension (MDE) around the GTV at pathology. Patients at low risk of 
MDE show smaller rates of disease at all distances around the GTV than patients at 
high risk. Both CT and PET accurately visualize the CTVpath in patients at low risk of 
MDE, but significantly underestimate the CTVpath in high risk patients. 
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Abstract 
Background and purpose 
To investigate the influence of selective irradiation of 18FDG-PET positive mediasti-
nal nodes on radiation fields and normal tissue exposure in limited disease small cell 
lung cancer (LD-SCLC). 
Methods and materials 
Twenty-one patients with LD-SCLC, of whom both CT and PET images were avail-
able, were studied. For each patient, two three-dimensional conformal treatment 
plans were made with selective irradiation of involved lymph nodes, based on CT 
and on PET, respectively. Changes in treatment plans as well as dosimetric factors 
associated with lung and esophageal toxicity were analyzed and compared. 
Results 
FDG-PET information changed the treatment field in 5 patients (24%). In 3 patients 
this was due to a decrease and in 2 patients to an increase in the number of in-
volved nodal areas. However, there were no significant differences in gross tumour 
volume (GTV), lung, and esophageal parameters between CT- and PET-based plans. 
Conclusions 
Incorporating FDG-PET information in radiotherapy planning for patients with LD-
SCLC changed the treatment plan in 24% of patients compared to CT. Both increases 
and decreases of the GTV were observed, theoretically leading to the avoidance of 
geographical miss or a decrease of radiation exposure of normal tissues, respec-
tively. Based on these findings, a phase II trial, evaluating PET-scan based selective 
nodal irradiation, is ongoing in our department. 
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3.1 Introduction 
Small cell lung cancer (SCLC) is a tumour with a poor prognosis, with only one-third 
of patients presenting with limited-disease (LD-SCLC) 1, 2. In LD-SCLC, long-term 
survival has improved with chemo-radiation and this is, therefore, currently the first 
choice treatment. This is at the expense, however, of severe reversible esophagitis 
and lung damage 3-6. Moreover, over 30% of patients still fail locally with this treat-
ment 7. Therefore, in the subgroup of patients with limited disease, strategies to 
reduce toxicity and increase local tumour control would be of great clinical value. A 
straightforward strategy to reduce toxicity is to diminish the radiation fields, which 
could be done by omitting routine elective nodal irradiation. In case of non-small 
cell lung cancer (NSCLC) elective nodal irradiation is no longer recommended 8. In 
NSCLC, radiation fields could be safely reduced by selective nodal irradiation, based 
on CT, and even further based on FDG-PET (18F-fluorodeoxyglucose-Positron Emis-
sion Tomography) scans 9-12. Treating only FDG-positive mediastinal areas decreased 
radiation exposure of the lungs and the esophagus sufficiently as to allow for radia-
tion dose-escalation in NSCLC 13, 14. However, contrary to NSCLC, in a phase II study 
in LD-SCLC, we observed isolated nodal failures outside of the clinical target volume 
(CTV) in 11 % of cases with selective nodal irradiation, based on CT 15. This finding 
illustrates that the positive results obtained for selective mediastinal node irradia-
tion in NSCLC cannot straightforwardly imply the same results in SCLC patients. To 
our knowledge, no clinical data are available on PET-based selective mediastinal 
irradiation in SCLC.  
 
The available literature suggests that FDG-PET scan has diagnostic value in SCLC 16-22. 
SCLC shows high uptake of FDG, with a mean SUVmax (maximal Standardized Uptake 
Value) for primary and mediastinal nodal lesions similar to that seen in NSCLC 16. In 
the largest reported series of 120 patients with SCLC, FDG-PET resulted in a stage 
migration for 14 patients, upstaging 10 patients to extensive disease and down-
staging 3 patients 20. In a retrospective analysis of 46 patients with SCLC, Pandit et 
al. described a 100% sensitivity of PET for detection of disease, based on pathologic 
correlation 21. It has been suggested that an FDG-PET scan can identify metastases 
to regional lymph nodes in 15-25% of patients whose mediastinal CT scan was nega-
tive 16, 22. It is therefore likely that, as in NSCLC, the use of FDG-PET scans will im-
prove the coverage of the mediastinal lymph node areas in LD-SCLC, hence resulting 
in less geographical miss and improved local tumour control. 
 
As FDG-PET scans may thus be more accurate than CT to stage the mediastinum, we 
investigated the possible role of FDG-PET scanning in the radiotherapy planning of 
patients with LD-SCLC. We hypothesized that (1) there would be changes in the 
radiotherapy fields using FDG-PET scanning compared to CT, theoretically resulting 
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in less geographical miss and (2) there would be differences in the radiation expo-
sure of dose limiting normal tissues such as lungs, esophagus and spinal cord, when 
radiation treatment planning is performed based on FDG-PET compared to CT. We 
compared the radiation treatment planning of involved mediastinal lymph node 
areas based on FDG-PET and on CT for 21 consecutive patients with LD-SCLC. Radio-
therapy was planned to the standard total radiation dose of 45 Gy delivered in 30 
fractions in 3 weeks (1.5 Gy BID) either based on FDG-PET or on CT scan. DVH (dose 
volume histogram) parameters of the lung, the esophagus, the heart and the spinal 
cord were compared. 
3.2 Methods and Materials 
Patients 
Patients diagnosed with LD-SCLC and referred for radical radiotherapy to MAASTRO 
clinic between January 1, 2004 and October 1, 2006 were reviewed retrospectively. 
Twenty-one patients, of whom either both a pre-treatment FDG-PET and a contrast-
enhanced CT scan, or a combined FDG-PET-CT scan (with contrast-enhancement) 
was available, were eligible for this planning study.  
Staging 
All patients underwent bronchoscopy with biopsy, standard haematological and 
biochemical workup, CT of the thorax and upper abdomen, including liver and adre-
nal glands, and a whole body FDG-PET scan. CT or MRI of the brain was performed 
as part of the routine workup for all patients.  
Imaging with CT and PET 
For CT-based planning, a contrast-enhanced CT scan of the thorax performed for 
radiotherapy planning was used. For PET-based planning, a combined PET-CT scan 
was performed either in the diagnostic process alone or both in the diagnostic proc-
ess and for radiotherapy simulation. In both cases, the PET-CT scan was made in 
radiotherapy position. Patients had to be fasting for at least 6 hours before the 
examination. The injected total activity of FDG was calculated based on the weight 
of the patient: (weight* 4 + 20) MBq. After a rest period of 60 minutes (time needed 
for uptake of FDG) PET and CT images were acquired. A CT-scan of the whole thorax 
was performed with intravenous contrast.  
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The CT-findings were interpreted by an experienced chest radiologist. Lymph nodes 
were considered to be pathological on CT when their axial diameter exceeded 1 cm. 
FDG-PET scans were visually interpreted by an experienced PET scan specialist.  
The involved lymph node stations were recorded according to the Mountain and 
Dresler classification scheme 23, both on the basis of the CT and FDG-PET scan, by 
the diagnostic radiologist and the nuclear medicine specialist, respectively.  
Radiation treatment planning and dosimetry 
Radiotherapy planning was performed with a XiO (Computerized Medical Systems 
(CMS) Inc.) treatment planning system, using inhomogeneity corrections based on a 
convolution algorithm. For all patients, a Gross Tumour Volume (GTV) and a Plan-
ning Target Volume (PTV) were defined based on CT data and PET data, respec-
tively, for the CT- and PET-CT based plans. This was carried out in two separate 
sessions by the same person (JvL), in order to avoid intra-observer variability. For 
the primary tumour, the GTV was delineated based on CT only using the lung win-
dow settings (W = 1700, L = -300). We deliberately avoided contouring on the basis 
of ill-defined areas on PET scan. Instead, the sharp boundaries of the CT scan images 
were used. These procedures aimed at minimizing the problems of tumour size 
determination on PET scans in general and of a moving part of the body in particu-
lar, as no respiratory gating was used. For delineation of the lymph nodes on CT, 
mediastinal window setting (W = 600, L = 40) was used. The involved anatomical 
region as described by the radiologist or nuclear medicine specialist in the original 
diagnostic report (i.e. before the start of chemotherapy) was delineated 24. With 
respect to the pathological lymph nodes on PET, the involved zones were delineated 
based on the anatomical information of the CT scan. In this way, the whole patho-
logical anatomical region of the mediastinum (e.g. area 7) was taken as GTV for that 
lymph node station. No SUV-threshold was used, as a visual scale has been shown 
to be at least as accurate as the use of a SUV-threshold to distinguish benign from 
malignant nodes 25, 26. CT and PET images were automatically registered based on 
Mutual Information and were subsequently fused using Focal (CMS Inc.). If the PET 
scan was negative in the mediastinum and the CT scan positive, the mediastinum 
was considered not to harbour cancer cells, and was hence not included in the PET-
CT based GTV. The margin from the GTV to the CTV (Clinical Target Volume) was 5 
mm, and from the CTV to the PTV also 5 mm, both for CT- and for PET- based treat-
ment planning. No assessments of tumour movement, for example by slow CT 
scans, were performed. No elective nodal irradiation was planned. 
Contouring of the lung was done automatically by the treatment planning system. 
For the calculation of the Vlung20 (Percentage of lung receiving more than 20 Gy), we 
followed the published guidelines namely: the volume of both lungs reduced by the 
PTV was used, whereas for the mean lung dose (MLD), the volume of both lungs 
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minus the GTV was considered 8. The esophagus was delineated from just below the 
larynx to the gastro-esophageal junction. Neither the GTV nor the PTV was sub-
tracted from this volume 8. The spinal cord was drawn throughout the whole CT 
scan and was considered to be at the inner margin of the bony spinal canal.  
The heart was contoured from its caudal part at the apex until its cranial level at the 
beginning of the large vessels. The latter were not included in the contour of the 
heart. The pericardium was a part of the contour of the heart.  
A 3-dimensional conformal treatment plan was calculated on the CT-based PTV and 
the PET-CT-based PTV for all patients, with a prescribed dose of 45 Gy in 30 frac-
tions delivered in 3 weeks (1.5 Gy BID) to the PTV, according to ICRU 50 guidelines 
27. Dosimetric values were calculated on the basis of DVH’s and dose distributions 
on each axial CT plane both for CT and PET-CT based planning.  
For the tumour and pathological lymph nodes, factors analyzed were GTV and PTV 
volume. Because no consistent DVH parameters are known to predict early and late 
esophageal toxicity, the Veso30 , the Veso35 , the Veso40, the Veso45 , the Veso50 , the maxi-
mal esophageal dose (Dmax) and the mean esophageal dose (MED) were analyzed 
8, 
28, 29. For the lung, the Vlung 20 and the MLD were analyzed as predictors for radiation 
pneumonitis 8. The maximal dose to the spinal cord was recorded, although it was 
not expected that in either the CT-based or in the PET-CT based plan the tolerance 
of the spinal cord (50 Gy) would be exceeded. The mean dose to the heart (Dheart-
mean), as well as the maximal dose (Dheartmax), the Vheart 30, the Vheart 35, the Vheart 40, the 
Vheart 45, and the Vheart 50 was recorded. 
Ethics  
As this was a retrospective planning/modelling study, patients were diagnosed and 
treated previously according to standard guidelines in our institute. No approval of 
the Ethical Committee was required. 
Statistics  
On the basis of literature at the start of the project, we hypothesized that introduc-
ing PET in radiotherapy planning would change the treatment fields in 25% of the 
patients 16. In order to detect this change with a 95% confidence interval of 5-45%, 
at least 19 patients should be included in this study 30.  
Results are either expressed as mean ± standard deviation (SD) or as a proportion 
with 95 % confidence intervals (95% CI). Statistical differences between paired pa-
rameters from CT versus PET-CT based plans were evaluated with the Wilcoxon 
signed rank test. Differences were considered to be significant when the two-tailed 
p-value was less than 0.05.  
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3.3 Results 
Patient characteristics and FDG-PET and CT correlations 
All 21 patients had LD-SCLC, as defined by PET-CT for the detection of distant metas-
tasis. Two patients had stage N0, while 14 patients had the same nodal areas in-
volved on both PET and CT. Five patients had mediastinal nodal involvement on 
both PET and CT, but in different nodal areas (Table 3.1).  
 
Table 3.1 Patient characteristics 
Pt. No. No. of involved 
lymph node 
stations:  
PET vs. CT 
Primary tumour Involved lymph node station 
   PET-scan CT-scan 
 PET<CT    
2  Right upper lobe  2L,3L,4L, 2R, 3R, 4R 2L,3L,4L, 2R, 3R, 4R, 
10R, 5, 7 
12  Left hilus 4L, 10L, 5, 7 4L,10L, 4R, 5, 7 
17  Left hilus 10L, 7 4L,10L, 7 
 PET>CT    
6  Right upper lobe 2R, 4R, 10R, 5, 7 2R, 4R, 10R, 7 
7  Left upper lobe 2L, 4L, 10L, 5, 7 2L, 4L,10L, 5 
 PET=CT    
1  Right upper lobe  4L, 2R, 4R, 10R, 7 4L, 2R, 4R, 10R, 7 
3  Left lower lobe None None 
4  Left upper lobe 2L, 4L, 5, 6 2L, 4L, 5, 6 
5  Right upper lobe  4R, 10R, 7 4R, 10R, 7 
8  Right hilus 4R, 10R 4R, 10R 
9  Left upper lobe None None 
10  Unknown 4L, 1R, 2R, 4R, 3, 7 4L, 1R, 2R, 4R, 3, 7 
11  Right upper lobe 4L, 2R, 4R, 10R, 3, 7 4L, 2R, 4R, 10R, 3, 7 
13  Lingula 6 6 
14  Unknown 2R, 4R, 10R, 5, 7 2R, 4R, 10R, 5, 7 
15  Right upper lobe 4R, 10R, 7 4R, 10R, 7 
16  Right upper lobe  10R 10R 
18  Left hilus 4L, 10L, 5, 6, 7, 8 4L, 10L, 5, 6, 7, 8 
19  Right upper lobe 2L, 4L, 7 2L, 4L, 7 
20  Left lower lobe 10L, 10R, 5, 6, 7 10L, 10R, 5, 6, 7 
21  Left hilus 2L, 4L, 10L, 2R, 5, 6, 7 2L, 4L, 10L, 2R, 5, 6, 7 
Pt. No.: patient number. PET: positron emission tomography. CT: computed tomography 
 
In three patients (14 %), there were less nodal stations involved on PET compared to 
CT: in the first patient, PET showed no involvement of the CT-involved stations 5, 7 
and 10; in the second and third patient, there was no involvement of station 4R 
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(Figure 3.1) and 4L, respectively. In two patients (10%), PET identified nodal stations 
that were negative on CT: station 5 and 7, respectively.  
 
 
Figure 3.1 Image of a patient with different nodal involvement on CT and PET (patient 12) 
Station 4R is positive on CT and negative on PET 
Radiotherapy (RT) plans 
In 5 of 21 patients (24%, 95% CI: 5-40%), there was a change in RT plans with the 
incorporation of the PET-data. For two patients (10%), the radiation fields based on 
PET were larger than based on CT, while in 3/21 (14%) patients the CT-based radia-
tion fields were larger.  
Nodal GTV 
Taken all 21 patients together, the nodal GTV was 57.9 ± 67.0 cm3 on CT and 56.8 ± 
66.5 cm3 on PET (p = 0.92). For the three patients with a nodal GTV on PET that was 
smaller than on CT (Table 3.1), the nodal GTV was 81.0 ± 50.9 cm3 on CT and 61.5 ± 
29.0 cm3 on PET. Two patients had a nodal GTV on PET that was larger than on CT. 
Their nodal GTV was 72.5 ± 71.4 cm3 on CT and 81.0 ± 76.4 cm3 on PET.  
Normal tissue radiation exposure 
An overview of the radiation exposure of normal tissues comparing CT- and PET- 
based plans is shown in Table 3.2. Incorporating the PET information in the radiation 
planning did not lead to a statistically significant change in any of the dosimetric 
factors analyzed. 
For the three patients in whom the nodal GTV decreased with PET, the MED de-
creased from 25.0 ± 8.5 to 21.0 ± 5.7 Gy and Dmax from 46.2 ± 0.2 to 45.5 ± 0.7 Gy. 
The V20 decreased from 25.5 ± 4.9% to 22.0 ± 7.1%; the MLD decreased from 13.2 ± 
2.5 to 11.6 ± 3.3 Gy. For the two patients in whom the nodal GTV was larger on PET, 
the MED increased from 23.0 ± 5.7 to 24.5 ± 3.5 Gy; Dmax remained the same with a 
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dose of 46.5 ± 0.7 Gy. The V20 increased from 16.0 ± 2.8% to 20.0 ± 1.4%; the MLD 
increased from 9.9 ± 1.6 to 11.7 ± 1.3 Gy. 
 
Table 3.2 Normal tissue radiation exposure 
Normal tissue  CT-based plan  
(± SD) 
PET-based plan 
(± SD) 
p-value 
Esophagus MED (Gy) 
Dmax (Gy) 
24.4 (± 8.6) 
45.8 (± 2.9) 
24.1 (± 8.5) 
45.7 (± 2.9) 
0.50 
0.32 
Lung V20 (%) 
MLD (Gy) 
25.6 (± 12.4) 
13.7 (± 5.6) 
25.6 (± 12.3) 
13.7 (± 5.6) 
1.00 
0.89 
Heart  Dmean (Gy) 
V30 (%) 
12.2 (± 9.7) 
19.7 (± 19.1) 
12.2 (± 9.7) 
19.5 (± 19.2) 
0.79 
0.46 
Spinal cord Dmax (Gy) 41.0 (± 5.1) 40.9 (± 5.1) 0.27 
SD: standard deviation; PET: positron emission tomography; CT: computed tomography; MED: mean 
esophageal dose; Dmax: maximal (esophageal, respective heart) dose; MLD: mean lung dose.; Dmean: 
mean (heart) dose 
3.4 Discussion 
The treatment of choice for patients with LD-SCLC consists of concurrent chemo-
radiotherapy 31, which is at the expense of dose-limiting toxicity, primarily of the 
esophagus and lung 6, 7. Moreover, there is still a considerable amount of local tu-
mour failure 7. 
 
An obvious way of reducing radiation fields and hence toxicity is by omitting elective 
nodal irradiation of clinically uninvolved nodal stations. This selective nodal irradia-
tion has been shown to be effective in NSCLC based on CT, and even further, based 
on FDG-PET, with an acceptable amount of isolated nodal failures 9, 11. In LD-SCLC 
however, we observed 11% of isolated nodal failures when only irradiating medi-
astinal nodal stations that were positive on CT 15. Because literature suggests that 
like in NSCLC, FDG-PET has a greater accuracy than CT for staging mediastinal nodal 
areas in SCLC as well 16-20, we hypothesized that there would be less geographical 
misses by using PET for radiation treatment planning. Furthermore, the differences 
in the nodal PTV could also change the radiation exposure of normal tissues. There-
fore, we retrospectively planned the radiation treatment for 21 consecutive pa-
tients with LD-SCLC using CT with and without PET information.  
 
The incorporation of FDG-PET data into RT planning led to a change in the radiation 
fields in 24% of patients. This is in line with previous studies on FDG-PET in the stag-
ing of SCLC 16, 32, showing a difference in positive nodal areas between PET and CT in 
25% and 21% of patients, respectively. In the present study, both increases (2/21) 
and decreases (3/21) in radiation fields were observed. Assuming that like in NSCLC, 
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PET is more accurate than CT in identifying pathologic lymph nodes in SCLC 16-20, the 
increase in radiation fields on the basis of PET could theoretically lead to the avoid-
ance of geographical misses. In 10% of patients, PET-based radiotherapy planning 
increased the radiation fields. In those patients, irradiation based on CT could theo-
retically result in a geographic miss. This percentage is about the same as the 
amount of geographical misses we found with selective nodal irradiation based on 
CT only (11%) 15. Theoretically, the decrease of the GTV in some patients could lead 
to a decreased radiation exposure of lung and esophagus and hence less toxicity 28, 
33. However, taken all patients together, no significant changes in the GTV or in the 
radiation exposure of the normal organs (esophagus, lungs, heart and spinal cord) 
were observed. This is in contrast to the incorporation of FDG-PET in radiotherapy 
planning of NSCLC, where generally reductions of the radiation fields were observed 
11-14.  
 
The present study has some limitations. First, no pathologic verification of the 
lymph nodes was obtained. However, as FDG-PET scans are likely to be more accu-
rate than CT to detect mediastinal nodal involvement in SCLC 16, 20-22, we believe that 
our results support the need to investigate in clinical studies the role of FDG-PET 
scans in radiotherapy planning of LD-SCLC. Second, no system was used to take into 
account respiratory movements. We therefore cannot rule out the possibility that 
the exact anatomical localisation of the mediastinal lymph nodes may have been 
blurred. However, motion artefacts are less of a problem in the mediastinum com-
pared to the primary lung tumour 34. In any case, new technology, such as combined 
4D-PET-CT scanners may further increase the usefulness of integrating PET scan 
data into PET-CT simulation 35, 36. Third, the fact that different individuals were in-
volved in the identification of nodal stations could theoretically introduce interob-
server variability. Regarding PET however, it has been published that in NSCLC a 
good interobserver agreement was found with respect to staging mediastinal lymph 
node stations 37. For contrast-enhanced CT, a good intra- and interobserver agree-
ment to detect enlarged mediastinal lymph nodes in patients with lung cancer was 
described 38. Therefore, as only contrast-enhanced CT images were used, we believe 
to have minimized possible interobserver variability. 
The largest potential benefit of incorporating FDG-PET scans in radiotherapy plan-
ning of LD-SCLC may be the reduction of isolated nodal failures compared to CT-
based planning 15. Therefore, a phase II trial, evaluating PET-scan based selective 
nodal irradiation in LD-SCLC, in which a larger amount of patients will be included, is 
ongoing in our department. 
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Abstract 
Background and Purpose 
To evaluate the results of selective nodal irradiation (SNI) on basis of FDG-PET scans 
in patients with limited disease small cell lung cancer (LD-SCLC), on isolated nodal 
failures.  
Methods and Materials 
A prospective study was performed of 60 patients with LD-SCLC. Radiotherapy was 
given to a dose of 45 Gy in twice daily fractions of 1.5 Gy, concurrent with car-
boplatin and etoposide chemotherapy. Only the primary tumour and the mediasti-
nal lymph nodes involved on the pre-treatment PET scan were irradiated. A chest 
CT-scan was performed 3 months after completion of radiotherapy and every six 
months thereafter. 
Results 
A difference was seen in the involved nodal stations between the pre-treatment 
FDG-PET and CT scans in 30% (95% CI: 20-43%) of patients. Of the 60 patients, 39 
(65%, 95% CI: 52-76%) developed a recurrence. Two patients (3%, 95% CI: 1-11%) 
experienced an isolated regional failure. The median actuarial overall survival was 
19 months (95% CI: 17-21 months). The median actuarial progression free survival 
was 14 months (95% CI: 12-16 months). 12% (95% CI: 6-22%) of patients experi-
enced acute grade 3 (CTCAE v 3.0) esophagitis.  
Conclusions 
FDG-PET based selective nodal irradiation for LD-SCLC resulted in a low rate of iso-
lated nodal failures (3%), with a low percentage of acute esophagitis. These findings 
are in contrast to those from our prospective study of CT-based selective nodal 
irradiation, which resulted in an unexpectedly high percentage of isolated nodal 
failures (11%). Because of the low rate of isolated nodal failures and toxicity, we 
believe that our data support the use of PET-based SNI for LD-SCLC. 
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4.1 Introduction 
The prognosis of patients with limited disease small cell lung cancer (LD-SCLC) has 
improved significantly with the application of accelerated radiotherapy (RT) and 
concurrent chemotherapy 1, which have become the current standard treatment. 
Although long term survival rates of approximately 25% have been reached, more 
than 30% of patients will still develop local failure with this treatment 1. Improving 
locoregional tumour control by simply increasing the radiation dose is not straight-
forward, because dose limiting toxicity occurs, consisting of severe reversible 
esophagitis and lung damage 2-4. An attractive strategy to reduce the toxicity is to 
diminish the radiation fields by omitting routine elective nodal irradiation (ENI) of 
the mediastinum. This strategy has proved its efficacy in non-small cell lung cancer 
(NSCLC), in which radiation fields could be safely reduced by selective nodal irradia-
tion (SNI), using CT, and even further using 18F-fluorodeoxyglucose (FDG) positron 
emission tomography (PET) scans 5-8. Treating only FDG-positive mediastinal areas 
decreased the radiation exposure of the lungs and the esophagus sufficiently as to 
allow for radiation dose-escalation in NSCLC 9, 10. Although selective irradiation of 
clinically involved nodes is also regularly applied in clinical practice for SCLC, no 
published data are available supporting this practice. A recent report from the In-
ternational Atomic Energy Agency meeting emphasized the need for prospective 
clinical evidence regarding SNI for SCLC 11. 
 
To date, only a few prospective data concerning selective nodal irradiation (SNI) for 
SCLC are available. In a previous phase II trial from our group, isolated nodal failures 
were observed outside of the clinical target volume (CTV) in 11 % of patients under-
going SNI, using CT 12. These isolated nodal failures all occurred in the ipsilateral 
supraclavicular fossa. Baas et al. 10 and Belderbos et al. 13 reported an isolated nodal 
recurrence in the ipsilateral supraclavicular fossa in 1 of 36 patients treated with 
concurrent chemotherapy and CT-based involved field irradiation. Although no 
definitive conclusions could be drawn because of the small sample size, those find-
ings imply that the safety of SNI in NSCLC cannot be straightforwardly extrapolated 
to SCLC patients. The available data suggest that FDG-PET scans are more accurate 
than CT in the primary staging of SCLC 14-17. In a planning study on FDG-PET based 
selective mediastinal node irradiation in 21 LD-SCLC patients to investigate the po-
tential role of FDG-PET in RT planning 18, we found a change in the treatment plan 
compared with the CT based plan in 24% of patients. Because of these results, we 
decided to prospectively evaluate SNI based on FDG-PET for LD-SCLC. Our primary 
end point was to evaluate the proportion of isolated nodal failures; secondary end 
points were the patterns of recurrence and esophageal and pulmonary toxicity. 
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4.2 Methods and Materials 
Patient population 
Patients diagnosed with LD-SCLC and referred for radical RT to Maastro clinic be-
tween December 2004 and November 2006 were prospectively evaluated. The 
inclusion criteria were cytologically or histologically proven SCLC; limited disease, 
defined as International Union Against Cancer Stage I-III, with the exclusion of T4 
lesions because of malignant pleural or pericardial effusion; World Health Organiza-
tion (WHO) performance status 0-2; age at least 18 years; adequate pulmonary 
function (forced expiratory volume in 1 second >1 litre). Patients with severe recent 
cardiac disease (e.g., arrhythmia, congestive heart failure, infarction) were ex-
cluded. The minimal follow-up time after the start of RT was 18 months.  
Staging 
All patients underwent bronchoscopy with biopsy and standard haematological and 
biochemical workup. Brain imaging was performed with either MRI or a contrast-
enhanced CT. Pre-treatment imaging of the chest consisted of either both a whole 
body FDG-PET scan and a contrast-enhanced CT scan of the chest, or a combined 
whole body FDG-PET-CT scan with contrast.  
Chest imaging with FDG-PET and CT 
For PET-based RT planning, a combined PET-CT scan was performed either during 
the diagnostic process only or during both the diagnostic process and for RT simula-
tion. In both cases, to ensure optimal co-registration, the PET-CT scan was obtained 
with the patient in the RT position with both arms above the head 19. Patients had 
to have fasted for at least 6 hours before the examination. The injected total activity 
of FDG was calculated from the weight of the patient: (weight* 4 + 20) MBq. After a 
rest period of 60 min (interval needed for FDG uptake), the PET and CT images were 
acquired. A CT scan of the whole thorax was performed with intravenous contrast 
during free-breathing.  
Lymph nodes were judged positive and included in the CTV on basis of the report of 
the PET and CT scan. The CT and PET findings were interpreted and reported inde-
pendently by an experienced chest radiologist and nuclear medicine specialist, re-
spectively. 
The CT-findings from the diagnostic CT scan were also interpreted by an experi-
enced chest radiologist. Lymph nodes were considered to be pathologic on CT when 
their axial diameter was >1 cm. The lymph nodes were considered positive on the 
FDG-PET scan on basis of visual interpretation by an experienced PET scan specialist. 
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No quantitative standardized uptake value (SUV) threshold was used, as a visual 
scale has been shown to be at least as accurate as the use of a SUV-threshold to 
distinguish benign from malignant nodes 20, 21. The involved lymph node stations 
were recorded according to the Mountain and Dresler classification scheme 22. 
Radiotherapy 
For RT planning, contrast-enhanced CT or combined FDG-PET-CT was performed 
that extended from the cricoid to the second lumbar vertebra, with a maximal slice 
thickness of 3 mm. Patients were scanned in the supine position with both arms 
above the head. The CT and PET images were automatically registered using a rigid 
registration technique based on mutual information and were subsequently fused 
using Focal software (Computerized Medical Systems (CMS), St Louis, MS). RT plan-
ning was performed with a XiO treatment planning system (CMS), using inhomoge-
neity corrections based on a convolution algorithm. For all patients, the gross tu-
mour volume (GTV) and planning target volume (PTV) were defined on basis of the 
PET and CT data. In the case of induction chemotherapy, the post-chemotherapy 
volume was considered as the GTV of the primary tumour, whereas for the lymph 
nodes, only the pre-treatment extension was considered. For the primary tumour, 
the GTV was delineated using the CT findings only, using lung window settings (W = 
1700, L = -300). We deliberately avoided contouring on the basis of ill-defined areas 
on the PET scan. Instead, the sharp boundaries of the CT scan images were used. For 
planning of the lymph nodes, the pre-treatment anatomic sites of the involved 
zones on the FDG-PET scan were delineated on the planning CT scan in a mediasti-
nal window setting (W = 600, L = 40). The whole pathologic anatomic region as de-
scribed by the nuclear medicine specialist in the original diagnostic report (i.e., be-
fore the start of chemotherapy) was delineated 23. If the PET scan was negative in 
the mediastinum and the CT scan positive, the mediastinum was not included in the 
GTV. The margin from the GTV to the CTV (Clinical Target Volume) was 5 mm, and 
from the CTV to the PTV 5 mm for the nodal areas and 10 mm for the primary lung 
tumour. No elective nodal irradiation was performed.  
Contouring of the lung was done automatically by the treatment planning system. 
The mean lung dose (MLD) was analyzed as a possible predictor for radiation pneu-
monitis. For the calculation of the MLD, the volume of both lungs minus the GTV 
was considered 24. The dose constraint to the lungs was set at a MLD of 19 Gy. The 
esophagus was delineated from just below the larynx to the gastro-esophageal 
junction. Neither the GTV nor the PTV was subtracted from this volume. The mean 
esophageal dose (MED) and the maximal esophageal dose (Dmax) were analyzed as 
possible predictors of early and late esophageal toxicity 24, 25. The spinal cord was 
drawn throughout the whole CT scan and was considered to be at the inner margin 
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of the bony spinal canal. The maximum allowed dose to the spinal cord was 54 Gy, 
and this dose constraint was not reached in the present study.  
All patients were treated with a three-dimensional conformal treatment plan using 
6-10 MV photons. The prescribed dose to the PTV was 45 Gy in 30 fractions within 3 
weeks (1.5 Gy twice daily, with a minimal interval between two fractions of 8 hours) 
according to the ICRU report 50 guidelines 26. During RT, patients were seen weekly 
by the radiation oncologist, for the evaluation of acute side effects. 
Chest RT was planned to start as early as possible after the beginning of chemother-
apy. After thoracic irradiation and 5 cycles of chemotherapy, re-staging was per-
formed including a chest X-ray and contrast-enhanced CT scan or MRI of the brain. If 
no progression was found on the chest X-ray and no brain metastases were seen, 
patients were offered prophylactic cranial irradiation (PCI) to a dose of 25 Gy in 10 
fractions. 
Chemotherapy 
Patients underwent chemotherapy according to the standard protocol in the Com-
prehensive Cancer Centre Limburg (the Netherlands). The standard protocol was 
carboplatin on day 1 and etoposide (120 mg/m2) on day 1-3. The carboplatin dose 
was based on the target area under the curve (5mg/ml/h) * (glomerular filtration 
rate + 25), with the glomerular filtration rate calculated according to the Cockroft-
Gault formula. The chemotherapy cycles were repeated every 21 days for a total of 
5 cycles.  
Post-treatment follow-up 
The follow-up consisted of a visit 3 weeks after the end of RT for the evaluation of 
acute side effects. Thereafter, visits every 3 months, including history taking and 
physical examination, were performed, for the first 2 years. After this period, 6-
month visits were performed until 5 years after treatment. CT of the thorax was 
performed 3 months after RT completion and every 6 months thereafter. When a 
patient presented with a recurrence outside of the follow-up visits, chest imaging 
was performed with chest X-ray and CT. After the detection of a recurrence, the 
follow-up visits were continued at 3 month intervals, with the type of imaging being 
guided by the site of progression and the presence of symptoms. 
Local tumour control was evaluated according to the criteria of Green et al. 27. An 
isolated nodal recurrence was defined as a recurrence in the regional nodes outside 
the CTV, in the absence of in-field failure or distant metastases.  
The pulmonary and esophageal toxicity were scored according to the Common 
Terminology Criteria for Adverse Events (CTCAE), version 3.0 (Table 4.1) 28. Toxicity 
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was scored before the start of RT, at the weekly visits during RT, and at the follow 
up visits.  
 
Table 4.1 Toxicity grading criteria according to the Common Terminology Criteria for Adverse Events, 
version 3.0  
 Grade 
Adverse event 1 2 3 4 5 
Esophagitis Asymptomatic, 
pathologic, 
radiologic or 
endoscopic 
findings only 
Symptomatic; 
altered eat-
ing/swallowing 
(e.g. altered 
dietary habits, 
oral supple-
ments); IV 
fluids indicated 
< 24 hrs 
Symptomatic and 
severely altered 
eating/swallowing 
(e.g. inadequate 
oral caloric or 
fluid intake); IV 
fluids, tube 
feedings, or TPN 
indicated ≥ 24 hrs 
Life threaten-
ing conse-
quences 
Death 
Cough Symptomatic, 
non-narcotic 
medication 
only indicated 
Symptomatic, 
narcotic medi-
cation indi-
cated 
Symptomatic, 
significantly 
interfering with 
sleep or ADL 
- - 
Dyspnea Dyspnea on 
exertion, but 
can walk 1 
flight of stairs 
without stop-
ping 
Dyspnea on 
exertion, 
unable to walk 
1 flight of 
stairs or 1 city 
block (0.1 km) 
without stop-
ping 
Dyspnea with ADL Dyspnea at 
rest; intuba-
tion/ 
ventilator 
indicated 
Death 
Ethics  
The trial was performed in accordance with the Dutch laws and regulations. The 
study protocol was registered at the National Institute of Health (NIH) clinical trial 
database, under NCT00572923.  
Statistical analysis  
On basis of the planning study we had previously performed 18, we hypothesized 
that introducing PET into the RT planning would change the treatment fields in 25% 
of the patients compared with CT-based planning 29. From the results of PET based 
SNI for NSCLC, we expected the percentage of isolated nodal failures to not exceed 
5%. As the upper bound of the 95% confidence interval (CI), we used the observed 
11% of isolated nodal failures with CT-based SNI 12. To detect this rate of failures, at 
least 50 patients were needed for the present study 30 
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The results are expressed as the mean ± standard deviation (SD) or as a proportion, 
with the 95 % CI’s. The estimates of overall survival (OS) and progression free sur-
vival (PFS) rates were calculated with the Kaplan Meier method, on an intent to 
treat basis, starting from the first day of RT. Correlations between the dose volume 
parameters and toxicity were calculated using a two-sided Spearman’s test or a chi-
square test in the case of nominal variables.  
4.3 Results 
Patient and treatment characteristics 
A total of 60 patients with LD-SCLC, referred to our institution between December 
2004 and November 2006 were included. The baseline patient characteristics are 
summarized in Table 4.2. Most patients were male (67%). All patients received 
chemotherapy, which in 97% consisted of carboplatin-etoposide. One patient re-
ceived carboplatin-paclitaxel because she was diagnosed with ovarian cancer during 
the diagnostic workup. A total of 59 patients (98%) received a dose of 45 Gy. Five 
patients were treated with sequential chemoradiotherapy instead of concurrent 
chemoradiotherapy. The reasons for this protocol violation were either a too high 
MLD owing to the size of the primary tumour, or a delay in patient referral. One 
patient was not considered fit enough to undergo accelerated RT with concomitant 
chemotherapy and was therefore treated with 5 cycles of induction chemotherapy, 
followed by RT to a dose of 54 Gy in 30 once-daily fractions.  
The median interval between the first day of chemotherapy and the start of chest 
RT for patients treated with concurrent chemo-radiotherapy was 18.0 ± 11.1 days 
(range: -13 to 49 days). The overall treatment time of RT was 21 ± 3.7 days (range 
17-41). The median interval between the start of chemotherapy and the end of RT 
(SER) was 39 ± 34.0 days (range: 7-176). The median SER for patients treated with 
concurrent chemoradiotherapy was 38 ± 11.6 days (range: 7-71 days). Of the 60 
patients, 50 (83%, 95% CI: 72-91%) received PCI. 
A difference in mediastinal staging according to CT and PET was observed in 30% 
(95% CI: 20-43%) of the patients (Figure 4.1). In 15% (95% CI: 8-26%), more nodal 
stations were involved on PET than on CT, and in 13% of patients (95% CI: 7-24%) 
fewer nodal stations were involved on PET than on CT. In 1 patient, nodal stations 
were involved on PET that were not involved on CT and vice versa. In 3 patients (5%, 
95% CI 2-14%) supraclavicular nodal stations were found to be involved on PET, but 
the CT scan was negative for these stations.  
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Table 4.2 Baseline patient and treatment characteristics 
Characteristic Value ± SD (%) 
Age (years) 
Median  
Range 
 
66.0 ± 8.9 
48-85 
Gender 
Male 
Female 
 
40 (66.7) 
20 (33.3) 
WHO performance status 
0 
1 
2 
 
13 (21.7) 
39 (65.0) 
8 (13.3) 
Lung function (Median FEV1, %) 70.0 ± 20.2 
Tumour location 
Right upper lobe 
Right middle lobe 
Right lower lobe 
Left upper lobe 
Left lower lobe 
Right hilus 
Left hilus 
Unknown 
 
17 (28.3) 
5 (8.3) 
4 (6.7) 
11 (18.3) 
6 (10.0) 
7 (11.7) 
8 (13.3) 
2 (3.3) 
Chemotherapy 
Carboplatin-Etoposide 
Carboplatin-Paclitaxel 
Unknown 
 
58 (96.7) 
1 (1.7) 
1 (1.7) 
Interval between CTx-RT (days) 
Mean 
Range 
 
27.8 
13-158 
Dose (Gy) 
45 
54 
 
59 (98.0) 
1 (2.0) 
OTT of RT (days) 
Median 
Range 
 
21.0 ± 3.7 
17-41 
SER (days) 
Median 
Range 
 
39.0 
7-176 
WHO: world health organization; FEV1: forced expiratory volume in 1 second; CTx: Chemotherapy; RT: 
radiotherapy; OTT: overall treatment time; SER: interval between the start of CTx and the end of RT 
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Figure 4.1 Difference in involved nodal stations between PET and CT 
a) Representative image of a patient with a positive nodal station 7 on PET, while CT is negative 
b) Representative image of a patient with a positive nodal station 4L on CT, while PET is negative 
Patterns of failure 
An overview of the frequency and site of relapses is listed in Table 4.3. 
 
Table 4.3 Frequency and location of recurrences as assessed by CT 
Recurrence Number of patients (%) 
None 21 (35) 
Local 
In field  
Out of field 
Both in field and out of field 
Isolated local 
Local and distant/nodal 
9 (15) 
3 (5.0) 
4 (6.7) 
2 (3.3) 
2 (3.3) 
7 (11.7) 
Nodal 
In field 
Out of field 
Both in field and out of field 
Isolated nodal 
Nodal and distant/local 
20 (33.3) 
8 (13.3) 
7 (11.7) 
5 (8.0) 
2 (3.3) 
18 (30.0) 
Distant 
Isolated distant 
Distant and local/nodal 
Isolated brain 
34 (56.7) 
19 (31.7) 
15 (25.0) 
9 (15.0) 
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The minimal follow up of all surviving patients was 18 months. The median follow-
up for all patients was 18.5 ± 10.3 months (range: 3-52 months). Of the 60 patients, 
39 (65%, 95% CI: 52-76%) developed a recurrence. Two patients (3%, 95% CI: 1-11%) 
experienced an isolated nodal recurrence. Both recurrences were treated with con-
current chemoradiotherapy. The first patient, whose primary tumour was located in 
the left lower lobe, developed a nodal recurrence in station 4R at 15 months after 
treatment. Different nodal stations had been involved before treatment on PET 
(stations 5 and 10L) and CT (station 10L), but station 4R was not involved before 
treatment on PET or CT. The second patient, with the primary tumour located in the 
lingula of the left lung, developed nodal recurrence in station 2L and the left supra-
clavicular region, also 15 months after treatment. Those stations were not involved 
before treatment on the basis of PET or CT (only station 6 involved).  
 
In 87% (95% CI: 73-94%), distant metastases (either isolated or combined with local 
or nodal recurrence) were present at recurrence. Nine patients (15%, 95% CI: 8-
26%) were diagnosed with isolated brain metastases, of whom 6 had previously 
received PCI. A nodal recurrence outside the treatment field combined with recur-
rence inside the treatment field occurred in 5 (8%, 95% CI: 4-18%) patients. In one 
of them, the nodal recurrence occurred in a nodal station that was positive on CT, 
but negative on PET, and hence had not been included in the treatment field.  
Survival 
The median actuarial overall survival (OS) time for all patients was 19 months (95% 
CI: 17-21 months) (Figure 4.2), with a 2 year OS rate of 35%. The median OS for 
patients treated with concurrent chemoradiotherapy was also 19 months (95% CI: 
16-22 months). The median actuarial progression free survival (PFS) was 14 months 
(95% CI: 12-16 months) (Figure 4.3), the 2 year PFS rate was 26%. 
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Figure 4.2 Actuarial overall survival 
 
 
 
Figure 4.3 Actuarial progression free survival 
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Toxicity 
An overview of the dose-volume-histogram (DVH) parameters according to the 
toxicity grade is presented in Table 4.4. The mean DVH parameters were as follows: 
mean MLD 12.9 ± 4.2 Gy; mean MED: 22.1 ± 8.6 Gy; mean Dmax: 44.5 ± 8.6 Gy. 
Treatment related toxicity to the lungs was relatively mild, with grade 3 cough in 1 
patient and grade 3 dyspnea in 2 patients. However, 62% of patients experienced 
acute esophagitis of grade 2 or more, with 12% (95% CI: 6-22%) experiencing grade 
3 esophagitis. The frequency of grade 3 esophagitis in patients treated with concur-
rent chemoradiotherapy was 13% (95% CI: 7-25%). No grade 4 or 5 toxicity was 
observed. The esophagitis resolved within 4 weeks after RT in all patients. No sig-
nificant correlation was found between the toxicity grade and the radiation parame-
ters, neither for lung, nor for esophageal toxicity.  
 
Table 4.4 Dose Volume Histogram (DVH) parameters according to the toxicity grade* 
Toxicity N of patients (%) Parameter 
Lung Toxicity    
Cough  MLD ± SD (Gy)  
G0 
G1 
G2 
G3 
11 (18.3) 
34 (56.7) 
14 (23.3) 
1 (1.7) 
12.0 ± 4.1 
13.8 ± 4.) 
13.5 ± 3.3 
6.9 ± 0.0 
 
Dyspnea  MLD ± SD (Gy)  
G0 
G1 
G2 
G3 
22 (36.7) 
27 (45.0) 
9 (15.0) 
2 (3.3) 
11.8 ± 3.7 
13.5 ± 3.9 
15.2 ± 4.1 
16.5 ± 3.4 
 
Esophageal toxicity    
Esophagitis  MED ± SD (Gy) Dmax ± SD (Gy) 
G0 
G1 
G2 
G3 
9 (15.0) 
14 (23.3) 
30 (50.0) 
7 (11.7) 
14.6 ± 9.7 
23.4 ± 9.3 
22.9 ± 7.8 
24.0 ± 6.8 
41.0 ± 10.2 
44.1 ± 9.7 
44.9 ± 3.4 
47.0 ± 0.9 
G: Grade; MLD: Mean Lung dose; MED: Mean esophageal dose; Dmax: maximal esophageal dose 
* Common Terminology Criteria for Adverse Events, version 3.0 
4.4 Discussion 
This is the first prospective study evaluating selective nodal irradiation based on 
FDG-PET scans in LD-SCLC patients.  
In the absence of clinical evidence regarding the safety of SNI, radiation oncologists 
are confronted with the choice between a possible reduction in treatment related 
toxicity and the possibility of increasing the risk of locoregional failure 11. A phase II 
trial by our group evaluating the safety of CT-based SNI resulted in an unacceptably 
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high percentage of isolated regional failures (11%, 95% CI: 2-29%). In contrast, in 
the present study with SNI based on PET, isolated nodal recurrences occurred in 3% 
of patients (95% CI: 1-11%). This proportion is comparable to that found with SNI in 
NSCLC, in which about 2% experienced an isolated nodal recurrence with SNI on 
basis of FDG-PET scans 5, 6.  
 
The remarkable difference between the value of SNI based on CT vs. PET in LD-SCLC, 
may be explained by the discrepancy in the involved nodal stations on the PET and 
CT scans. Indeed, we observed different lymph node stations involved on PET com-
pared with those on CT in 30% of our LD-SCLC patients. The proportion of patients 
in whom more nodal stations were involved on PET than on CT was similar to the 
percentage in whom fewer nodal stations were involved on PET than on CT. These 
data correspond to those found in the planning study we performed, in which a 
difference in involved nodal stations in 24% of patients was observed. In our pro-
spective study concerning CT-based SNI for SCLC, all isolated nodal failures occurred 
in the ipsilateral supraclavicular area 12. The present study showed involvement of 
the ipsilateral supraclavicular nodes on PET in 5% of patients whose CT scan was 
negative for this region. This confirms that PET scanning can result in the upfront 
detection of supraclavicular lymph node metastases, thereby reducing the risk of an 
isolated nodal recurrence in this area. 
 
Patients with an isolated nodal failure could theoretically have been cured if elective 
nodal irradiation had been performed instead of SNI. However, aside from the nodal 
recurrences, both local and distant recurrences still occurred in most patients, em-
phasizing the need for better treatment strategies for this disease.  
The median OS in our study of 19 months (2 year OS rate: 35%) was lower than that 
reported in the trial by Turrisi et al. 1, in which LD-SCLC patients were treated with 
concurrent chemoradiotherapy with elective nodal irradiation (median OS of 23 
months and 2 year OS rate of 47%). A possible explanation for this difference in 
survival is the relatively long SER in our study (39 days, range: 20-176). Moreover, 
the standard chemotherapy regimen in our region consisted of carboplatin-
etoposide, not cisplatin-etoposide chemotherapy as in the trial by Turrisi et al. 1. 
Although one randomized prospective trial showed equal efficacy for both treat-
ment regimens in the treatment of SCLC 31, no definitive conclusions could be drawn 
regarding the outcomes with concurrent chemoradiotherapy for LD-SCLC. Finally, in 
the trial by Turrisi et al. 1, patients with contralateral hilar or supraclavicular in-
volvement were excluded, whereas they were included in our study. 
 
Lung toxicity was generally mild and rare, with only 5% of patients experiencing 
grade 3 toxicity (cough or dyspnea according to the CTCAE 3.0 criteria). A remarka-
bly low percentage of severe acute esophagitis was found, with only 12% (95% CI: 6-
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22%) of patients experiencing grade 3 esophagitis. In patients who have undergone 
elective nodal irradiation, or CT based SNI, grade 3 esophagitis usually occurs in 
about 30% of patients 1, 6. This cannot be straightforwardly explained by a reduction 
of radiation fields, because both our previous planning study and the present trial 
showed an equal percentage of increases and decreases in radiation fields when 
using PET instead of CT. Possible hypotheses include the relatively long SER in the 
present study 32, a lower than average neutropenia level 33, which was not investi-
gated in the present study, or simply an observation due to chance. If the current 
finding of lower esophageal toxicity holds true, PET based SNI could provide oppor-
tunities for dose escalation and hence, improvement of locoregional tumour con-
trol. Therefore, more studies are warranted to investigate this finding.  
The use of FDG-PET-CT is likely to be the most accurate non-invasive staging method 
for the mediastinum in SCLC 15, 29, 34. However, the most reliable method to detect 
mediastinal nodal involvement remains pathological verification. The available stud-
ies have indicated that CT underestimates mediastinal nodal involvement 35-37. No 
prospective data exist concerning correlation of the pathologic findings with PET 
findings in SCLC. Because of the low rate of isolated nodal failures found in the pre-
sent study and the morbidity associated with invasive staging, we believe that our 
data support the use of PET-based SNI for LD-SCLC. 
4.5 Conclusion 
This prospective study shows that PET-based SNI in LD-SCLC is safe and is associated 
with low toxicity. 
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Abstract 
Background and purpose 
Follow-up of patients treated with curative intent for non-small cell lung cancer 
(NSCLC) with X-ray or CT-scans is of unproven value. Furthermore, most patients 
with progressive disease present with symptoms outside of follow-up visits. Because 
the accuracy of 18FDG-PET-CT is superior to CT, we hypothesized that FDG-PET-CT 
scans 3 months post-treatment could lead to early detection of progressive disease 
(PD) amenable for radical treatment.  
Methods and Materials 
Hundred patients with NSCLC, treated with curative intent with (chemo) radiation, 
were prospectively evaluated. All patients underwent a planned FDG-PET-CT scan 
three months after the start of radiotherapy. 
Results 
Twenty-four patients had PD 3 months post-treatment. 16/24 patients were symp-
tomatic. No curative treatment could be offered to any of these patients. In 3/8 
asymptomatic patients progression, potentially amenable for radical therapy was 
found, which were all detected with PET, not with CT only.  
Conclusions 
PET scanning after curative treatment for NSCLC led to the detection of progression 
potentially amenable for radical treatment in a small proportion (3%) of patients. 
Selectively offering a PET-CT scan to the patient group without symptoms could 
possibly lead to an effective follow-up method. 
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5.1 Introduction 
Lung cancer is the leading cause of cancer death, with an estimated 161.000 pa-
tients dying of this disease in the United States in 2008 1. The survival of non-
metastatic non small cell lung cancer (NSCLC) patients remains poor, with 5-year 
survival rates of about 50 % in stages I-II and 20 % in stage III disease 2, 3. This poor 
survival is due to a high amount of both locoregional and distant progression 4. 
Theoretically, early detection of progressive disease (PD) at a time when radical 
therapy is an option, could improve the survival. In NSCLC however, there are at 
present no convincing data supporting that early detection of progression improves 
survival 5-8. Moreover, most patients who have PD present with symptoms outside 
of planned follow-up visits 5, 9. A recent study showed no significant improvement of 
survival with intensive follow-up by repeated CT-imaging compared to less intensive 
radiologic follow-up 5. A major restriction of both conventional chest X-ray and CT 
after curative treatment for NSCLC is the poor discriminating capacity between 
residual or recurrent tumour and post-treatment changes 7, 10. Therefore, repeated 
imaging is often needed to confirm PD. This delay could lead to missing the chance 
for salvage treatment. 
 
18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) scanning, which 
allows imaging of glucose uptake of tissues, has shown to be superior to CT in the 
evaluation of lung lesions and mediastinal lymph nodes 11-13, as well as in the detec-
tion of distant metastases in the primary staging of NSCLC 14. Furthermore, FDG-
uptake of the primary tumour before and during therapy, as well as 3 months after 
treatment is prognostic for outcome 15-22. Finally, PET is more accurate than CT in 
the distinction of tumour from post-radiotherapy (RT) effects 18, 23, 24. Based on 
these data, we hypothesized that the use of PET-CT in the follow-up of patients with 
NSCLC treated with curative intent would be superior to CT alone. The aim of our 
study was to evaluate the detection rate of PD amenable for salvage treatment 
using routine PET-CT in the follow-up of NSCLC patients treated with curative intent 
with (chemo) radiation. Therefore, we prospectively investigated the impact of 
follow-up with PET-CT 3 months after therapy on the outcome in 100 consecutive 
patients with NSCLC, who were treated with curative intent. 
5.2 Methods and Materials 
Patient population and study design 
Patients with stages I-III NSCLC, who were treated with curative intent with (chemo) 
radiotherapy at our institute from February 2005 until August 2007, consenting to 
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an additional PET-CT in the follow-up, were prospectively evaluated. Patients with 
stage IV disease on the basis of a solitary brain metastasis, treated with curative 
intent, were also included. As part of the primary staging, all patients underwent  an 
FDG-PET-CT and imaging of the brain (either MRI or CT) before the start of treat-
ment. The follow-up consisted of a visit 3 weeks after the end of treatment for the 
evaluation of acute side effects. Thereafter, 3-monthly visits, comprising history 
taking and physical examination, were performed alternately by the pulmonologist 
and radiation oncologist, for the first 2 years. Thereafter, 6-monthly visits were 
performed until 5 years post-treatment.  AN FDG-PET-CT scan was planned irrespec-
tive of the presence of symptoms at 3 months after the start of radiotherapy, with a 
minimum interval of 2 months (60 days) to account for persistent increased FDG-
uptake immediately after therapy. Within 1 week following the PET-CT scan, a fol-
low-up visit was planned. Request of other diagnostic imaging procedures was left 
at the decision of the physician, as indicated by the presence of symptoms.  
Treatment characteristics 
Patients were treated with radical radiotherapy (RT), either alone (medically inop-
erable stage I-II disease) or in combination with concurrent or sequential chemo-
therapy in stage III disease. For stages I and II NSCLC, radical RT was given in frac-
tions of 1.8 Gy, twice daily, to a mean lung dose (MLD) of 19 Gy (maximal total tu-
mour dose: 79.2 Gy) 25. Patients with stage III disease received induction chemo-
therapy with one cycle of carboplatin-gemcitabine (carboplatin (total dose: target 
AUC*(GFR+25) on day 1 - gemcitabine 1250 mg/m2 on days 1 and 8). This was fol-
lowed by concurrent chemoradiotherapy. RT was given to a dose of 45 Gy in twice 
daily fractions of 1.5 Gy, followed by 2 Gy daily fractions to a MLD of 19 Gy (maximal 
total tumour dose: 69 Gy), concurrent with cisplatin 50 mg/m2 and vinorelbine 20 
mg/m2 on days 1 and 8. Patients with stage III disease who were considered unable 
to undergo concurrent chemo-radiotherapy were treated either with radical RT 
alone, or with sequential chemo-radiotherapy, consisting of three cycles of induc-
tion chemotherapy (carboplatin-gemcitabine) followed by RT as described for stages 
I/II.  
PET-CT imaging 
A combined whole-body PET-CT scan was performed about 3 months (but at least 2 
months) after the start of radiotherapy. Patients had to be fasting for at least 6 
hours before the examination. The injected total activity of FDG was calculated 
based on the weight of the patient: (weight * 4) + 20 MBq. After a rest period of 60 
minutes (time needed for uptake of FDG), PET and CT images were acquired. A 
whole-body CT-scan was performed with intravenous contrast. The CT- and FDG-
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PET findings were first interpreted and reported independently by an experienced 
chest radiologist and nuclear medicine specialist, respectively. Tumour progression 
was defined according to the EORTC criteria for PET 26 and to the RECIST criteria for 
CT 27. Thereafter, both specialists jointly evaluated the combined PET-CT images, 
from which a distinct report was written.  
Data acquisition 
For each patient, the following data were collected: patient demographics; initial 
tumour characteristics (stage according to the TNM-classification (UICC, 6th edition), 
location and histology); and treatment characteristics (dose, overall treatment time 
(OTT) of radiotherapy and treatment modality).  
Results of the PET-CT scan were recorded as described in the diagnostic report of 
the radiologist and nuclear medicine specialist. Progressive disease was defined as 
locoregional when situated at or around the original tumour site or regional lymph 
nodes and further specified as within or outside the RT field. Progression was de-
fined as distant when situated either in a different lobe as the primary tumour, or 
outside of the thorax. The site of distant relapse was recorded as well. If both loco-
regional and distant progression was detected, both were recorded. PD was judged 
as either diagnosed on basis of CT alone when it was described in the distinct report 
of the CT (PD according to the RECIST criteria), or as diagnosed with PET when it was 
only described in the distinct report of the PET (PD according to the EORTC criteria) 
and/or the report of the combined PET-CT, with the report of the CT being either 
negative or inconclusive.  
PD was defined as amenable for salvage treatment when it was either locoregional, 
or in case of oligometastasis, defined as 1 or 2 metastases, amenable for radical 
local treatment by either radiotherapy or surgery 28. The distinction between loco-
regional progression and post-RT changes was recorded on the basis of the diagnos-
tic report and was made on visual interpretation by the nuclear medicine physician. 
Because these radiation-induced changes can normally be readily distinguished 
from persistent or recurrent tumour by their FDG-uptake distribution, no quantita-
tive threshold was used 24, 29. 
The absence or presence of symptoms at time of the PET-CT was noted. Further-
more, it was judged whether at least one of the symptoms was corresponding to 
the site (or one of the sites) of progression found on PET-CT. This was based on the 
following assumptions: pain was defined as corresponding to the site of progression 
when it was localized at the dermatome corresponding to the site. Pulmonary 
symptoms (cough, dyspnoea) were defined as corresponding when progression was 
either locoregional or metastases in the lung, and symptoms had increased over 
time after RT. Neurological symptoms were judged corresponding when either brain 
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metastases were diagnosed, or symptoms were consistent with the site of metasta-
sis in the central or peripheral nervous system.  
No distinction was made between the detection of a second primary or PD. Because 
of the short interval between the primary treatment and the PET-CT scan 3 months 
after therapy, a second tumour in the same lobe was considered as PD, while a 
second tumour in another lobe was considered a distant relapse rather than a sec-
ond primary. Survival data were obtained by consultation of the Dutch Communal 
Data (GBA) register. Follow-up time was defined as the time from the end of radio-
therapy until death or the last time of follow-up. At the time of analysis, 51 patients 
had died. For three patients, survival data could not be retrieved. 
Statistical analysis 
We estimated that 25% of the patients would have detectable PD at the time of the 
post-treatment FDG-PET-CT scan 30, 31, with an estimated 25% of them being eligible 
for salvage treatment. In order to detect this proportion (6%) with a 95% confidence 
interval (CI) of 1-11%, at least 85 patients evaluable 3 months post-treatment would 
be needed. To account for possible dropouts, 100 patients were included.  
Statistical calculations were performed using SPSS (Version 15.0 for Windows). Re-
sults were described as either median or mean ± one standard deviation (SD) when 
the results were normally distributed. When there was no normal distribution, re-
sults were described as either median or mean with the range. For the calculation of 
95% confidence intervals (95% CI) for proportions, the Wilson score interval was 
used 32. P-values were calculated with the Chi-square test for proportions. 
Ethics 
The trial was performed according to the required Dutch laws and regulations. All 
patients gave informed consent for the study, which was part of two study proto-
cols, NCT00573040 and NCT00572325. 
5.3 Results 
Patient and treatment characteristics 
From February 2005 until August 2007, 100 NSCLC patients, stages I-III, treated with 
curative intent, were included. Patient, tumour and treatment characteristics are 
listed in Table 5.1. The mean follow-up of all patients was 55.9 ± 29.2 weeks, rang-
ing from 13 to 182 weeks. Seventy males and 30 females were included, with a 
mean age of 66.0 ± 9.7 years (range: 44-86).  
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Table 5.1 Patient, tumour and treatment characteristics 
 N ± SD (%) 
Age 
Mean (years)) 
Range 
 
66.0 ± 9.7 
44-86 
Gender 
Male 
Female 
 
70 (70) 
30 (30) 
Stage 
IA 
IB 
IIA 
IIB 
IIIA 
IIIB 
IV 
 
4 (4) 
6 (6) 
0 (0) 
3 (3) 
25 (25) 
61 (61) 
1 (1) 
Histology 
Adenocarcinoma 
Large cell carcinoma 
Squamous cell carcinoma 
Bronchioloalveolar cell carcinoma 
NSCLC, NOS 
 
15 (15) 
30 (30) 
18 (18) 
1 (1) 
36 (36) 
Treatment 
Radical RT only 
Sequential Chemo-RT 
Concurrent Chemo-RT 
 
16 (16) 
65 (65) 
19 (19) 
Dose (Gy) 
Median 
Range 
 
63.5 
50.4-79.2 
Time interval* 
Median 
Range 
 
16 ± 3.1 
9-27 
Follow-up**  
Mean 
Range 
 
55.9 ± 29.2 
13-182 
N= number of patients; SD= standard deviation; NOS: not otherwise specified 
*Weeks from the start of radiotherapy to the date of PET-CT  
**Weeks from the end of radiotherapy until death or lost to follow-up 
 
The median radiation dose delivered was 63.5 Gy, ranging from 50.4 to 79.2 Gy. 
Most (86/100) patients had stage III disease at time of presentation. 84% of patients 
received chemotherapy, either sequential to or concurrent with radiotherapy. One 
patient had stage IV disease. This patient had a solitary brain metastasis, which was 
treated with stereotactic radiotherapy before radical treatment of the lung tumour.  
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Results of PET-CT scanning 3 months after treatment 
The mean time interval from start of RT until planned surveillance PET-CT scan was 
16 ± 3.1 weeks (range: 9-27 weeks). All patients underwent the scan more than 2 
months after the start of RT, and 75% underwent the scan within 4 months after 
start of RT. Twenty-four patients had PD, of which 7 had locoregional progression 
only, 7 distant only and 10 had both locoregional and distant progression. The pri-
mary stage and treatment of the patients with progression are described in Table 
5.2. Of the 24 patients with progression, 17 (71%, 95% CI: 51-85%) were detected 
with CT only, while for 7 patients, the PET scan was necessary for the detection of 
the progression, with CT being either negative or inconclusive (Figure 5.1). Of the 8 
patients who were symptomatic at the time of progression, PET was required for 
the detection in 4/8 patients (50%, 95% CI: 22-78%), while for the symptomatic 
patients, PET was required in 3/16 patients (19%, 95% CI: 6-43%).  
In 36 patients (36%, 95% CI: 27-46%), the PET-scan showed findings that were de-
fined in the diagnostic report as post-RT effects. In all patients, these findings could 
easily be distinguished from PD on the basis of the combined PET-CT images.  
 
Table 5.2 Characteristics of progressive disease 
 N (%) 
Primary stage 
I 
II 
III 
IV 
 
2 (8) 
0 (0) 
21 (88) 
1 (4) 
Primary treatment 
Radical RT 
Sequential Chemo-RT 
Concurrent Chemo-RT 
 
2 (8) 
16 (67) 
6 (25) 
Site of progression 
Locoregional 
Inside RT-field 
Outside RT-field 
Both Inside and Outside 
Distant 
Bone 
Brain 
Liver 
Muscle 
Adrenal gland 
Lung 
Axilla 
 
17 
10 (59) 
6 (35) 
1 (6) 
17 
9 (38) 
4 (17) 
2 (8) 
1 (4) 
4 (17) 
4 (17) 
1 (4) 
N: number of patients 
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Figure 5.1 Disease progression: detection modality and treatment intent according to presence of
symptoms 
Sites of progression 
An overview of the sites of progression at the time of the PET-CT scan is shown in 
Table 5.2. Seventeen patients had locoregional PD. In 10 patients, the progression 
was located inside the RT-field, in 6 patients outside the RT-field and in one patient 
both inside and outside the RT field. Six of 17 patients with distant metastases had 
metastases at more than one site.  
Correlation of PET-CT findings with symptoms 
The presence and distribution of symptoms are described in Table 5.3. Forty five 
patients (45%, 95% CI: 36-55%) had symptoms at the time of the PET-CT scan. Six-
teen of them (36%, 95% CI: 23-50%) had PD on PET-CT. The sensitivity and specific-
ity of symptoms for the presence of progression was 67% (95% CI: 47-82%) and 62% 
(95% CI: 51-72%), respectively. In 13/16 (81%, 95% CI: 57-93%) patients, the symp-
toms were in agreement with the site of progression. In the whole group, cough was 
the most common symptom, followed by pain. In the subgroup of patients with 
progression, pain was by far the most common symptom.  
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Table 5.3 Type and frequency of symptoms according to the presence or absence of progression 
Symptoms All patients 
(%) 
Pts without progression 
(%) 
Pts with progression 
(%) 
p-value 
Cough 18 20 13 0.42 
Pain 15 5 46 <0.001 
Dyspnea 14 15 13 0.81 
Neurological 6 3 17 0.01 
Dysphagia 3 3 4 0.70 
Malaise 2 1 4 0.38 
Palpable mass 1 0 4 0.07 
Fatigue 1 1 0 0.57 
Treatment at the time of progression 
The type of treatment of the patients after detection of PD is described in Figure 
5.1. Of the 24 patients, 18 (75%, 95 CI: 55-88%) underwent treatment directly after 
the detection of PD. 
PD amenable for salvage treatment was detected in 3/100 (3%, 95% CI: 1-8%) pa-
tients (Table 5.4), of which two eventually received a radical treatment.  
 
Table 5.4 Patients with progressive disease amenable for radical treatment 
Case Primary 
stage 
Follow 
up* 
Interval* Results PET Results CT Therapy Outcome** 
1 T4N0M0 22 12 Partial remis-
sion of 
primary 
tumour 
Hotspot left-
adrenal 
gland 
 
Volume 
reduction 
of primary 
tumour 
Nodus 1.8 
cm left 
adrenal 
gland 
Proposed for 
pneumonectomy 
and resection of 
adrenal metasta-
sis 
No candidate for 
pneumonectomy 
→ second line CTx
10 wks:  
alive 
2 T1N0M0 70 18 Hotspot left 
hilar node  
Negative Radical RT 52 wks:  
alive; NED  
3 T2N3M0 89 13 Pathological 
uptake in 
both adrenal 
glands 
Slight 
increase in 
volume of 
both 
adrenal 
glands 
Bilateral extirpa-
tion of adrenal 
glands 
76 wks:  
alive; NED  
CTx: chemotherapy; RT: Radiotherapy; NED: no evidence of disease. 
*Weeks from start of radiotherapy 
**Weeks from diagnosis of progressive disease 
 
All 3 were detected by PET, and none of the 3 patients had symptoms at the time of 
detection of PD. The first patient finally underwent palliative chemotherapy be-
cause her lung function did not allow a pneumonectomy. The second patient had 
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regional progression in the left hilus, which was treated with radical RT, and was 
alive without evidence of disease 1 year after the diagnosis of PD. The third patient 
was diagnosed with bilateral adrenal metastases (Figure 5.2), for which he under-
went a bilateral extirpation of the adrenal glands. Pathological examination con-
firmed the presence of adrenal metastases. He was alive without evidence of dis-
ease 1.5 years after diagnosis of the distant metastases. 
 
 
Figure 5.2 Case 3. Bilateral adrenal metastases  
5.4 Discussion 
At present, no data from randomized trials are available concerning the optimal 
follow-up in NSCLC, while other available data show inconsistent results 33. Guide-
lines from different cancer associations differ widely in their recommendations 
concerning chest imaging, from either no routine imaging to surveillance chest CT-
scanning. No evidence exists that extensive follow-up with surveillance chest CT-
imaging is superior to routine follow-up with physical examination and a chest X-
ray. A major disadvantage of CT- scanning is the poor sensitivity and specificity for 
distinguishing post treatment changes from progressive disease, which is reflected 
in a high negative predictive value (99%) and a low positive predictive value (53%) 7, 
10. The accuracy of PET after treatment is assumed to be lower than that at initial 
staging because of inflammatory and perfusion changes due to therapy 12. Never-
theless, PET has still shown to have a high accuracy in detecting recurrent lung can-
cer, with a sensitivity up to 98% and a specificity of 62-92% 9, 12, 34. In this study, by 
using combined PET-CT scans, post-RT changes could be distinguished from PD in all 
patients.  
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Early detection of isolated locoregional progression or oligometastasis could allow a 
radical treatment, with long term survival rates up to 30% and 22%, respectively 28, 
35-37. In the present trial, PET-CT scanning 3 months after curative treatment for 
NSCLC led to the detection of PD potentially amenable for radical treatment in 
3/100 (3%, 95 % CI 1-8 %) patients. These 3 patients were all asymptomatic and 
progression was only detected with PET, not with CT alone. The most important 
question is whether an earlier detection of progression results in a longer overall 
survival. The improved overall survival reported in some retrospective studies, could 
be attributable to lead time bias 5, 8, 38. In the present study, we showed that none of 
the symptomatic patients with PD were amenable for radical treatment. Further-
more, none of the patients in whom progression was detected with CT only were 
amenable for radical treatment, while 3 out of 8 patients with progression (all de-
tected with PET) in asymptomatic patients were potentially amenable for radical 
treatment. The detection of PD with PET-CT in the 2 patients who finally received a 
radical treatment, being alive without evidence of disease 52 and 76 weeks after 
salvage therapy, has almost certainly led to a longer overall survival compared to a 
policy in which diagnostics were only performed at the time when symptoms devel-
oped. Of the 3 patients with PD potentially amenable for radical treatment, two had 
(either uni- or bilateral) adrenal metastases. Because radical treatment by adrena-
lectomy may result in long term survival rates of 25% 39, we believe that there are 
good arguments to treat this patient group with radical intent.  
 
No pathological confirmation was obtained in the patient with regional progression 
in the left hilus and in one of the patients with adrenal metastases on PET. As re-
ported earlier, the accuracy of FDG-PET-scanning for the detection of a recurrence is 
high, with a specificity of 84% 9. The accuracy of FDG-PET for the diagnosis of adre-
nal metastasis is reported to be 92-100% 40-42. 
Another important aspect is the timing of the PET-CT. It is recommended to perform 
a PET-CT scan not earlier than 3 to 6 months after treatment to avoid false positive 
results due to post-radiotherapy changes 12, 43. Hicks and colleagues found no con-
founding of the evaluation of tumour response by the presence of post radiother-
apy inflammatory changes in 73 patients who underwent a PET-CT scan 70 days 
after radical radiotherapy 44. Our data support those findings, as post-radiotherapy 
changes, being present in 36% of patients, did not influence the response evalua-
tion. Furthermore, uptake associated with post radiotherapy pneumonitis can last 
for 15 months after the end of radiotherapy 45. Theoretically, performing a PET-CT 
scan earlier after therapy could result in the detection of more cases with poten-
tially curable disease.  
 
A potential drawback of PET-CT is that it is rather costly. An important topic for 
further research is therefore whether the effects of PET-CT are worth the extra 
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costs and for which patient groups routine PET-CT would be deemed cost-effective. 
As PD amenable for salvage treatment was only detected in asymptomatic patients, 
the added value of routine PET-CT imaging seems to be confined to this group (55% 
of the patients). In patients with symptoms three months after treatment, the type 
of symptoms could guide the choice for an additional investigation, and routine PET-
CT imaging could possibly be reserved for the selection of patients without symp-
toms. Hereby, a potentially cost-effective follow-up method could be developed. 
The cost-effectiveness of PET-CT imaging in the follow-up will be examined in a 
separate study. 
5.5 Conclusion 
For all patients, PET-CT scanning after curative treatment for NSCLC led to the de-
tection of progression amenable for salvage treatment in a small proportion, which 
is of questionable clinical value. The possible advantage seems to be confined to the 
patient group without symptoms. Selectively offering a PET-CT scan to this patient 
group could lead to an effective follow-up method. Further research is needed in 
this field. 
Chapter5
C H A P T E R  5  
 86 
5.6 References 
1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008. 
2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7. 
3. Auperin A, Le Pechoux C, Pignon JP, et al. Concomitant radio-chemotherapy based on platin com-
pounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of indi-
vidual data from 1764 patients. Ann Oncol 2006;17:473-83. 
4. Patterns of failure in patients with resected stage I and II non-small-cell carcinoma of the lung. The 
Ludwig Lung Cancer Study Group. Ann Surg 1987;205:67-71. 
5. Benamore R, Shepherd FA, Leighl N, et al. Does intensive follow-up alter outcome in patients with 
advanced lung cancer? J Thorac Oncol 2007;2:273-81. 
6. Edelman MJ, Schuetz J. Follow-up of local (stage I and stage II) non-small-cell lung cancer after surgi-
cal resection. Curr Treat Options Oncol 2002;3:67-73. 
7. Korst RJ, Gold HT, Kent MS, Port JL, Lee PC, Altorki NK. Surveillance computed tomography after 
complete resection for non-small cell lung cancer: results and costs. J Thorac Cardiovasc Surg 
2005;129:652-60. 
8. Walsh GL, O'Connor M, Willis KM, et al. Is follow-up of lung cancer patients after resection medically 
indicated and cost-effective? Ann Thorac Surg 1995;60:1563-70; discussion 70-2. 
9. Rubins J, Unger M, Colice GL. Follow-up and surveillance of the lung cancer patient following curative 
intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 2007;132:355S-
67S. 
10. Korst RJ, Kansler AL, Port JL, Lee PC, Altorki NK. Accuracy of surveillance computed tomography in 
detecting recurrent or new primary lung cancer in patients with completely resected lung cancer. 
Ann Thorac Surg 2006;82:1009-15; discussion 15. 
11. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the 
current evidence. Chest 2003;123:137S-46S. 
12. Bruzzi JF, Munden RF. PET/CT imaging of lung cancer. J Thorac Imaging 2006;21:123-36. 
13. van Baardwijk A, Baumert BG, Bosmans G, et al. The current status of FDG-PET in tumour volume 
definition in radiotherapy treatment planning. Cancer Treat Rev 2006;32:245-60. 
14. Baum RP, Hellwig D, Mezzetti M. Position of nuclear medicine modalities in the diagnostic workup of 
cancer patients: lung cancer. Q J Nucl Med Mol Imaging 2004;48:119-42. 
15. Ahuja V, Coleman RE, Herndon J, Patz EF, Jr. The prognostic significance of fluorodeoxyglucose 
positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 
1998;83:918-24. 
16. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission 
tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin 
Oncol 2004;22:3255-60. 
17. Jeong HJ, Min JJ, Park JM, et al. Determination of the prognostic value of [(18)F]fluorodeoxyglucose 
uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med 
Commun 2002;23:865-70. 
18. Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed 
tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in 
patients with non-small-cell lung cancer. J Clin Oncol 2003;21:1285-92. 
19. Patz EF, Jr., Connolly J, Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for 
non-small cell lung cancer. AJR Am J Roentgenol 2000;174:769-74. 
20. van Baardwijk A, Dooms C, van Suylen RJ, et al. The maximum uptake of (18)F-deoxyglucose on 
positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and 
GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007;43:1392-8. 
F D G - P E T - C T  I N  T H E  F O L L O W - U P  O F  N S C L C  
 87 
21. Berghmans T, Dusart M, Paesmans M, et al. Primary tumor standardized uptake value (SUVmax) 
measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for 
survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the 
European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 
2008;3:6-12. 
22. Kased N, Erasmus JJ, Komaki R, Cox JD. Prognostic value of posttreatment [18F] fluorodeoxyglucose 
uptake of primary non-small cell lung carcinoma treated with radiation therapy with or without 
chemotherapy: a brief review. J Thorac Oncol 2008;3:534-8. 
23. Duhaylongsod FG, Lowe VJ, Patz EF, Jr., Vaughn AL, Coleman RE, Wolfe WG. Detection of primary and 
recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG 
PET). J Thorac Cardiovasc Surg 1995;110:130-9; discussion 9-40. 
24. Patz EF, Jr., Lowe VJ, Hoffman JM, Paine SS, Harris LK, Goodman PC. Persistent or recurrent broncho-
genic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 1994;191:379-82. 
25. van Baardwijk A, Bosmans G, Boersma L, et al. Individualized Radical Radiotherapy of Non-Small-Cell 
Lung Cancer Based on Normal Tissue Dose Constraints: A Feasibility Study. Int J Radiat Oncol Biol 
Phys 2008. 
26. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using 
[18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommenda-
tions. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J 
Cancer 1999;35:1773-82. 
27. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in 
solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Insti-
tute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16. 
28. Khan AJ, Mehta PS, Zusag TW, et al. Long term disease-free survival resulting from combined modal-
ity management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). 
Radiother Oncol 2006;81:163-7. 
29. Hellwig D, Groschel A, Graeter TP, et al. Diagnostic performance and prognostic impact of FDG-PET in 
suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 
2006;33:13-21. 
30. van Baardwijk A, Bosmans G, Dekker A, et al. Time trends in the maximal uptake of FDG on PET scan 
during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer 
(NSCLC) patients. Radiother Oncol 2007;82:145-52. 
31. Mac Manus MP, Hicks RJ, Matthews JP, Wirth A, Rischin D, Ball DL. Metabolic (FDG-PET) response 
after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns 
of failure. Lung Cancer 2005;49:95-108. 
32. Wilson. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 
1927;22:209-12. 
33. Smith TJ. Evidence-based follow-up of lung cancer patients. Semin Oncol 2003;30:361-8. 
34. Hicks RJ, Kalff V, MacManus MP, et al. The utility of (18)F-FDG PET for suspected recurrent non-small 
cell lung cancer after potentially curative therapy: impact on management and prognostic stratifica-
tion. J Nucl Med 2001;42:1605-13. 
35. Curran WJ, Jr., Herbert SH, Stafford PM, et al. Should patients with post-resection locoregional 
recurrence of lung cancer receive aggressive therapy? Int J Radiat Oncol Biol Phys 1992;24:25-30. 
36. Okamoto Y, Murakami M, Yoden E, et al. Reirradiation for locally recurrent lung cancer previously 
treated with radiation therapy. Int J Radiat Oncol Biol Phys 2002;52:390-6. 
37. Zimmermann FB, Molls M, Jeremic B. Treatment of recurrent disease in lung cancer. Semin Surg 
Oncol 2003;21:122-7. 
38. Westeel V, Choma D, Clement F, et al. Relevance of an intensive postoperative follow-up after sur-
gery for non-small cell lung cancer. Ann Thorac Surg 2000;70:1185-90. 
Chapter5
C H A P T E R  5  
 88 
39. Tanvetyanon T, Robinson LA, Schell MJ, et al. Outcomes of adrenalectomy for isolated synchronous 
versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and 
pooled analysis. J Clin Oncol 2008;26:1142-7. 
40. Boland GW, Goldberg MA, Lee MJ, et al. Indeterminate adrenal mass in patients with cancer: evalua-
tion at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;194:131-4. 
41. Erasmus JJ, Patz EF, Jr., McAdams HP, et al. Evaluation of adrenal masses in patients with broncho-
genic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 
1997;168:1357-60. 
42. Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A. 18F-FDG PET in characterizing adrenal lesions 
detected on CT or MRI. J Nucl Med 2001;42:1795-9. 
43. Keidar Z, Haim N, Guralnik L, et al. PET/CT using 18F-FDG in suspected lung cancer recurrence: diag-
nostic value and impact on patient management. J Nucl Med 2004;45:1640-6. 
44. Hicks RJ, Mac Manus MP, Matthews JP, et al. Early FDG-PET imaging after radical radiotherapy for 
non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response 
and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 2004;60:412-8. 
45. Bury T, Corhay JL, Duysinx B, et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell 
lung cancer. Eur Respir J 1999;14:1376-80. 
  89 
 
CHAPTER 6 
18FDG-PET-CT in the follow-up of  
non-small cell lung cancer patients after 
radical radiotherapy with or without 
chemotherapy: an economic evaluation 
Judith van Loon 
Janneke Grutters 
Rinus Wanders 
Liesbeth Boersma 
Anne-Marie Dingemans 
Gerben Bootsma 
Wiel Geraedts 
Cordula Pitz 
Jean Simons 
Boudewijn Brans 
Gabriel Snoep 
Monique Hochstenbag 
Philippe Lambin 
Dirk De Ruysscher 
European Journal of Cancer 2010;46:110-9 
 
 
 
C H A P T E R  6  
 90 
Abstract 
Background and purpose 
The optimal follow-up strategy of non-small cell lung cancer (NSCLC) patients after 
curative intent therapy is still not established. In a recent prospective study with 
100 patients, we showed that  an FDG-PET-CT 3 months after radiotherapy could 
identify progression amenable for curative treatment in 2% (95% CI: 1-7%) of pa-
tients, who were all asymptomatic. Here, we report on the economic evaluation of 
this study. 
Methods and Materials 
A decision-analytic Markov model was developed in which the long-term cost-
effectiveness of 3 follow-up strategies was modelled with different imaging meth-
ods 3 months after therapy: a PET-CT scan; a chest CT scan; and conventional fol-
low-up with a chest X-ray. A probabilistic sensitivity analysis was performed to ac-
count for uncertainty. Because the results of the prospective study indicated that 
the advantage seems to be confined to asymptomatic patients, we additionally 
examined a strategy where a PET-CT was applied only in the subgroup of asympto-
matic patients. Cost-effectiveness of the different follow-up strategies was ex-
pressed in incremental cost-effectiveness ratios (ICERs), calculating the incremental 
costs per quality adjusted life year (QALY) gained. 
Results 
Both PET-CT and CT based follow-up were more costly but also more effective than 
conventional follow-up. CT-based follow-up was only slightly more effective than 
conventional follow-up, resulting in an incremental cost-effectiveness ratio (ICER) of 
€ 264.033 per QALY gained. For PET-CT based follow-up, the ICER was € 69.086 per 
QALY gained compared to conventional follow-up. The strategy in which a PET-CT 
was only performed in the asymptomatic subgroup resulted in an ICER of € 42.265 
per QALY gained as opposed to conventional follow-up. With this strategy, given a 
ceiling ratio of € 80.000, PET-CT based follow-up had the highest probability of be-
ing cost-effective (73%).  
Conclusions 
This economic evaluation shows that a PET-CT scan 3 months after (chemo)-
radiotherapy with curative intent is a potentially cost-effective follow-up method, 
and is more cost-effective than CT alone. Applying a PET-CT scan only in asympto-
matic patients is probably as effective and more cost-effective. It is worthwhile to 
perform additional research to reduce uncertainty regarding the decision concern-
ing imaging in the follow-up of NSCLC.  
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6.1 Introduction 
The most effective follow-up strategy for non-small cell lung cancer (NSCLC) pa-
tients treated with curative intent with radiotherapy (RT) with or without chemo-
therapy is still not established. This uncertainty is reflected in the large heterogene-
ity in recommendations from the different cancer societies, diverging from no imag-
ing at all to repeated imaging with chest CT scans 1. The added value of chest X-rays 
and/or chest CT has not been confirmed in any prospective study. A major reason 
for this lack of efficacy is the poor discriminating capacity of both imaging modali-
ties. Here, 18FDG-PET-CT could have additional benefit, which has shown to be more 
accurate than CT in the evaluation of response to treatment as well as in outcome 
prediction 2-4. We recently reported the results of a prospective study in 100 pa-
tients treated with chemo-radiotherapy or RT alone with curative intent, which 
showed that indeed, an FDG-PET-CT 3 months after therapy can detect progression 
amenable for treatment with curative intent, and hereby, possibly lead to an in-
crease in survival 5. Progressive disease (PD) amenable for curative treatment, how-
ever, was only found in 2% (95% confidence interval (CI): 1-7%) of patients. The 
study showed that the advantage seemed to be confined to the patient group that 
did not have symptoms at the time that the PET-CT scan was performed. In this 
patient group, 5% (95% CI: 2-15%) had progression, potentially amenable for cura-
tive therapy, which were all detected with FDG-PET, not with CT alone. In contrast, 
none of the symptomatic patients were diagnosed with progression with curative 
treatment options. 
While a PET-CT scan 3 months post-treatment thus seems to be potentially benefi-
cial, at least in a subset of patients, it is also more costly. This raises the question 
regarding the cost-effectiveness of a PET-CT-based follow-up method compared to 
usual follow-up with either repeated chest X-rays or CT scans, or imaging on the 
basis of symptoms. In order to make an evidence-based decision regarding which 
follow-up strategy to prefer, the costs of each strategy are essential to take into 
account. Information regarding cost-effectiveness can be obtained through an eco-
nomic evaluation, in which a comparative analysis is performed of alternative 
courses of action in terms of both their costs and consequences 6, on the basis of 
the currently available evidence. 
To be able to add this information to the decision making process, we performed 
the current economic evaluation to evaluate the cost-effectiveness of PET-CT based 
follow-up as opposed to conventional follow-up in NSCLC patients treated with 
curative (chemo)RT. 
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6.2 Methods and Materials 
Three follow-up strategies were compared with different imaging methods 3 
months after therapy: the “usual” or conventional follow-up (anamnesis, physical 
examination and a chest X-ray), the PET-CT based follow-up (anamnesis, physical 
examination and a PET-CT scan) and the CT based follow-up (anamnesis, physical 
examination and a chest CT scan). After the 3 months post-treatment time-point, 
the follow-up was the same for the different strategies. Details regarding these 
follow-up policies are provided in Table 6.1. Because the results of the prospective 
study implied that the advantage of the PET-CT seems to be confined to the patient 
group without symptoms at the time of the PET-CT scan (55% of patients) 5, we 
additionally examined a strategy where a PET-CT was applied only in the asympto-
matic subgroup. Within this strategy, symptomatic patients did not receive a stan-
dard PET-CT scan, but underwent imaging on the basis of the location of symptoms 
(conform Table 6.1). 
 
Table 6.1 Alternative follow-up strategies 
Follow-up strategy Imaging 3 months 
after RT 
Imaging at follow-up visits after 3 months 
  No recurrence PD, treated PD, not treated 
Usual CXR + on basis of 
symptoms* 
CXR Chest CT none 
CT based Chest CT + on basis of 
symptoms* 
CXR Chest CT none 
PET-CT based PET-CT CXR Chest CT none 
     
*Imaging on basis of symptoms 
Symptoms Diagnostics 
Pain 
Localized 
Diffuse 
 
Conventional radiography of involved region 
Bone scintigraphy 
Dyspnea CXR 
Cough CXR 
Dysphagia Chest CT  
Malaise CXR + screening blood sample 
Neurological CT brain 
Palpable mass CT of involved region 
Fatigue Screening blood sample 
CXR: Chest radiography; PD: progressive disease 
Model structure 
A Markov transition model was constructed with mutually exclusive health states to 
compare long-term costs and effects of the different follow-up strategies (Figure 
6.1) 7. The model simulated the course of events in a hypothetical cohort of NSCLC 
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patients treated with curative RT with or without chemotherapy. Health states in 
the model were based on the absence or presence of progression and on the treat-
ment of progression. Patients without progression were in the health state “no 
evidence of disease”. Patients with progression were subdivided according to their 
treatment: progression without treatment, progression with palliative treatment or 
progression with curative treatment. Patients in the CT based or usual follow up 
strategy, who had progression 3 months after treatment that was only detected 
with PET-CT and not with CT alone, were assigned the health state “progression not 
detected”. The final health state was “death”.  
 
Progression, 
radically 
treated
Progression,
undetected
No evidence of 
disease
Death
Progression 
palliatively 
treated
Progression 
not         
treated
 
Figure 6.1 Markov Model 
A hypothetical cohort of patients enters the model after the follow-up visit 3 months after radical 
(chemo-)RT. Patients are divided over the different health states according to the results of the prospec-
tive study 
 
The start of the model was set after the first follow-up visit 3 months after radical 
therapy. At this time point, patients were divided between the different health 
states on the basis of the results of our prospective study 5. In the model, patients 
moved between health states according to a set of transition probabilities. The cycle 
length of the model was 6 months, with a time horizon of 5 years.  
Data sources 
Input parameters were derived from the prospective study performed at our insti-
tute, published literature, the Dutch Health Insurance Board, and, if no other source 
was available, expert opinion. Details of the prospective study are published else-
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where 5. In short, 100 patients with NSCLC, treated with curative intent with 
(chemo)radiation, were prospectively evaluated. All patients underwent a planned 
FDG-PET-CT scan 3 months after the start of radiotherapy, regardless of the pres-
ence of symptoms. Patients were judged symptomatic when any symptom was 
either new or had increased over time from the end of RT. Twenty-four percent 
(95% CI: 17-33%) of patients had progression 3 months post-treatment. No curative 
treatment could be offered to any of the patients who were symptomatic at the 
time of progression. In 2 of the 55 asymptomatic patients (4%, 95% CI: 1-12%), tu-
mour progression, amenable for curative therapy, was found, which was detected 
with PET, not with CT only. The first patient was treated with re-irradiation for a 
locoregional recurrence, the 2nd patient was treated with adrenal resection for bi-
lateral adrenal metastases. 
Probabilities 
All probabilities are listed in Table 6.2. As the cycle length was 6 months, probabili-
ties of moving from one health state to another were calculated as 6 monthly tran-
sition probabilities. The median age of patients assumed to enter the model was 62 
years, based on the patient characteristics of the prospective study 5. The extra 
mortality risk for surviving lung cancer patients as opposed to the general popula-
tion was 1.4 8, 9. Age-specific mortality rates were used for 5 year age groups (Cen-
tral Bureau for Statistics, 2007). The probability of progression after 3 months was 
calculated on basis of a prospective study of Mac Manus and colleagues (1-, 2-, 3- 
and 4 year progression free survival rates of 62%, 44%, 26% and 20% respectively) 3. 
Patients with progression that was not treated were assumed to have a 1-year 
overall survival (OS) for an OS of 19% 8; patients who were palliatively treated for 
progression were assumed to have a 1 year OS of 30% 9. The 1 year OS for patients 
who were treated with curative intent was assumed to be 45 %, based on published 
results with re-irradiation and adrenal resection 10, 11. Percentages of patients re-
ceiving 2nd and 3rd line chemotherapy were based on a retrospective chart review of 
417 patients with advanced NSCLC 12.  
Costs 
An overview of the costs associated with the follow-up procedures, treatment, and 
terminal care is outlined in Table 6.2. All costs are reported in Euros and converted 
to the year 2008. Future costs and effects were discounted to their present value by 
a rate of 4% and 1.5%, respectively 13. Costs of diagnostic procedures and treatment 
were derived from the Dutch Health Insurance Board, adjusted to the 2007 price 
level (Central Bureau for Statistics 2007). The costs for first line chemotherapy were 
based on 4 cycles of docetaxel 75 mg/m2. Costs of second line chemotherapy were 
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based on treatment with erlotinib during 125 days. Costs associated with side ef-
fects were based on calculations from the National Institute for Clinical Excellence 
14. The costs associated with dying were based on a report of Kommer and Polder 15, 
in which costs associated with cancer death are described separately from costs 
associated with dying from other causes.  
Effects 
Global health-related quality of life (QOL) data were expressed in utility scores, 
varying from zero (death) to one (perfect health). The use of utility scores allows the 
calculation of Quality Adjusted Life Years (QALYs) and cost per QALY ratios. Utility 
scores were derived from a cross-sectional study performed by Trippoli and col-
leagues 16. Based on this study, patients with progression had a utility score of 0.53, 
while patients without progression had a utility score of 0.68. Patients with progres-
sion that was curatively treated were assumed to have the same utility score as 
patients without progression, based on expert opinion (DDR). Furthermore, patients 
that were treated with palliative intent for PD were assumed to have the same util-
ity as patients who received no treatment, on the basis of literature showing no 
significant difference in QOL with the administration of docetaxel 75 mg/m2 as sec-
ond line chemotherapy 17. All utility scores are listed in Table 6.2.  
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Table 6.2 Inputs 
 Estimated value SE Distribution Source 
    
Transition probabilities    
     
First 3 months     
     
Strategy independent probabilities     
     
PD 0.24 0.04 beta [1] 
Symptoms with PD 0.68 0.09 beta [1] 
Symptoms without PD 0.38 0.06 beta [1] 
     
Strategy dependent probabilities     
     
PET-CT     
Detection of symptomatic PD  1 fixed  EO 
Detection of asymptomatic PD  1 fixed  EO 
Treatment of asymptomatic PD 0.63 0.16 beta [1] 
Treatment of symptomatic PD 0.81 0.095 beta [1] 
Radical treatment of asymptomatic PD 0.4 0.2 beta [1] 
Radical treatment of symptomatic PD 0 fixed  [1] 
     
CT     
Detection of symptomatic PD  1 fixed   
Detection of asymptomatic PD  0.5 0.17 beta [1] 
Treatment of asymptomatic PD 0.63 0.16 beta [1] 
Treatment of symptomatic PD 0.81 0.095 beta [1] 
Radical treatment of asymptomatic PD 0 fixed  [1] 
Radical treatment of symptomatic PD 0 fixed  [1] 
     
Usual     
Detection of symptomatic PD  1 fixed  EO 
Detection of asymptomatic PD  0 fixed  EO 
Treatment of asymptomatic PD 0 fixed  [1] 
Treatment of symptomatic PD 0.81 0.095 beta [1] 
Radical treatment of asymptomatic PD 0 fixed  [1] 
Radical treatment of symptomatic PD 0 fixed  [1] 
     
After 3 months     
     
Progression     
Detection of undetected PD 0.8 fixed  EO 
PD, 1st year 0.21 0.036 beta [2] 
PD, 2nd year 0.16 0.036 beta [2] 
PD, 3rd year 0.23 0.036 beta [2] 
PD, 4th year 0.12 0.036 beta [2] 
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Table 6.2 Inputs 
 Estimated value SE Distribution Source 
Treatment     
Radical  0.01 0.02 dirichlet EO 
Palliative 0.56 0.02 dirichlet [3] 
No treatment 0.43 0.02 dirichlet [3] 
     
Death     
Death with PD, no treatment 0.56 0.025 beta [4] 
Death with PD, palliative treatment 0.46 0.025 beta [5] 
Death with PD, radical treatment     
1st year 
2nd year 
3rd year 
0.33 
0.18 
0.02 
0.019 
0.019 
0.019 
beta 
beta 
beta 
[6, 7] 
Death with undetected PD 0.54 0.025 beta EO1 
     
Utility scores     
     
No PD 0.68 0.1 beta [8] 
PD, not treated 0.53 0.1 beta [8] 
PD, palliatively treated 0.53 0.1 beta EO 
PD, radically treated 0.68 0.1 beta EO 
PD, undetected 0.53 0.1 beta [8] 
     
Costs     
     
Diagnostics     
     
First 3 months     
PET-CT whole body 1364 fixed  [9] 
Chest-CT 206 fixed  [9] 
CXR 39 fixed  [9] 
Follow-up visit 59 fixed  [9] 
     
After 3 months2     
Follow-up, No PD3    [9] 
1st year 
2nd year 
3rd+ year 
196 
98 
49 
fixed  [9] 
Follow-up, PD     
Treated4 529 fixed  [9] 
Untreated5 118 fixed  [9] 
     
Treatment     
     
Probability of 2nd line chemotherapy 0.47   [3] 
Probability of palliative RT 0.18 0.018 beta [10] 
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Table 6.2 Inputs 
 Estimated value SE Distribution Source 
Unit costs     
     
Radical6 5746 fixed  [1, 9] 
Palliative chemotherapy    
1st line7 
No of cycles 
Costs/cycle 
Side effects 
Total costs 
2nd line8 
Mean treatment time (days) 
Costs/treatment 
Side effects 
Total costs 
 
4 
1302 
349 
5557 
 
125 
9100 
120 
9220 
 
 
 
 
fixed 
 
 
 
 
fixed 
  
[5] 
[9] 
[11] 
 
 
[9] 
[9] 
[11] 
 
Palliative RT 1017 fixed  [9] 
     
Dying     
Dying of cancer, terminal care9 11602 800 gamma [12] 
Dying of other causes 15448 800 gamma [12] 
 
EO: expert opinion; CXR: Chest X-ray; RT: radiotherapy; DHIB: Dutch Health Insurance Board 
1 Calculated from the probability of dying with a recurrence without treatment and with palliative 
treatment 
2 Costs per 6 monthly cycle 
3 Based on follow-up visit with CXR, 4 times in 1st year, twice in 2nd year and once a year thereafter 
4 Based on follow-up visit with chest-CT, 4 times/year 
5 Based on follow-up visit without imaging, 4 times/year 
6 Based on type of radical treatment in prospective study, being adrenal resection and radical 
radiotherapy  
7 Docetaxel, 3-weekly cycles  
8 Erlotinib 
9 The costs of dying from cancer described in Kommer et al. were discounted by the costs of palliative 
treatment calculated in the current study 
 
Sources:  
1. van Loon, J., et al., Follow-up with 18FDG-PET-CT after radical radiotherapy with or without 
chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung 
cancer patients: a prospective study. Eur J Cancer, 2009. 45(4): p. 588-95. 
2. Mac Manus, M.P., et al., Metabolic (FDG-PET) response after radical radiotherapy/chemo-
radiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer, 2005. 
49(1): p. 95-108. 
3. Murillo, J.R., Jr. and J. Koeller, Chemotherapy given near the end of life by community oncologists for 
advanced non-small cell lung cancer. Oncologist, 2006. 11(10): p. 1095-9. 
4. Shepherd, F.A., et al., Prospective randomized trial of docetaxel versus best supportive care in 
patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J 
Clin Oncol, 2000. 18(10): p. 2095-103. 
5. Hanna, N., et al., Randomized phase III trial of pemetrexed versus docetaxel in patients with non-
small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 2004. 22(9): p. 1589-97. 
6. Khan, A.J., et al., Long term disease-free survival resulting from combined modality management of 
patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol, 
2006. 81(2): p. 163-7. 
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7. Tanvetyanon, T., et al., Outcomes of adrenalectomy for isolated synchronous versus metachronous 
adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin 
Oncol, 2008. 26(7): p. 1142-7. 
8. Trippoli, S., et al., Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life 
Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics, 2001. 19(8): p. 
855-63. 
9. Oostenbrink J, B.C., Koopmanschap M, Rutten F, Handleiding voor kostenonderzoek, methoden en 
standaard kostprijzen voor economische evaluaties in de gezondheidszorg, C.v. Zorgverzekeringen, 
Editor. 2004. 
10. Tyldesley, S., et al., Estimating the need for radiotherapy for lung cancer: an evidence-based, 
epidemiologic approach. Int J Radiat Oncol Biol Phys, 2001. 49(4): p. 973-85. 
11. NHS, Nice guideline costing statement: Erlotinib for the treatment of NSCLC. 2008, National Institute 
for Clinical Excellence 
12. Kommer G, S.L., Polder J., Risicosolidariteit en Zorgkosten, Quantes, Editor. 2005, Raad voor de 
Volksgezondheid en Zorg: Zoetermeer 
Cost-effectiveness analysis 
The analysis was performed from a health care perspective. The cost-effectiveness 
of the different follow-up strategies was compared using incremental cost-
effectiveness ratios (ICERs), calculating the incremental costs per QALY gained. 
Whether a follow-up strategy is deemed cost-effective depends on how much the 
society is willing to pay for a gain in effect, which is referred to as the ceiling ratio. 
The Dutch Health Council advises an informal ceiling ratio of € 80.000 18.  
The input parameters of the model are inevitably associated with uncertainty. Prob-
abilistic modelling is used to reflect this uncertainty in the parameters and to de-
scribe the effects on uncertainty over the outputs of interest 19. Distributions to the 
model parameters, based on their mean value and standard error, were assigned to 
reflect the uncertainty in the estimation of that parameter (Table 6.2) 20. A probabil-
istic sensitivity analysis was performed using Monte Carlo simulation with 5,000 
random iterations from the assigned distributions. To illustrate the results of the 
simulation, cost-effectiveness acceptability curves (CEACs) were calculated to char-
acterize the likelihood that a certain follow-up strategy would be deemed cost-
effective at different ceiling ratios 19, 21, representing the uncertainty surrounding 
the cost-effectiveness for this range of thresholds. 
Expected Value of Perfect Information 
As uncertainty exists, there is always a chance that the ‘‘wrong’’ decision will be 
made 19, 22. In this case, society would suffer a loss as a consequence. The decision 
to reduce the chance of a wrong decision by performing additional research in-
volves balancing between the costs of acquiring more information with the value 
associated with it. The EVPI (expected value of perfect information) is the expected 
value of obtaining perfect knowledge of the ‘‘true’’ values of all parameters. We 
calculated the total EVPI by subtracting the net monetary benefit of the follow-up 
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strategy we would choose under conditions of uncertainty, from the net monetary 
benefit of the optimal decision we would make if we knew the ‘‘true’’ parameter 
values. The population EVPI was then calculated by multiplying the EVPI per patient 
by the number of patients that could potentially benefit from additional research. In 
the present study, this is the total number of patients with inoperable NSCLC treated 
with curative intent with (chemo)RT. We estimated that of the 1.35 million lung can-
cer patients per year, of whom 80% have NSCLC, 30% are amenable for curative 
(chemo)RT, being a total of 1,5 million patients worldwide in the next 5 years. 
6.3 Results 
Cost effectiveness of different follow-up strategies 
Results of the analysis regarding the cost-effectiveness of the different follow-up 
strategies are presented in Table 6.3A. With regard to PET-CT based follow-up, the 
additional costs per extra curatively treated patient were € 64.096 compared to 
conventional follow-up. The ICER (incremental cost-effectiveness ratio) for PET-CT 
based follow-up was € 69.086 per QALY gained compared to conventional follow-
up. Although CT-based follow-up was less costly, it was also less effective than PET-
CT based follow-up, resulting in an ICER of € 264.033 per QALY gained.  
Figure 6.2 shows cost-effectiveness acceptability curves for the 3 follow-up strate-
gies. The figure shows that there is considerable uncertainty regarding which follow-
up strategy is deemed cost-effective around the informal threshold of the Dutch 
Health Council. Given this ceiling ratio of € 80.000 18, PET-CT based follow-up and 
conventional follow-up had a similar probability of being cost-effective (48% and 
47%, respectively), while the probability of CT-based follow-up being cost-effective 
was only 5% (Figure 6.2). 
Cost-effectiveness of a follow-up strategy with a PET-CT in the asymptomatic 
subgroup 
The same analysis was performed, but a PET-CT scan was now only performed in 
patients who were asymptomatic 3 months after treatment (55% of patients) (Table 
6.3B). Symptomatic patients received imaging on the basis of the location of symp-
toms. The usual follow-up strategy and CT-based follow-up strategy remained the 
same. Performing PET-CT based follow-up only in the asymptomatic subgroup had 
no influence on the effects, but reduced the costs per patient from €15.265 to 
€14.767. Hence, this strategy resulted in a lower ICER of € 42.265 per QALY gained 
as opposed to conventional follow-up. With this strategy, PET-CT based follow-up 
had the highest probability of being cost-effective (73%) compared to conventional 
follow-up (27%) at a ceiling ratio of € 80.000 Figure 6.3).  
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Table 6.3 Cost-effectiveness of different follow-up strategies 
Follow-up strategy Expected 
costs/patient in €
(95%CI*) 
 
Expected survival 
in months 
(95%CI) 
Expected 
QALYs 
(95%CI) 
ICER** 
A) Whole group    
Conventional 13.983  
(12.783-15.156) 
24 (22-27) 1.28 (0.98-1.58)  
CT-based follow-up 14.269  
(13.076-15.441) 
24 (22-27) 1.28 (0.99-1.59) 264.033 
PET-CT-based follow-up 15.266 
 (14.072-16.440) 
25 (22-28) 1.30 (1.00-1.61) 69.086 
B) Asymptomatic patients only    
Conventional 13.983  
(12.805-15.162) 
24 (22-27) 1.28 (0.98-1.58)  
CT-based follow-up 14.269  
(13.101-15.444) 
24 (22-27) 1.28 (0.99-1.59) 264.033 
PET-CT-based follow-up 14.768  
(13.584-15.952) 
25 (22-28) 1.30 (1.00-1.61) 42.265 
QALY: Quality Adjusted Life Year; ICER: Incremental Cost Effectiveness Ratio 
*95% Confidence Intervals (CI) based on probabilistic analysis 
**Expressed in €/QALY gained compared to conventional follow-up 
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Figure 6.2 Cost-effectiveness acceptability curve (CEAC) for the strategy in which a PET-CT is performed 
in all patients 
The probability of cost-effectiveness of a certain follow-up strategy is plotted against the willingness to 
pay per quality adjusted life year (QALY) gained 
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Figure 6.3 Cost-effectiveness acceptability curve (CEAC) for the strategy in which a PET-CT is performed 
in asymptomatic patients only  
The probability of cost-effectiveness of a certain follow-up strategy is plotted against the willingness to 
pay per quality adjusted life year (QALY) gained  
Expected value of perfect information 
In the current analysis, the uncertainty surrounding the decision whether or not to 
implement PET-CT based follow-up resulted in an EVPI of € 282 per person, given a 
ceiling ratio of € 80.000. Implementing PET-CT based follow-up affects all patients 
with locally advanced NSCLC, treated with curative (chemo)RT, involving a total of 
1,5 million patients worldwide in the next 5 years. This makes the population EVPI 
( ) 290105.1 6 ∗∗  = € 423 million, meaning that perfect information on this topic is 
worth € 423 million.  
The EVPI for the implementation of PET-CT based follow-up only in the subgroup of 
asymptomatic patients was € 83 per person, given a ceiling ratio of € 80.000. The 
population EVPI for this strategy was € 125 million. The population EVPI for differ-
ent ceiling ratios, both for the total group and for the asymptomatic subgroup, is 
presented in Figure 6.4.  
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Figure 6.4 Expected Value of Perfect Information (EVPI) 
The expected value of perfect information at different ceiling ratios. 
Total group: EVPI for the strategy in which a PET-CT is performed in all patients. 
No symptoms: EVPI for the strategy in which a PET-CT is performed in asymptomatic patients only 
6.4 Discussion 
Until now, no imaging procedure has become standard in the follow-up of NSCLC, 
mainly because of the fact that progression or recurrence is mostly detected at a 
stage that no curative treatment is possible, and hence, no survival benefit can be 
expected 23. Our recent prospective study on a single 18FDG-PETscan 3 months post-
therapy confirmed the hypothesis that this imaging modality, in contrast to CT 
alone, is able to detect progression amenable for curative treatment in a small per-
centage of patients. The question remained, however, whether this potential bene-
fit for the individual patient outweighs the increased costs 24. 
The current economic evaluation shows that performing a PET-CT scan 3 months 
after curative (chemo-)RT is a potentially cost-effective follow-up method, and is 
more cost-effective than CT alone. Performing a PET-CT scan only in the subgroup of 
asymptomatic patients is probably as effective and more cost-effective.  
 
Chapter6
C H A P T E R  6  
 104 
Inherently to the design of the study, there are some limitations that need to be 
addressed. Firstly, the current results are surrounded by considerable uncertainty, 
caused by uncertainty in the input parameters of the model. One important cause is 
the relatively small patient population (N=100) in the prospective study, from which 
the extent of the potential benefit of PET-CT was derived 5. This economic evalua-
tion aimed however, to base the decision regarding which follow-up strategy is to 
be preferred on the currently available evidence. Decisions will have to be made 
anyway, so it is better to support the decision with the available evidence including 
its uncertainties than doing something without any evidence at all 25. Using deci-
sion-analytic modelling we were able to incorporate this uncertainty in the model 
by assigning distributions to the model parameters. The incorporation of uncer-
tainty also makes results easier to interpret by decision makers, as one can calculate 
which strategy has the highest probability of being cost-effective at different ceiling 
ratios (Figure 6.2 and Figure 6.3). The EVPI analysis shows us to what extent reduc-
tion of uncertainty by performing additional research is worthwhile. The value of 
totally eliminating uncertainty of the input parameters of the model was € 435 mil-
lion, for a ceiling ratio of € 80.000, implying that additional research on this subject 
is of great value and outweighs the associated costs.  
Secondly, the threshold (also referred to as the ceiling ratio) below which a certain 
strategy is considered cost-effective is arbitrary and differs between countries. In 
the current analysis, a threshold of € 80.000 (informal ceiling ratio of the Dutch 
Health Council) was used. Thresholds reported in literature range from € 35.000 ($ 
50.000) to € 210.000 ($ 300.000) 24, 26, 27. With a higher ceiling ratio, the probability 
that the PET-CT based follow-up strategy is cost-effective becomes higher, while the 
usual follow-up strategy has the highest probability of being cost-effective at lower 
ceiling ratios. Hence, whether a strategy is deemed cost-effective depends on how 
much the society is willing and able to pay for a gain in effect.  
Thirdly, the use of a model to estimate costs and effects is always associated with a 
simplification of reality 25. In the current analysis, we have chosen to compare the 
PET-CT based follow-up method with two follow-up strategies most commonly used 
according to the guidelines of the different institutions 1. Furthermore, in the 
model, the difference between the 3 strategies was based upon different imaging 
only at one time point during follow-up, i.e. 3 months after curative treatment. This 
time point was chosen based on the prospective study which showed a possible 
advantage of PET over CT in detecting potentially curable progression at 3 months 
after treatment and because a PET scan performed at this interval has shown to be 
prognostic of outcome2, 4. In none of the patients in the prospective study, addi-
tional investigations were requested to confirm the findings of the PET-CT scan. 
Hence, in the current economic evaluation, no costs were calculated to take into 
account false positive findings in the PET-CT strategy. No costs were calculated for 
false positive findings in the usual and CT-based follow-up strategy either, minimiz-
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ing the chance of overestimating the cost-effectiveness of PET-CT. Another draw-
back of the limitation to one time-point is that the potential gain of repeated imag-
ing with e.g. chest CT scans cannot be derived from this study. The available litera-
ture however, does not confirm a benefit of repeated CT-scanning in the follow-up 
28. A definitive answer regarding the value of CT based follow-up can be expected 
from a multicentre phase III trial which is currently ongoing in France, in which con-
ventional follow-up with chest X-rays is compared with an intensive follow-up strat-
egy with repeated chest CT scans in NSCLC patients after curative resection 29. 
 
The performed economic evaluation is aimed to guide decision making regarding 
which strategy to choose, and is not intended to reveal scientific truth 20. On the 
basis of the currently available evidence, however, the following conclusions can be 
drawn: Firstly, performing a chest CT scan in the follow-up is less cost-effective than 
performing a PET-CT scan 3 months after treatment. Hence, if any imaging is wished 
to be performed for treatment evaluation, one would prefer to perform a PET-CT 
scan 3 months after therapy above CT alone. Secondly, irrespective of the question 
whether certain imaging is cost-effective, the final decision to perform the test 
depends on what the society can afford 24. Finally, the results show that it is worth-
while to perform additional research to reduce the uncertainty surrounding the 
decision whether to implement PET-CT in the follow-up, including questions regard-
ing the time-point and frequency and what the additional financial burden is. 
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Abstract 
Background and purpose 
Non-invasive PET imaging of tumour hypoxia could help in the selection of patients 
who could benefit from chemotherapy or radiation with specific anti-hypoxic treat-
ments such as bioreductive drugs or hypoxic radio-sensitizers. In this phase I trial, 
we aimed to determine the toxicity of [18F]HX4, a member of the 2-nitroimidazole 
family, at different dose levels. The secondary aim was to analyze image quality 
related to the HX4 dose and the timing of imaging.  
Methods and Materials 
Patients with a histologically proven solid cancer without curative treatment options 
were eligible for this study. A study design with two dose-steps was used in which a 
single dose of a maximum of 222 MBq (step 1) or 444 MBq (step 2) [18F]HX4 was 
injected. Toxicity was scored on day 0 and on days 3 and 7 after injection, according 
to the CTCAE 3.0 scoring system. PET-CT images of the largest tumour site were 
acquired 30, 60 and 120 minutes after injection.  
Results 
Six patients with stage IV carcinomas were included: four with non-small cell lung 
carcinoma, one with thymus carcinoma and one with colon carcinoma. No toxicity 
was observed in any of the patients at either dose level. The median tumour to 
muscle ratio 120 minutes after injection was 1.40 (range: 0.63-1.98).  
Conclusions 
The findings of this study show that [18F]HX4 PET imaging for the detection of hy-
poxia is not associated with any toxicity. Imaging was successful; however, future 
trials are needed to determine the optimal image parameters. 
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7.1 Introduction 
Tumour hypoxia is an important marker of cancer prognosis, being associated with 
aggressive growth, metastasis, and resistance to anticancer therapy 1. Non-invasive 
PET imaging with hypoxia-specific 2-nitro-imidazoles has the ability to quantify tu-
mour hypoxia and could help in the selection of those patients who could benefit 
from chemotherapy or radiation with specific anti-hypoxic treatments such as bio-
reductive drugs or hypoxic radio-sensitizers 2. Furthermore, in contrast to invasive 
electrode measurements, PET imaging provides the opportunity to display the spa-
tial distribution of hypoxia, which is essential for its integration with radiation dose 
distribution. [18F]Fluoromisonidazole ([18F]FMISO) is the first radiolabelled 2-
nitroimidazole derivative proposed for hypoxia imaging with PET 3, 4. The relatively 
low uptake of [18F]FMISO observed in hypoxic lesions coupled with its slow clear-
ance from normoxic tissue however, limits the clinical potential of this agent 5. A 
number of other 18F-labelled nitroimidazole derivatives have been identified, inves-
tigated and reported to overcome these problems 6, 7.  
 
The 2-nitroimidazole nucleoside analogue, 3-[18F]fluoro-2-(4-((2-nitro-1H-imidazol-
1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol ([18F]HX4), was developed as a poten-
tial marker and radio-sensitizer for hypoxic tumour cells. Because of better water 
solubility and faster clearance, we expect that [18F]HX4 has better pharmacokinetic 
properties than currently used nitroimidazole hypoxia markers such as [18F]FMISO. 
In this phase I trial, we aimed to determine the toxicity of [18F]HX4 at different dose 
levels, with the secondary aim of analyzing image quality in relation to the HX4dose 
and timing of imaging.  
7.2 Methods and Materials 
Patient inclusion 
Patients with a histologically or cytologically confirmed stage IV solid cancer at any 
site, primary or secondary, without curative treatment options, were eligible. Pa-
tients were required to have a WHO performance status of 0 to 1, normal white 
blood cell count and differential, normal platelet count and no anaemia requiring 
blood transfusion or erythropoietin. Additional eligibility criteria were adequate 
hepatic function; adequate renal function (calculated creatinine clearance at least 
60 ml/min); no administration of 18F in the previous 24 hours; and a minimum age of 
18 years. Patients with a recent (< 3 months) myocardial infarction, uncontrolled 
infectious disease, pregnancy, or concurrent treatment with anti-cancer agents or 
radiotherapy were excluded.  
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Approval for the study protocol (NCT00690053) was obtained from the medical 
ethics committee and the radiation safety committee. All patients gave written 
informed consent. 
Study design 
A study design with two dose steps was used (Figure 7.1). In step 1, a single dose of 
up to 222 MBq [18F]HX4 was injected, and in step 2 a single dose of up to 444 MBq 
was injected. Six patients were included, three in each dose step. If in any patient a 
toxicity of grade 2 or more was observed, three more patients were included in this 
dose step. If another toxicity of grade 2 or more occurred in one or more of these 
three patients, the study would be stopped. If no more than one of six patients 
experienced grade 2 toxicity, the step was considered safe. 
 
Synthesis of [18F]HX4 
[18F]HX4 was synthesized from the HX4 precursor in a two-step process (Figure 7.2). 
The product obtained was purified and formulated into a sterile and pyrogen-free 
solution, suitable for use in humans. The radiochemical purity was required to be 
 
Dose step 1
Dose step 2
Incurable solid 
tumour,   
eligible
Toxicity ≥G2 
in 0 patients
3 patients 
step 1
Step 2
Toxicity≥G2 
in 1 or more 
patients
3 more 
patients  step 
1*
Step 1 
considered safe
Toxicity ≥G2 
in 0 patients
3 patients 
step 2
Step 2 
considered 
safe
Toxicity ≥G2 
in 1 or more 
patients
3 more 
patients  step 
2*
 
Figure 7.1 Flowchart of the study  
* If toxicity of grade 2 or more was observed in none of these patients, the step was considered safe. If
toxicity of grade 2 or more was observed in one or more patients, the study was stopped 
H Y P O X I A  P E T  U S I N G  [ 1 8 F ] H X 4  
 115 
higher than 95% in every batch. The specific radioactivity of [18F]HX4 exceeded 14.8 
MBq/μmol. The radiopharmaceutical was produced at the government-licensed 
GMP-compliant (EMEA Eudralex 4) radiopharmaceutical production facility of the 
Department of Nuclear Medicine and PET Research of the VU University Medical 
Centre (license number 108897F). 
 
 
Figure 7.2. Synthesis of [18F]HX4 
The precursor was supplied by Siemens Molecular Imaging (Erlangen, Germany). The first step incorpo-
rates a nucleophilic substitution of radioactive fluorine (in the form of 18F) onto the precursor material, 
yielding the fluorinated intermediate which is then hydrolyzed to obtain the active drug product 
PET-CT imaging 
PET-CT images of the largest tumour site were acquired 30, 60 and 120 minutes 
after injection. Imaging at later time-points after injection was deliberately avoided 
to minimize the burden of the study in these patients with advanced stage disease. 
Images were acquired with the patient in the supine position. CT and PET images 
were automatically registered based on mutual information and were subsequently 
fused using dedicated software (TrueD, version VC50; Siemens Medical, Erlangen, 
Germany).  
The tumour was delineated on the CT scan by the same observer (JvL). The location 
of the [18F]HX4 uptake and the SUVmax (maximal standardized uptake value) were 
determined within the delineated tumour using a gradient-based method which 
was implemented in the software. Tumour to muscle ratios (TMR) for [18F]HX4 up-
take were calculated at all time-points by dividing the tumour SUVmax by the skeletal 
muscle SUVmax. The skeletal muscle SUVmax was determined by calculating the aver-
age SUVmax in two circular regions of interest drawn in the paraspinal muscles.  
In patients in whom an [18F]FDG-PET scan was performed for diagnostic purposes 
during the week before or after the [18F]HX4 scan, uptake of [18F]FDG and [18F]HX4 
was compared. The location of the [18F]FDG uptake was determined using auto-
mated SUV-thresholding with the threshold depending on the tumour-to-
background signal ratio (SBR-method) 8. 
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Toxicity scoring 
Toxicity was scored on day 0 and days 3 and 7 after injection, according to the 
CTCAE (Common Terminology Criteria for Adverse Events) version 3.0 scoring sys-
tem. Blood was sampled before injection and at each control point, and tests in-
cluded haematology and kidney and liver function. Due to the relatively short physi-
cal half-life of 18F (110 min) and biological half-life of HX4 (less than 3 hours), after 1 
day the radio-activity of both the drug and its metabolites have disappeared and no 
additional toxicity from the radiation is expected.  
The timeline for each patient entering the study is illustrated in Figure 7.3.  
 
0 3 7 days
PET/CT imaging:
30, 60 and 120 min after injection
Toxicity scoring:
WHO performance status
Symptoms according to CTCAE 3.0
Blood pressure, hart rate
Concomitant medication 
Blood sampling: Glucose, Na, K, Ca, Cl, creatinin, total protein, albumin,                                              
liver function, haematology
Injection [18F]HX4:
222 MBq (step 1)
444 MBq (step 2)
 
Figure 7.3 Time line of the study 
CTCAE 3.0: Common Terminology Criteria for Adverse Events, version 3.0 
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7.3 Results 
Patient characteristics 
Six patients, with a median age of 63 years (range: 54-68), were included. The pa-
tient characteristics are shown in Table 7.1. 
 
Table 7.1 Patient characteristics 
 Age Sex Length Weight WHO* Primary tumour Prior therapy 
      Site Histology  
1 67 f 1.58 58 1 Lung Adenocarcinoma Chemotherapy, 
radiotherapy 
brain 
2 54 f 1.76 64 0 Lung Adenocarcinoma Chemotherapy 
3 58 m 1.79 82 0 Thymus Carcinoid Surgery, radio-
therapy 
4 62 m 1.90 80 1 Lung Adenocarcinoma Surgery, chemo-
therapy, radio-
therapy 
5 63 f 1.70 70 1 Lung Squamous cell 
carcinoma 
Surgery, chemo-
therapy 
6 68 m 1.68 80 0 Colon Adenocarcinoma Surgery, chemo-
therapy 
*World Health Organisation performance status 
 
All patients had a stage IV carcinoma: four had a non-small cell lung carcinoma, one 
had a thymus carcinoma and one patient a colon carcinoma. Three patients had 
stage IV disease at primary diagnosis, while the other had developed metastases 
after therapy with curative intent. All patients had previously undergone anti-cancer 
therapy. Two patients were unable to undergo the last scan at 120 minutes after 
injection due to pain (not drug-related). 
Toxicity 
Results of the toxicity scoring are shown in Table 7.2. No toxicity according to the 
CTCAE 3.0 criteria was observed at any time-point in the first three patients in-
cluded in dose step 1. Hence, it was considered safe to continue with dose step 2. 
Again, no toxicity was observed in any of the three patients. One patient reported 
mild transient headache (grade 1) the day after the [18F]HX4 injection, which was 
considered unlikely to be related to the injection.  
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Table 7.2 Toxicity scoring 
Pt Injected 
activity (MBq) 
Vital 
signs* 
 
Toxicity scoring** 
 
Medication* 
 
   Haematology Liver 
function 
Renal 
function 
Symptoms  
1 222 0 0 0 0 0 0 
2 222 0 0 0 0 0 0 
3 222 0 0 0 0 0 0 
4 444 0 0 0 0 1*** 0 
5 444 0 0 0 0 0 0 
6 444 0 0 0 0 0 0 
Toxicity was scored before study entry (baseline) and on days 0, 3, and 7 of the study. The blood test 
results were compared with those at baseline and evaluated by the physician 
*Every change in vital signs or medication compared to the baseline values was scored, with “0” 
indicating no change 
**Grade according to the CTCAE version 3.0 
***Mild headache, not related to the 18F[HX4] administration 
Image analysis 
Images of two patients at 120 minutes after injection are presented in Figure 7.4. 
They show a heterogeneous uptake of [18F]HX4 throughout the tumour. The median 
TMR at 30, 60 and 120 minutes after injection was 1.17 (range: 0.20-1.83), 1.25 
(range: 0.25-1.67) and 1.40 (range: 0.63-1.98). In two of four patients in whom im-
ages were available at 120 minutes after injection a considerable increase was seen 
in the TMR compared to 60 minutes after injection.  
In three patients an [18F]FDG-PET scan performed during the week before or after 
the [18F]HX4-PET scan was available. In these three patients, there was a good corre-
lation between the uptake of FDG and [18F]HX4, as shown in Figure 7.5. 
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Figure 7.4 [18F]HX4 images of 2 patients 
a), b) Patient 4, TMR=1.35; a) coronal, b) transversal images 
c), d) Patient 5, TMR=1.98; c) coronal, d) transversal images 
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Figure 7.5 Correlation between the uptake of [18F]HX4 and 18FDG (patient 5) 
FDG-uptake in the tumour was delineated using automated SUV-thresholding depending on the tumour-
to-background signal ratio. The HX4 positive regions in the tumour were delineated using gradient-based 
image analysis 
a) 18FDG -PET-CT images, axial view; b) 18FDG -PET-CT images, coronal view 
c) [18F]HX4-PET-CT images, axial view; d) [18F]HX4-PET-CT images, coronal view 
7.4 Discussion 
Preclinical experience gained with [18F]HX4 and unlabelled HX4 did not indicate any 
adverse events at the dose levels used in these exploratory trials. The current phase 
I trial confirmed these preclinical data, with no toxicity according to the CTCAE 3.0 
criteria observed in any of the patients. The time curves of the TMR showed a large 
divergence between the patients. In two patients, a substantial increase in the TMR 
was seen in the second hour after injection, indicating that the optimal TMR for 
imaging may be at later time points. In the three patients in whom an 18FDG-PET 
scan was available, a good correlation was found between the hypoxic areas imaged 
with HX4 and the areas of high FDG uptake. This is consistent with the often ob-
served relationship between tumour hypoxia and FDG uptake 9, 10. 
 
From the imaging perspective, there were some limitations inherent in the study 
design. Firstly, the imaging was limited to 120 minutes after injection. This time 
horizon was chosen to limit the burden on the patients, who were all suffering from 
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end-stage disease. Future studies, with the final aim of adapting treatment accord-
ing to hypoxia, will be performed in patients with earlier stage disease, in whom 
imaging at later time points would be acceptable. Secondly, only static PET imaging 
was performed. Hence, no correction could be made for heterogeneity in tumour 
perfusion. With kinetic imaging, tumour perfusion can be measured, thereby offer-
ing the opportunity to differentiate between differences in delivery of [18F]HX4 and 
differences in pO2 within the same tumour 
4. Finally, in order to allow radiotherapy 
dose distribution within the tumour on the basis of hypoxia, the stability of hypoxic 
regions within the tumour before and at different time-points during chemo- and 
radiotherapy should be assessed.  
7.5 Conclusion 
The results presented show that [18F]HX4 PET imaging is not associated with any 
toxicity. Future trials are needed to determine optimal imaging conditions, with the 
final aim of developing adaptive treatment strategies based on [18F]HX4-imaged 
hypoxia.  
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Abstract 
Background and Purpose 
Non invasive PET imaging of cetuximab uptake could help to select patients with the 
highest chance of benefit from this treatment. Cetuximab labelled with Zirconium-
89 is a promising new conjugate to determine tumour uptake of cetuximab, which 
has been tested in pre-clinical animal models with excellent results (Aerts et al, J 
Nucl Med 2009).  
In this trial (NCT00691548), we aimed to determine the toxicity of 89Zr-cetuximab in 
incurable cancer patients, with tumour visualization as a secondary aim. 
Methods and Materials 
The safety of two different dose schedules was tested. In step 1, the toxicity of two 
consecutive low radioactivity doses of 89Zr-cetuximab (60 MBq) was investigated. In 
step 2, the toxicity of a single larger dose (120 MBq) was investigated. Labelled 
cetuximab administration was preceded by a standard loading dose of unlabelled 
cetuximab. Toxicity was scored twice weekly up to 14 days after injection, according 
to the CTCAE 3.0 scoring system and with blood tests for haematological and 
liver/kidney function. Total body PET-CT scans were acquired on day 4, 5 and 6 (step 
1) and 5, 6, 7 (step 2) post injection. Images were analyzed using dedicated soft-
ware. 
Results 
Seven patients with a histologically proven solid tumour without curative treatment 
options were included. One patient was excluded before administration of the stud-
ied drug because of hypertension during the administration of unlabelled cetuxi-
mab. Six patients had NSCLC, whereas 1 patient had a tonsillar carcinoma. Five of six 
patients who completed the study experienced skin toxicity. No additional toxicity 
was associated with the administration of 89Zr-cetuximab. The maximal tumour to 
blood ratio (TBR) observed was 1.6. In general, the most optimal TBR was found at 
later imaging time points (day 6 and day 7). 
Conclusions 
No additional toxicity was observed for 89Zr-cetuximab administration. 89Zr-
cetuximab is thus safe to be implemented in immuno-PET studies guiding cetuximab 
therapy.  
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8.1 Introduction 
Monoclonal antibodies are increasingly used in oncology as a mean to specifically 
target receptors at the surface of tumour cells that are associated with tumour 
aggressiveness, such as proliferation, hypoxia and angiogenesis. Cetuximab is a 
monoclonal antibody that blocks the Epidermal Growth Factor Receptor (EGFR). The 
EGFR is a transmembrane glycoprotein which is commonly expressed in many nor-
mal human tissues. It is a member of the tyrosine kinase family of growth factor 
receptors and is overexpressed in many human malignancies 1, 2. EGFR is activated 
upon ligand binding to the extracellular domain, which results in the induction of a 
signal transduction pathway that cascades many cellular operations concerning cell 
growth and division. EGFR activation and overexpression appear to be important 
tumour cell mechanisms in the development of resistance to radiation and chemo-
therapy in epithelial cancers, with decreased rates of local tumour control and sur-
vival 3-7.  
 
Cetuximab specifically binds to the EGFR with high affinity, internalising the recep-
tor and thus effectively blocking ligand-induced EGFR phosphorylation. It is a very 
promising drug to combine with radiotherapy alone or with concurrent chemo-
radiation, as it has shown to improve local tumour control without enhancing the 
toxicity of radiotherapy or chemotherapy 8, 9. It plays currently a role as part of the 
standard treatment for a variety of cancers, including colorectal cancer and 
squamous cell carcinoma of the head and neck. The selection of patients with the 
highest chance of benefit from cetuximab treatment is of obvious relevance, also in 
view of its high costs. As no direct relationship has been observed between EGFR 
expression determined with immunohistochemistry and response to cetuximab 
treatment, EGFR status of the primary tumour cannot be used as a selection crite-
rion. As the expression of EGFR can be induced by radiation and chemotherapy, it is 
possible that an initially EGFR-negative tumour may become positive early during 
therapy, thereby still benefiting from cetuximab treatment 10-12. On the other hand, 
EGFR expressing tumours will not respond to cetuximab when cetuximab does not 
reach therapeutic concentrations in the tumour because of e.g. interstitial pressure 
and vascular perfusion changes in the micro-environment of the tumour or the 
surrounding tissues. In this regard, non-invasive visualization and quantification of 
tumour uptake of cetuximab with positron emission tomography (PET) before and 
during therapy could contribute significantly to patient selection and determination 
of the needed dosage 13.  
 
As the biologic half-life of cetuximab in the blood is 70-100 hours, a positron emitter 
with a long half-life is needed to visualize its uptake. Zirconium-89 (89Zr), a positron 
emitter with a half life of approximately 78 hours, can successfully be coupled to 
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cetuximab and has shown excellent results in preclinical animal models 14. In the 
preclinical study, tumour cell lines with varying EGFR expression levels were used 
for in vivo imaging experiments. PET with 89Zr-labeled cetuximab was performed on 
tumour-bearing NMRI-nu mice at several time points after injection and uptake was 
quantified within regions of interest on selected tissues. Uptake of 89Zr-labeled 
cetuximab was demonstrated in the EGFR-positive tumours. Furthermore, it was 
shown that indeed, levels of EGFR expression did not correlate with 89Zr-cetuximab 
uptake, implying that pharmacokinetic and -dynamic factors influence the cetuxi-
mab distribution in the tumour 14.  
Here, we report the results of a phase I study to determine toxicity of Zirconium-89 
labelled cetuximab in incurable cancer patients, with tumour visualisation as a sec-
ondary end point.  
8.2 Methods and Materials 
Patient selection 
Patients with a histologically or cytologically confirmed solid cancer at any site with-
out curative treatment options were eligible. Inclusion criteria were as follows: 
WHO performance status 0 to 2; adequate bone marrow, hepatic and renal function 
(calculated creatinine clearance at least 60 ml/min); life expectancy > 3 months and 
written informed consent to the study. Patients with a recent (< 3 months) myocar-
dial infarction, uncontrolled infectious disease, pregnancy, previous administration 
of cetuximab or concurrent treatment with anti-cancer agents or radiotherapy were 
excluded. EGFR expression and mutation status as well as k-ras mutation were as-
sessed for the primary tumour.  
The study protocol (NCT00691548) was approved by the medical ethical committee 
and the radiation safety committee (MECazM 083039.7 and 2008-8, respectively). 
Study design 
A two dose-step study design was used, graphically represented in Figure 8.1. The 
study design anticipated on the future aim, which is to determine the tumour up-
take of 89Zr-cetuximab before and during therapy. Therefore, in step 1, the toxicity 
of two consecutive low doses of 89Zr-cetuximab was investigated. A standard load-
ing dose of 400 mg/m2 of cetuximab was administered, followed by administration 
of the cetuximab labelled with 89Zr (60 MBq) on day 0. The second injection on day 
14 consisted of a dose of 250 mg/m2 of cetuximab, followed by cetuximab labelled 
with 60 MBq 89Zr.  
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As a larger radioactivity dose of 89Zr is possibly needed to obtain the best image 
quality, the toxicity of a single larger dose of 89Zr-cetuximab was investigated in step 
2. A loading dose of 400 mg/m2 of cetuximab was administered in 3 patients, fol-
lowed by administration of the cetuximab labelled with 120 MBq 89Zr. 
 
*
28
Injection Zr-cetuximab
400 mg/m2, 60 MBq
Injection Zr-cetuximab
250 mg/m2, 60 MBq
day 0 7 14 21
Step 1
day 0 7 14 21 28
Injection Zr-cetuximab
400 mg/m2, 120 MBq
Step 2
* days of scanning in step 2 depend on imaging results in step 1
Figure 8.1 Timeline of the study 
A two dose-step study design was used. In step 1, the toxicity of two low doses of 89Zr-cetuximab was 
investigated. In step 2, the toxicity of a single larger dose of cetuximab was tested. PET-CT imaging was 
performed at three consecutive days after administration, starting at day 4 in dose step 1 
* In step 2, PET-CT scans on day 3 and 7 after injection were optional and depended on the imaging 
results in step 1: If in step 1 two or more patients had a higher tumour to blood ratio (TBR) on day 4 then
on day 5, an additional scan on day 3 would be performed. If in step 1 two or more patients had a higher
TBR on day 6 then on day 5, an additional scan on day 7 would be performed 
 
In both steps, the 89Zr-labelled cetuximab was administered within one hour after 
the administration of the loading dose. Six patients were included, three in each 
dose step. If grade 2 or higher toxicity was observed related to the administration of 
the studied drug (89Zr-labelled cetuximab) in any patient, 3 more patients had to be 
included in this dose step. When at maximum 1/6 patients experienced grade 2 
toxicity, the step was considered safe. 
Toxicity scoring 
Toxicity was assessed during treatment, and twice weekly thereafter until 14 days 
after the last injection, according to the CTCAE 3.0 scoring system. At baseline and 
on days 7 and 14 after injection, blood testing was performed for haematology 
(haemoglobin, hematocrite, mean cell volume, reticulocytes, white blood cell count 
and differentiation, platelets), kidney function (creatinine) and liver function (aspar-
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tate aminotransferase, alanine aminotransferase, alkalic phosphatase, γ-GT, 
bilirubin).  
The most common side effect of cetuximab administration that was anticipated for 
was skin toxicity (acne-form rash). The classification of the degree of skin toxicity 
according to the CTCAE is provided in Table 8.1 15. 
 
Table 8.1 Grading of toxicity related to cetuximab administration 
Toxicity grade Clinical presentation 
1 Follicular localized pustules 
Asymptomatic 
2 Follicular localized pustules 
< 50% of body surface 
Itchy 
3 Follicular localized pustules 
> 50% of body surface 
Itchy 
4 Exfoliative or ulcerative erythroderma 
Synthesis of 89Zr labelled cetuximab 
89Zr was produced by a (p,n) reaction on natural 89Y as described by Verel et al. 16. 
Subsequently, labelling of 89Zr to the mAb cetuximab was performed as previously 
reported 17. In short, desferrioxamine B was succinylated (N-sucDf), temporarily 
filled with iron (Fe3+), and coupled to cetuximab using a tetrafluorophenol-N-sucDf 
ester. The premodified mAb was purified on a PD10 column after removal of Fe3+ by 
transchelation to ethylenediaminetetraacetic acid (EDTA). Approximately 1 N-sucDf 
moiety was coupled per cetuximab molecule, assessed by using 59Fe. Next, N-sucDf-
cetuximab was labelled with 89Zr in 0.5 M N-(2-hydroxyethyl)piperazine-N9-(2-
ethanesulfonic acid) (HEPES) buffer at pH 7.0 and again purified on a PD10 column 
to remove unbound 89Zr. 89Zr-cetuximab preparations contained 10 mg 89Zr-
cetuximab in 5 mg/ml gentisic acid in 0.9% NaCl, containing 60 or 120 MBq 89Zr. 
89Zr-cetuximab release criteria were: radiochemical purity > 90%; immunoreactivity 
> 70%; pH = 4.7 – 5.3; sterile and free of endotoxins (European Pharmacopeia). 
PET-CT imaging 
Whole body immuno-PET-CT imaging was performed at day 4, 5 and 6 after injec-
tion in dose step 1. Imaging time points in step 2 were adapted based on the tu-
mour to blood ratios at subsequent days in step 1. A list mode acquisition of the 
largest tumour site was carried out in addition to the whole body PET-CT. Further-
more, an optional 18F-fluorodeoxyglucose (FDG-)PET scan was performed within the 
study period, at least 24 hours before or 10 days after the 89Zr-cetuximab admini-
stration.  
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Images were acquired with the patient in supine position. CT and PET images were 
automatically registered based on mutual information and fused using dedicated 
software (TrueD, version VC50, Siemens Medical, Erlangen, Germany).  
The tumour was delineated on the CT scan by the same observer (JvL). If available, 
FDG-PET information was used in addition to the CT. The maximum standardized 
uptake value (SUVmax) and the location of the 
89Zr-cetuximab uptake within the 
delineated tumour were determined using dedicated software (TrueD VC50, Sie-
mens Medical, Erlangen, Germany). Maximal tumour to blood ratios (TBRs) for 89Zr-
cetuximab uptake were calculated at all time points by dividing the tumour SUVmax 
by the SUVmax in the aortic arch.  
For patients in whom an 18F-FDG-PET scan was performed within one week before 
or after the 89Zr-cetuximab scan, the 18FDG and 89Zr-cetuximab uptake was visually 
compared. The location of the 18FDG uptake was determined using automated 
SUV-thresholding with the threshold depending on the tumour-to-background sig-
nal ratio (SBR-method) 18, 19. 
8.3 Results 
Patient characteristics 
Seven patients, with a median age of 63 years (range: 53-75), were included. The 
third patient was excluded from the study before injection of the 89Zr-labelled 
cetuximab, because of malignant hypertension during the administration of the 
unlabelled cetuximab. The tension normalized within two hours of observation 
without further sequelae. Patient and tumour characteristics are shown in Table 
8.2. 
Six patients had a non-small cell lung carcinoma (NSCLC) and 1 had a tonsillar carci-
noma. All patients had previously undergone anti-cancer therapy. In one patient, 
EGFR expression and mutation and k-ras mutation status of the primary tumour 
could not be assessed due to insufficient quantity of histological material. In the 
other patients, none of the primary tumours showed overexpression of EGFR or a 
mutation in exons 18-21 of the EGFR gene. In one patient, the primary tumour 
showed a mutation in the k-ras gene. 
Each patient received 89Zr-labelled cetuximab administration as planned. In two 
patients (patient 2 and 4) enrolled in the first dose step, however, the second series 
of PET-CT scans could not be completed due to pain and dyspnea attributable to 
disease progression.  
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Table 8.2 Patient characteristics  
 Age Sex Length Weight WHO 
PS 
Primary tumour Prior 
therapy 
      Site Histology Mutation* Overexpression  
1 72 m 1.85 75 0 Lung SCC NA NA CTx 
2 61 m 1.76 82 1 Lung LCC k-ras: + 
EGFR: - 
No CTx, RT 
3** 55 f 1.56 61 0 Lung LCC - - CTx 
4 75 m 1.79 74 2 Lung AC k-ras: - 
EGFR: - 
No CTx 
5 53 m 1.80 91 1 Lung SCC k-ras: - 
EGFR: - 
No CTx 
6 63 m 1.78 86 0 Lung AC k-ras: - 
EGFR: - 
No CTx 
7 63 m 1.86 95 1 Tonsil SCC k-ras: - 
EGFR: - 
No RT, CTx 
*k-ras: codons 12 and 13; EGFR: exons 18-21 
**Excluded patient: 55 year old female, NSCLC 
WHO PS: World Health Organisation performance status; m: male; f: female; SCC: squamous cell 
carcinoma; LCC: large cell carcinoma; AC: adenocarcinoma; NA: not assessable due to insufficient 
quantity of histological material; CTx: Chemotherapy; RT: Radiotherapy 
Toxicity 
An overview of the toxicity per patient is presented in Table 8.3.  
 
Table 8.3. Toxicity scoring 
Pt Injected 
activity 
(MBq) 
Vital 
signs* 
Toxicity scoring* Medication* 
   Haematology Liver 
function 
Renal 
function 
Skin Symptoms  
1 2x60 0 0 0 0 2 0 1** 
2 2x60 0 0 0 0 1 0 0 
3 none NA NA NA NA NA NA NA 
4 2x60 0 0 0 0 0 0 0 
5 120 0 0 0 0 2 0 1** 
6 120 0 0 0 0 2 0 1** 
7 120 0 0 0 0 1 0 0 
Toxicity was scored before study entry (baseline) and at days 7 and 14 after cetuximab administration 
NA: not assessed because of premature exclusion from the study 
*Every change in vital signs or medication compared to the baseline values was scored, with “0” 
indicating no change.  
**Doxycycline 100 mg, Hydroxyzine 25 mg, Metronidazolcream 10 mg/g 
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Image analysis 
Images of 89Zr-cetuximab uptake in the tumour of 2 patients are presented in Figure 
8.2. For these patients, an 18F-FDG-PET scan was performed 1 week after the 89Zr-
cetuximab scan. A heterogeneous uptake of 89Zr-cetuximab was observed through-
out the tumour and the rest of the body. In patient 1, a remarkable mismatch was 
observed between FDG- and 89Zr-cetuximab uptake (Figure 8.3).  
For the patients in dose step 1, the average maximum TBR at day 4, 5 and 6 after 
injection was 0.89 (range: 0.83-0.94), 0.98 (range: 0.88-1.05) and 1.09 (range: 0.76-
1.60), respectively. As the most optimal TBR was found at day 6 after injection, 
imaging in dose step 2 was performed at days 5, 6 and 7. For patients in dose step 2, 
the average maximum TBR at day 5, 6 and 7 after injection was 0.88 (range: 0.57-
1.05), 0.86 (range: 0.54-1.02) and 0.91 (range: 0.42-1.20). Three patients had a 
maximum TBR of ≥ 1 at any of the imaging time points: patient 4 had a maximum 
TBR of 1.60, patient 6 had a maximum TBR of 1.20 and the maximum TBR of patient 
7 was 1.11. 
 
 
Figure 8.2. 89Zr-cetuximab and 18FDG images of 2 patients 
89Zr –cetuximab images at day 7 after injection are shown. 18FDG images were acquired at day 14 after 
89Zr –cetuximab administration. 
a), b) Patient 6, max TBR=1.20; a) FDG-PET-CT, b) 89Zr-cetuximab-PET 
c), d) Patient 7, max TBR=1.11; c) FDG-PET-CT, d) 89Zr-cetuximab-PET 
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Figure 8.3. Correlation between 89Zr-cetuximab and 18FDG uptake in patient 1 
a) FDG-PET-CT (day 12 after 89Zr –cetuximab administration) 
b) 89Zr-cetuximab-PET-CT (day 6 after injection) 
8.4 Discussion 
Although zirconium-89 labelled with other monoclonal antibodies has been evalu-
ated in patients before without additional toxicity 20, the current phase I trial is the 
first study in humans evaluating 89Zr labelled with cetuximab. No additional toxicity 
was associated with the 89Zr administration. Acne-form eruption was observed in 
83% of patients, a rate comparable to that found with the therapeutic administra-
tion of cetuximab 8, 15, 21. One patient developed malignant hypertension during the 
administration of unlabelled cetuximab. Although rare, this side-effect has been 
described previously 22.  
Many preclinical data show additive anti-tumour effects for cetuximab with radio-
therapy and chemo-radiotherapy in experimental models 9, 23, 24. The mechanisms 
underlying clinical response or resistance to treatment against EGFR with cetuximab 
are unknown. Until now, the only factors found to be associated with tumour-
response to cetuximab are wild-type K-RAS and an increased EGFR gene copy num-
ber. EGFR status was not associated with significant differences in response rates or 
survival. Also, time-frames of EGFR-expression during the course of (chemo)-
radiation are largely unknown. EGFR tyrosine kinase activity can be initiated by a 
single dose of radiation in experimental tumour models 25. Repeated doses of daily 
radiation, similar to standard clinical therapy, stimulate increased EGFR expression 
in experimental models 26. Visualization and quantification of cetuximab uptake in 
the tumour with PET before and during (chemo-)radiotherapy would have major 
benefit in the appropriate selection of patients for cetuximab treatment 13. 
The maximal TBR of 89Zr-cetuximab uptake in the patients included in this phase I 
study was 1.6. Correlation of the 89Zr-cetuximab and FDG uptake showed a remark-
able mismatch between the two tracers in one patient. Although a large divergence 
was observed between patients in the time curves of the TBR, overall, the most 
optimal TBR was observed at the latest time point of imaging, being day 6 for dose 
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step 1 and day 7 for dose step 2. Therefore, we would suggest the time point of 6 to 
7 days after administration to perform Zr-cetuximab imaging. 
 
Several possibilities may explain the low TBRs observed in this study. First, the re-
sults may represent true negative findings in this selected patient group. Biopsies 
taken prior to any treatment of the primary tumours of the patients enrolled in this 
study did not show overexpression of EGFR or a mutation in the EGFR gene. All 
patients, however, had undergone extensive treatment with chemotherapy or ra-
diotherapy, of which the long term effect on EGFR expression is largely unknown. 
Five of the 6 included patients had NSCLC. Although 40-80% of NSCLC tumours show 
EGFR expression 1, response rates to cetuximab monotherapy in pre-treated pa-
tients with EGFR expressing primary tumours of only 5% are reported 21. Second, 
the loading dose administered in this study (400 mg/m2), which is the standard in 
therapeutic regimens might be either too low or too high to enable adequate tu-
mour visualization. The rationale of the loading dose of cetuximab is that cetuximab 
first binds irreversibly to EGFR expressing liver cells, and that tumour cells are only 
targeted after the liver has been saturated 27. This rationale is supported by animal 
studies as well as by the positive relation between skin toxicity and tumour re-
sponse to cetuximab, implying that skin saturation only occurs after the liver has 
been saturated 28-30. On the other hand, it cannot be excluded that the unlabelled 
cetuximab is already sufficient to saturate the EGF receptors on the tumour cells. 
Future studies should address these critical questions. Finally, it is possible that 
cetuximab might not reach its target receptor at tumour cells due to limited blood 
supply and interstitial pressure of the tumour 31. Hereby, a disparity could result 
between the in vivo EGFR expression and the uptake of cetuximab, a finding that 
has been confirmed in our preclinical study with 89Zr-cetuximab 14. 
Future studies are planned addressing the role of each of these contributing factors. 
Patients will be studied at primary diagnosis before the start of any antitumour 
therapy, to allow correlation of EGFR expression at histology with imaging results. 
As radiotherapy induces upregulation of EGFR expression, visualization of 89Zr-
cetuximab uptake before and after a single fraction of RT will be evaluated. 89Zr-
cetuximab administration with different loading doses of unlabelled cetuximab will 
be evaluated to address its influence on tumour visualization. Finally, kinetic imag-
ing enables the measurement of tumour perfusion, and this should thus be incorpo-
rated in future clinical trials.  
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8.5 Conclusion 
The administration of 89Zr labelled cetuximab to image EGFR expression in vivo is 
not associated with any additional toxicity. Based on the tumour to background 
ratios, a time delay of 6-7 days after injection is advised for further research.  
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Abstract 
With the introduction of targeted chemotherapy and radiotherapy techniques, 
accurate definition of the tumour volume becomes increasingly important. Molecu-
lar imaging with PET, and certainly integrated PET-CT, combining functional and 
anatomical imaging, has many potential advantages over anatomical imaging alone 
in the combined modality treatment of lung cancer. The aim of the current article is 
to review the available evidence regarding PET with FDG and other tracers in the 
combined modality treatment of locally advanced lung cancer. The following topics 
are addressed: tumour volume definition, outcome prediction and the added value 
of PET after therapy, and finally its clinical implications and future perspectives. 
The additional value of FDG-PET in defining the primary tumour volume has been 
established, mainly in regions with atelectasis or post-treatment effects. Selective 
nodal irradiation (SNI) of FDG-PET positive nodal stations is the preferred treatment 
in NSCLC, being safe and leading to decreased normal tissue exposure, providing 
opportunities for dose escalation. First results in SCLC show similar results. FDG-
uptake on the pre-treatment PET scan is of prognostic value. Data on the value of 
pre-treatment FDG-uptake to predict response to combined modality treatment are 
conflicting, but the limited data regarding early metabolic response assessment 
during treatment do show predictive value. FDG response after radical treatment is 
of prognostic significance. An FDG-PET scan in the follow-up has potential benefit in 
NSCLC, while data in SCLC are lacking. Radiotherapy boosting of radioresistant areas 
identified with FDG-PET is subject of current research. 
Tracers other than 18FDG are promising for treatment response assessment and the 
visualization of intra-tumour heterogeneity, but more research is needed before 
they can be clinically implemented.  
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9.1 Background 
Lung cancer accounts for 219,000 new cancer cases and 159,000 deaths a year in 
the United States, representing 15% of cancer cases and 28% of cancer deaths in 
2009 1. As patients often present with primary irresectable disease, the majority of 
patients with localized disease is currently treated with multimodality treatment 
using a combination of surgery, chemotherapy (CTx), radiotherapy (RT) and targeted 
agents. Although survival has significantly improved with combined modality treat-
ment, still, about one third of locally advanced lung cancer patients experience local 
failure as their first site of relapse. Furthermore, these combined treatment strate-
gies are often associated with dose limiting toxicity, prohibiting further intensifica-
tion of treatment. This could potentially be overcome by targeted antitumour ther-
apy with more conformal RT techniques and targeted agents. This provides oppor-
tunities to increase locoregional control without increasing toxicity. Furthermore, 
progress is made in strategies directed at an early adaptation of therapy dependent 
on the treatment response, which may lead to optimization of the therapeutic ratio 
in each individual. After completion of curative treatment, improvement of out-
come could be accomplished by an early detection of local progression, increasing 
the possibility for those patients to be offered salvage therapy.  
 
The introduction of these techniques makes accurate definition of the tumour vol-
ume to be treated increasingly important. This emphasizes the need for imaging 
techniques enabling accurate definition of the presence and extent of tumour be-
fore, during and after curative treatment in cancers of the respiratory tract. While 
CT and MRI are the most accurate imaging modalities with respect to anatomical 
information, they often lack the potential to distinguish between vital tumour and 
non-malignant tissue. Here, molecular imaging with positron emission tomography 
(PET), providing metabolic information, has additional value. Different radiophar-
maceuticals have been evaluated for the imaging of malignant tumours, of which 
18F-fluorodeoxyglucose (18FDG) is by far most commonly used. FDG-PET scanning 
utilizes the difference in accumulation of FDG between normal and cancerous tis-
sues, based on an enhanced glucose metabolism in cancer cells. Other PET tracers, 
visualizing specific molecular pathways in tumours such as proliferation (e.g., 11C-
methionine, 11C-choline, 18F-fluorothymidine) hypoxia (e.g., 18F-FMISO) or expres-
sion of certain receptors (Her2Neu, EGFR) are increasingly being used in the evalua-
tion of malignancies.  
 
Thus, metabolic imaging with PET, and certainly integrated PET-CT, combining func-
tional and anatomical imaging, has many potential advantages over anatomical 
imaging alone in the combined modality treatment of lung cancer. PET using FDG is 
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at present most widely applied in the clinical practice of non-small cell lung cancer 
(NSCLC). Its use in small cell lung cancer (SCLC) is rapidly emerging.  
The aim of the current article is to review the available evidence on the use of PET 
in the combined modality treatment of locally advanced lung cancer. For NSCLC and 
SCLC separately, the role of PET imaging will be addressed with respect to the fol-
lowing topics: 
 
• Definition of the tumour volume to be treated, both with respect to the primary 
tumour and the locoregional lymph nodes 
• Outcome prediction on basis of PET before or early after the start of treatment, 
and the added value of PET after therapy  
 
With regard to both these topics, the clinical implications of the use of PET are ad-
dressed, and future perspectives are provided. 
 
Because 18FDG is by far most commonly applied in clinical practice, the majority of 
evidence comes from this tracer. Therefore, where “PET” is used in this article, this 
refers to “18FDG-PET”, unless otherwise stated. Wherever other tracers have shown 
additional value, or are regarded as promising in the near future, they will be dis-
cussed.  
9.2 Search strategy 
A comprehensive literature search was conducted using the “Pubmed” database. 
Included search terms were: “Non small cell lung cancer”, “Small cell lung cancer”, 
“NSCLC”, “SCLC”, “Target volume definition”, “Delineation”, “Gross tumour volume 
(GTV)”, “Clinical target volume (CTV)”, “Tumour heterogeneity”, “Selective nodal 
irradiation”, “Prognostic value”, “Outcome prediction”, “Follow-up”, “Combined 
modality treatment”, “Chemotherapy”, “Radiotherapy” or “Radiation” in combina-
tion with “PET”, “Positron emission tomography” or “Molecular imaging”.  
Reference lists of relevant articles were searched for further studies. Only publica-
tions in the English language and published online before February 1, 2010 were 
included.  
9.3 Non-small cell lung cancer (NSCLC) 
NSCLC represents more than 80% of lung cancer cases 2. Combined chemoradio-
therapy is the standard treatment for locally advanced (stage III), inoperable NSCLC. 
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NSCLC is the tumour type in which the role of 18FDG-PET imaging has been investi-
gated most extensively.  
The added value of PET to select patients for combined modality treatment has 
been studied extensively 3-5, and it was shown that PET staging results in superior 
outcome due to stage migration: up to 30% of stage III patients are diagnosed with 
distant metastases 6, 7. This clearly affects patient outcome as it withholds toxic 
therapy in individuals who will not benefit from it.  
Below, we will discuss the role of PET in the radiation treatment planning and 
evaluation of combined chemoradiotherapy for stage III NSCLC. 
9.3.1 Definition of the tumour volume to be treated 
Primary tumour 
Although FDG-PET has a high sensitivity for the detection of the primary tumour, an 
important drawback is its lack of anatomic detail, which limits its ability to define 
the exact tumour boundaries. The spatial resolution of current PET scanners is lim-
ited to 4-6 mm 8, which is far lower than that of modern CT scanners, with a resolu-
tion down to 1 mm. There are cases, however, where anatomic imaging modalities 
such as CT and MRI are compromised in their ability to define the exact tumour 
border, such as in patients with atelectasis or tumours near the thoracic wall 9. Mul-
tiple studies have shown a large interobserver variation in delineation of the tumour 
on CT 9, 10. This interobserver variation is significantly diminished by using the infor-
mation of an FDG-PET scan, co-registered with CT 11-14. Overall, volumes delineated 
using PET-CT are smaller 12. Differences between PET and CT were mainly found in 
the regions with atelectasis 12, 15, 16. 
 
Various quantitative methods have been developed for automatic tumour delinea-
tion using PET instead of visual interpretation of the PET signal. The most straight-
forward method uses an absolute threshold of the standardized uptake value (SUV). 
The SUVmax threshold of 2.5 is often used for this purpose 
17. An absolute threshold 
should be used with caution, however, as the SUV is associated with considerable 
variety due to both technical and biological factors 18. An alternative method is the 
use of a relative threshold, e.g. a certain percentage of the SUVmax. Recently, more 
complex methods have been developed, including the application of an individual-
ized threshold based on the source-to-background ratio (SBR) or the watershed 
clustering method 19-21. An example of the difference in interobserver variation 
between manual and autocontour based delineation is provided in Figure 9.1. Nes-
tle et al. compared absolute (SUVmax ≥ 2.5), relative (40% SUVmax) and individual (SBR 
algorithm) quantitative methods and a visual interpretation method with CT-
volumes 22. There were large differences in the resulting volumes, particularly in 
patients with a heterogeneous pattern of FDG-uptake. 
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Figure 9.1 Example of a manual (a) and autocontour based (b) delineation of the primary tumour  
For autocontouring, the SBR based method was used 
Arrows indicate changes in interobserver variation in delineation between the two methods 
 
Ideally, validation of the delineated tumour volume should be obtained by correlat-
ing it with the tumour volume at pathologic examination, being the gold standard. 
The currently available data are based on two-dimensional correlations in early 
stage disease 23-25. With the use of a relative threshold, a better correlation was 
found for CT than for PET (correlation coefficient 0.87 versus 0.77) 23. Yu et al. found 
the best correlation with integrated PET-CT based on an absolute threshold (SU-
Vmax≥2,5) 24. A correlation coefficient of 0.90 was found between the maximal tu-
mour diameter obtained with SBR-based autodelineation and pathology 25. Promis-
ing attempts are made to develop a three-dimensional model (Figure 9.2), but re-
sults in large patient cohorts are to be awaited 26-28.  
 
The methods described above are aimed at an accurate definition of the gross tu-
mour volume (GTV) in order to ensure that this region is adequately covered by the 
RT treatment fields. Characteristics associated with radioresistance, such as hy-
poxia, cell density and proliferation, however, are known to be heterogeneous 
across the tumour 29-31. FDG-PET scans may allow the identification of therapy-
resistant areas within the tumour. It would be logical to selectively boost the radio-
resistant areas, whilst decreasing the dose to the less resistant zones, resulting in 
higher tumour control with similar side effects 32-35. It has been demonstrated that 
regions with high FDG uptake prior to radiotherapy correspond well with the loca-
tion of recurrent/persistent tumour after sequential chemo-radiotherapy or RT 
alone (Figure 9.3) 36, 37. Furthermore, those regions remain stable during a course of 
RT (Figure 9.4) 38. Thus, selective boosting of areas of assumed radioresistance iden-
tified with FDG-PET before the start of RT appears to have a good rationale. 
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Figure 9.2 Example of the procedure to correlate imaging with pathology in three dimensions: Estima-
tion of the orientation of the CT with respect to the macroscopic slices 
In (A), the volumes of interest (lobe, GTV-CT, bronchus entrance) are delineated in the CT slices. In (B) a 
3D representation of the CT volumes is depicted. In (C) the inflated specimen after surgery is photo-
graphed. The slice direction is indicated by the dashed lines. In (D) the 3D CT volumes are rotated in such 
a way that the orientation corresponds to the macroscopic specimen 
In (E) the CT data are resliced accordingly and for each macroscopic slice the corresponding CT slice can
be found. After this procedure, X corresponds approximately to the medio-lateral direction, Y to antero-
posterior, and Z to cranio-caudal 
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Figure 9.3 Correlation between pre-treatment high FDG-uptake areas and location of residual disease 
Representative FDG-PET-CT images of three patients pre- and post-radiotherapy. 
The light grey lines indicate the 50%SUVmax FDG high-uptake area pre-radiotherapy. The dark lines 
indicate the residual metabolic-active areas post-radiotherapy, also transposed on the pre-radiotherapy 
scan. Visual evaluation shows a large correspondence between the residual areas post-radiotherapy with 
the high FDG uptake areas pre-radiotherapy 
 
 
Figure 9.4 Stability of high FDG-uptake areas during a course of RT 
PET-CT images of 3 patients before treatment (Day 0) and during treatment (Days 7 and 14). Lines indi-
cate 60% of maximal standardized uptake value (SUVmax) threshold. Visual inspection showed that
location of the hotspot remained at the same location during treatment; however, the volume of the
hotspot changed 
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The additional value of FDG-PET scanning in defining the primary tumour volume is 
thus beyond doubt. However, the drawbacks of FDG-PET should be kept in mind. 
Due to the poor resolution, blurring does occur, particularly at the tumour edges 18. 
Those blurring effects at the tumour boundary are even more pronounced by mo-
tion artefacts. Although the long acquisition time of PET is disadvantageous with 
respect to defining an absolute tumour edge and quantifying metabolic activity, it 
may have additional value in determining the extent of tumour motion. The acquisi-
tion time of several minutes results in a tumour volume incorporating the averaged 
position of the tumour over multiple respiratory and cardiac cycles. In a phantom 
study, PET-based treatment volumes resulted in an adequate coverage of the tu-
mour, while CT-based volumes harboured the risk of a geographical miss 39. Respira-
tory gating or 4D imaging techniques allow the incorporation of the extent of tu-
mour movement, while optimizing image quality and quantification as the blurring 
effect is reduced 40. Those techniques are presently being evaluated in clinical stud-
ies 40, 41.  
Microscopic disease extension 
The poor spatial resolution of PET precludes a direct evaluation of the presence and 
extent of microscopic disease around the macroscopic tumour border. Definition of 
the area of potential microscopic spread in patients treated with chemoradiother-
apy is important as this region should be covered in the radiation field. The only way 
to quantify microscopic spread beyond the tumour border visible on imaging is by 
correlating imaging with the findings at pathologic examination. Until now, this 
correlation has only been performed between CT and pathology 42-44. Furthermore, 
no correction was applied for deformation of the lung lobe after surgery. Methods 
for the correlation of both PET and CT with pathology, which do take into account 
deformation, are under development 26, 27. First results indicate an average micro-
scopic spread in vivo of 9 mm 27, suggesting that currently applied margins might be 
too small to cover microscopic disease. 
Lymph nodes 
Accurate identification of nodal metastases has become of particular importance 
since routine elective nodal irradiation, i.e. the prophylactic irradiation of clinically 
uninvolved lymph nodes, is no longer recommended in NSCLC 45, 46. FDG-PET has a 
higher sensitivity and specificity for the detection of lymph node involvement in 
NSCLC than CT (sensitivity: 83% vs. 62%; specificity: 97% vs. 91%, respectively) 47. 
Both PET- and CT-based selective irradiation of involved lymph nodes has proven its 
safety in NSCLC, with the occurrence of isolated nodal failures (INF) in less than 5% 
of patients 48-51. One study found INF in up to 15% with PET-based SNI 52. However, 
the accuracy of the identification of lymph nodes in this study was questionable, as 
only visual interpretation of non-coregistered PET images was used. In general, the 
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PET-based treatment volumes are smaller than CT-based volumes 53, 54. Selective 
nodal irradiation (SNI) has shown not only to be safe, but also to result in a reduc-
tion of radiation fields based on CT, and even further based on PET 50. A modelling 
study showed that treating only FDG-positive mediastinal areas decreases radiation 
exposure of the lungs and the esophagus sufficiently as to allow for radiation dose-
escalation 50, 54. An example of the difference resulting from RT planning with PET-
CT compared to CT alone is illustrated in Figure 9.5. 
 
 
Figure 9.5 Example of the effects of RT planning with PET-CT compared to CT alone 
Projection of the planning target volume (PTV) of a 66-yearold female with a large cell carcinoma of the 
right lower lobe with pathological lymph nodes on CT scan in areas 4R and 3R and on FDG-PET scan in 
area 7. Although the lung exposure was lower with PET-CT than with CT (V20 25 vs. 30% and MLD 15.4 
vs. 19.3 Gy, respectively), the oesophageal exposure was higher with PET-CT because of the involvement 
of level 7 (MED 16.9 vs. 14.1 Gy, V55 18 vs. 4%, Dmax 60.1 vs. 58.6 Gy, respectively, for PET-CT and CT) 
 
Although PET-defined SNI appears to be safe, ideally, pathological confirmation of 
PET-positive mediastinal nodes should be obtained. Pathological validation of the 
CT-and PET-based nodal treatment volumes was performed in 998 lymph nodal 
stations from 105 patients 55. The coverage of all pathologic lymph nodes was 89% 
with PET-based treatment volumes compared to 75% with CT (p=0.005). Neverthe-
less, a false negative rate with PET up to 14% has been reported in operable pa-
tients 56. A possible explanation for the low amount of isolated nodal failures is the 
incidental irradiation of clinically negative lymph node stations through coverage by 
the beam penumbra of conventional RT fields. The Michigan group showed that risk 
factors of nodal metastases, such as a large tumour size and central location, were 
associated with a considerable dose to the high-risk nodal regions 57, indicating that 
incidental nodal irradiation might play an important role. Therefore, caution is war-
ranted with the application of new RT technologies, such as stereotactic body radio-
therapy (SBRT), intensity modulated radiotherapy (IMRT) and particle therapy, as 
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they are associated with a more conformal dose distribution and altered penumbra 
characteristics.  
 
Different methods can be used for delineation of the involved lymph nodes on PET. 
Nestle et al. compared the nodal volumes resulting from visual delineation and 
absolute (SUVmax ≥ 2.5), relative (40% SUVmax) and individual (SBR-based) thresholds 
58. There were no clinically relevant differences in resulting volumes. SBR-based 
contouring of lymph nodes generally showed a good correlation with pathology 25. 
Regardless of the delineation method, the question remains how to incorporate the 
lymph nodes in the treatment volume. There are no data available on the micro-
scopic extension of disease outside lymph nodes. This residual uncertainty can be 
overcome by encompassing the whole anatomical mediastinal region in the treat-
ment volume, as was done in the Maastricht studies described above 50, 53, 54.  
As for the primary tumour, the exact anatomical localization of the mediastinal 
lymph nodes may be blurred because of respiratory motion. Ideally, individually 
determined margins should be applied to cover the lymph nodes in all respiratory 
phases, as there is a large intra- and inter-individual variation in lymph node motion, 
not related to the motion of the primary tumour 59-61. 
Clinical implications and future perspectives 
The incorporation of PET in RT planning has shown the potential for dose escalation 
through a reduction of the radiation fields, mainly because of avoidance of irradiat-
ing PET negative lymph nodes 53, 54, 62. With individualized radiation dose escalation 
based on normal tissue constraints, patients treated with sequential chemo-
radiation had survival rates comparable to results with concurrent chemo-radiation 
schedules while less toxicity was observed 63. These results imply that PET-based RT 
planning might ultimately lead to higher cure rates, and randomized prospective 
studies are warranted to investigate this further. 
 
Further optimization of the radiotherapy treatment volume could be obtained by an 
accurate definition of the appropriate margin around the delineated tumour to 
cover microscopic disease. This information should become available from studies 
correlating PET-CT findings with pathology.  
 
Recently, an increasing tendency has emerged to move away from the concept of 
homogeneous irradiation. Studies have been performed to investigate the feasibility 
of selectively boosting areas with residual FDG-uptake after 40-60 Gy, with diverg-
ing results 64, 65. Prospective trials are awaited to investigate whether radiation dose 
redistribution leads to better treatment outcome, for which preparations are cur-
rently being performed 33, 66. In the studies mentioned before, 18FDG was used as a 
tracer for radioresistant areas. Other tracers, e.g. for hypoxia (18F-FMISO, 18F-HX4) 
Chapter9
C H A P T E R  9  
 150 
or proliferation (18F-FLT) could be used complimentary to or instead of FDG 67-71. 
These tracers deserve further investigation for this purpose.  
Conclusion 
FDG-PET has an important additional role to anatomic imaging in defining the pri-
mary tumour volume. Automatic delineation with adaptive techniques, such as SBR-
based methods is to be preferred above absolute thresholding. Models are under 
development that correlate imaging findings with pathology in three dimensions. 
These could finally allow validation of different thresholds for SUV-based contouring 
and evaluation of microscopic spread and intra-tumour heterogeneity. Selective 
boosting of radioresistant areas identified with FDG-PET is subject of current re-
search. 
Selective irradiation of FDG-PET positive nodal stations is safe and leads to de-
creased normal tissue exposure, providing opportunities for dose escalation. With 
the increased use of more conformal radiation techniques, the safety of PET-based 
SNI should be re-evaluated. Disparities in treatment volumes resulting from differ-
ent contouring methods are smaller than for the primary tumour.  
9.3.2 Outcome prediction on basis of PET before or early after the start of 
treatment, and the added value of PET after therapy  
Despite the improved outcome of inoperable stage III NSCLC achieved with com-
bined chemoradiotherapy, the majority of patients still show disease progression 
after treatment, with 23-43% having an isolated local recurrence as their first site of 
progression 72-76. As the treatment is associated with considerable toxicity, it would 
be of great value to be able to select patients before or early during treatment, with 
the highest probability to benefit from treatment.  
Early response assessment with conventional chest X-ray and CT is limited by their 
poor discriminating capacity between residual tumour and treatment induced 
changes 77, 78. PET scanning allows for the assessment of changes in glucose con-
sumption of the tumour during chemo- and radiotherapy. Several studies have 
shown a correlation between the SUV and tumour cell proliferation 79-81, supporting 
the hypothesis that an early change in FDG uptake has predictive value.  
Prognostic value of pre-treatment PET 
Most evidence regarding the prognostic value of pre-treatment PET comes from 
studies in heterogeneous patient populations with both early and late stage disease, 
treated with different modalities. A meta-analysis was performed within the IASLC 
lung cancer staging project. 11/13 eligible studies in stage I-IV NSCLC identified a 
high SUV as a poor prognostic factor for survival, with a combined HR for survival of 
2.27 (95% CI: 1.43-3.04) for low versus high SUV 82. The threshold was variable be-
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tween the studies, ranging from 5 to 20. Those differences are due to both technical 
and patient related factors, such as different scanners, time intervals between injec-
tion and scanning and fasting times. Furthermore, the relationship between SUV 
and prognosis is rather gradual than fixed at a single cut-off point. 
Regarding the ability of PET to predict response to combined modality treatment, 
the first study in patients with advanced disease treated with (chemo-)radiotherapy 
showed a positive correlation between the tumour to muscle ratio (TMR) and re-
sponse, but no significant correlation with outcome 83. Two later studies revealed 
SUVmean and SUVmax to be significantly associated with overall survival 
84, 85. In the 
first population, both tumour grade and UICC stage showed a stronger correlation 
with survival than the SUV 84, while in the second study, SUVmax was the strongest 
predictor 85. In contrast, the most recent study in the largest cohort of stage III and 
IV NSCLC patients thus far (n=214), did not show a significant relationship with sur-
vival 86. This study was not included in the mentioned IASLC meta-analysis. 
Outcome prediction on basis of early PET response during combined modality 
treatment 
Because FDG is preferentially accumulated in viable tumour cells 87, 88, FDG-PET 
imaging is an attractive method to visualize early treatment response, as the change 
in SUV should reflect the rate of tumour cell killing. In advanced NSCLC, the predic-
tive value of an early metabolic response to palliative chemotherapy, as well as to 
radical treatment with (chemo)radiotherapy has been evaluated. Prospective ob-
servational studies have consistently shown that in advanced NSCLC treated with 
palliative chemotherapy, the metabolic response after 1-3 cycles of chemotherapy 
is strongly correlated with final outcome 89-92.  
With respect to radical treatment, metabolic response to induction chemotherapy 
prior to radiotherapy or surgery in locally advanced NSCLC patients has been shown 
to correlate with outcome in multiple studies as well 90, 93, 95, 96. One study, however, 
did not show predictive value 98.  
While the evidence regarding the predictive value of a metabolic response to induc-
tion chemotherapy is abundant, far less is known about its value early during the 
course of radical treatment itself. One study investigated the predictive value of 
response assessment during concurrent chemoradiotherapy 99. A significant differ-
ence in long-term survival was found between patients with and without a meta-
bolic response after 3 weeks of concurrent chemoradiotherapy. A study evaluating 
response during radical RT revealed a large intra-patient heterogeneity in the evolu-
tion of SUVmax during and after radical RT 
100. Different time patterns were seen for 
responders and non-responders, but due to the limited patient numbers, the pre-
dictive value of the SUVmax changes could not be assessed.  
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To make FDG response assessment a valuable tool in routine clinical practice, a clear 
definition of response should be prescribed, as the intra-patient variability of re-
peated tumour SUV-measurements is in the range of 10-15% 101-103. Furthermore, 
early response should be assessed at a fixed time interval. Ideally, the interval 
should be short enough to switch to a potentially more successful treatment as 
early as possible. This should be balanced, however, with a time interval sufficient 
to allow for a reliable response assessment. In 1999, the EORTC published consen-
sus guidelines on which cut-off points should be used to define response at differ-
ent time intervals 104, which are still widely applied in clinical practice. Weber et al. 
defined a metabolic response after the first cycle of chemotherapy as a decrease in 
FDG uptake of more than twice the standard deviation, calculated to be 20%. This 
definition correlated with final response according to RECIST, as well as with time to 
progression and overall survival 91. In 2009, the PET Response Criteria in Solid Tu-
mours (PERCIST, version 1) have been proposed resulting from a review of qualita-
tive and quantitative methods of metabolic response assessment 97. PERCIST rec-
ommends to correct SUV for lean body mass (SUL) as this accounts for variations 
due to differences in body composition. A comparison between the EORTC criteria 
and PERCIST is provided in Table 9.1. Overall and most importantly, the same defini-
tion of response criteria should be used by different groups to be able to compare 
metabolic response studies across different centres.  
Concerning the type of measurement, semiquantitative methods, such as the rela-
tive change in SUV, appear to perform equally well as more complex quantitative 
methods such as change in the net-influx constants (Ki) or metabolic rate of glucose 
(MRglu) 90-92. This facilitates the use of early PET response for outcome prediction in 
daily clinical practice.  
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Table 9.1 Criteria of metabolic response according to EORTC and PERCIST 
 EORTC  PERCIST 
Progressive Metabolic 
Disease (PMD) 
• > 25% increase in SUV of tumour 
defined on pretreatment scan, 
or 
• > 20% increase in the longest 
dimension of FDG-uptake, or 
• Appearance of new FDG-uptake 
in metastatic lesions 
• > 30% increase in SUL peak and 
absolute increase of SUL units ≥ 
0.8 from baseline scan in pat-
tern typical of tumour and not 
of infection /treatment effect, 
or 
• Visible increase in extent of 
FDG-uptake (> 75% increase in 
total lesion glycolysis), or  
• Appearance of new FDG-avid 
lesions typical of cancer and not 
related to infection /treatment 
effect 
Stable Metabolic Disease 
(SMD) 
• < 25% increase or < 15% de-
crease in SUV of tumour defined 
on pretreatment scan, and 
• < 20% increase in the longest 
dimension of FDG-uptake 
• No CMR, PMR or PMD 
Partial Metabolic Re-
sponse (PMR) 
• > 15% decrease in SUV of tu-
mour defined on pretreatment 
scan (after 1 cycle) 
• > 25% decrease in SUV of tu-
mour defined on pretreatment 
scan (after > 1 cycle) 
• > 30% decrease in SUL peak and 
absolute drop in SUL units ≥ 0.8 
of the most intense lesion be-
fore and after treatment (not 
necessarily the same lesion)  
• No new FDG-avid lesions typical 
of cancer 
Complete Metabolic 
Response (CMR) 
• Complete resolution of FDG-
uptake within tumour defined 
on pretreatment scan, not dis-
tinguishable from surrounding 
normal tissue 
• Complete resolution of FDG-
uptake within measurable tar-
get lesion, less than mean liver 
activity and indistinguishable 
from surrounding background 
blood-pool levels 
• Disappearance of all other 
lesions to background blood-
pool levels  
• No new FDG-avid lesions typical 
of cancer  
SUL: Standardized uptake value corrected for lean body mass 
 
Added value of PET after combined modality treatment 
The accuracy of PET after treatment is assumed to be lower than at initial staging 
because of therapy induced inflammatory and perfusion changes 105. Nevertheless, 
PET still has a high accuracy in detecting recurrent lung cancer, with a sensitivity up 
to 98% and a specificity of 62-92% 105-107, and is more accurate than CT in the dis-
tinction of tumour from post-RT effects 108-110. Here, the added value of a post-
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treatment PET is addressed with regard to the prognostic value of a PET early after 
treatment as well as the role of PET in the follow-up after combined modality ther-
apy. 
 
We identified four studies addressing the prognostic value of PET after radical 
treatment in locally advanced NSCLC patients, consisting of (chemo-)RT 74, 83, 100, 112. 
Four studies evaluated the predictive value of PET after induction chemoRT before 
surgery 94, 96, 111, 113. The studies were unambiguous in their conclusion that the FDG 
response after chemoradiotherapy has prognostic and predictive value, respec-
tively. Mac Manus proved the superiority of PET response above CT. Response on 
PET and CT were identical in only 40% of patients. In multivariate analysis, only the 
PET response was significantly associated with survival 109.  
Clear cut-offs should be prescribed to define the different prognostic subgroups. In 
the aforementioned studies, however, there is a large heterogeneity in the way 
FDG-uptake after therapy was measured. Some studies reported an absolute 
threshold post-treatment 83, 96, 111, 113, while others stratified patients according to 
the relative change in SUV 74, 94, 100, 109, 112. In none of the studies a direct comparison 
was made between the different methods. Until more data are available we rec-
ommend the use of the EORTC criteria for PET response 104 for prognostic stratifica-
tion, as the results of the larger studies are mainly based on these criteria.  
Another important aspect is the timing of the PET-CT. The median time interval in 
the studies described above was 14 to 70 days. It is recommended to perform a 
PET-CT scan not earlier than 3 to 6 months after treatment to avoid false positive 
results due to post-therapy inflammatory changes 105, 114. The time interval should 
not be excessive either, as the final aim is to select patients for further therapy. 
Hicks et al. observed no confounding effect through post-RT inflammatory changes 
for response assessment with a PET-CT scan performed 70 days after radical RT 115. 
As different time-points have not been compared directly, we recommend the use 
of the time point 70 days post-treatment.  
 
It should be noted that the results described above only apply for patients treated 
with conventional or hyperfractionated RT with or without chemotherapy. In hy-
pofractionated SBRT, where 3 to 5 large fractions are applied, persistently elevated 
SUVmax of > 3.5 have been described up to one year post treatment 
116, 117. These 
different findings may be explained by localized normal tissue changes induced by 
SBRT, such as segmental atelectasis or focal fibrosis, that are not distinguishable 
from persistent or recurrent tumour. 
 
PET in the follow-up of NSCLC could improve outcome when progressive disease can 
be detected early enough to allow radical retreatment. There are no convincing 
data supporting that early detection of progression with chest X-ray or CT scan im-
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proves survival 77, 118-120. This might be different for FDG-PET scanning, as PET is 
more accurate than CT in the distinction of tumour from post-RT effects 108, 109, 121, 
and is known to be prognostic for outcome 82, 88, 122-124. A prospective study was 
performed to evaluate whether PET-CT 3 months after therapy can detect poten-
tially curable progression in locally advanced NSCLC 125, which was the case in a 
small proportion (3%) of patients, who were all asymptomatic. An economic evalua-
tion based on these results showed that a PET-CT scan 3 months after (chemo-
)radiotherapy is potentially cost-effective, and is more cost-effective than CT alone 
126. As the advantage was confined to the asymptomatic patients, a PET-CT scan in 
this group only is probably as effective and more cost-effective.  
Other tracers 
As response assessment early during and after therapy is complicated by the limited 
ability of FDG to discriminate between inflammation and tumour activity, it is 
worthwhile to investigate alternative tracers, corresponding more specifically with 
tumour proliferative activity. 
 
The uptake of 18F-fluorothymidine (18F-FLT), a marker of DNA synthesis, has been 
correlated with tumour proliferative activity in various tumour sites including NSCLC 
127-132. Recent (pre)clinical studies have demonstrated that FLT can detect changes in 
proliferation during and after irradiation in colorectal tumours and breast cancer 
cell lines 133-135. One pilot study in NSCLC has shown the feasibility of FLT to image 
proliferation during chemo-radiotherapy 71.  
 
Amino-acid tracers theoretically have an advantage over FDG in that it more specifi-
cally accumulates in viable cancer cells 136. However, data on its usefulness in evalu-
ating treatment response are scarce. One study compared 18FDG and the amino-
acid tracer 11C-methionine (11C-Met) for evaluation of treatment response in lung 
cancer, but this study focussed on early stage patients treated with stereotactic RT 
117. In this study, FDG and Met showed an equal accumulation in inflammatory tis-
sue, a finding that is supported by the results of other research groups 137-139. An-
other amino-acid tracer has recently been put forward for monitoring treatment 
response, being 18F-fluoromethyltyrosine (18F-FMT). Two animal studies showed a 
rapid response to antitumour therapy, and less accumulation in inflammatory cells 
140, 141.  
Clinical implications and future perspectives 
The clinical impact of patient selection before or early during treatment is beyond 
doubt, as it avoids ineffective treatment with the associated side-effects and en-
ables alternative therapy in case of an inadequate early response. Before this prin-
ciple can be implemented in clinical practice, additional research is needed to define 
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clear cut-off points for FDG uptake to stratify patients into different treatment mo-
dalities. With regard to early response assessment, attention should be paid to 
other tracers, in particular proliferation markers, as they are less susceptible to 
uptake in inflammatory tissue 71. 
A final option for improvement in outcome is the use of PET in the follow-up. Cur-
rently available data do show a potential benefit of PET in the follow-up compared 
to CT. Ideally, different follow-up strategies, including PET-CT based follow-up, 
should be compared in a randomized controlled trial to provide a definitive insight 
in the added value of PET in the follow-up of NSCLC patients after combined modal-
ity therapy. 
Conclusion 
In the overall NSCLC patient group, pre-treatment FDG-uptake is of prognostic 
value. Results on its ability to predict response to combined modality therapy in 
advanced stage NSCLC are conflicting. The most recent study in the largest patient 
cohort did not show a significant correlation with survival. 
The predictive value of an early metabolic (FDG) response during induction chemo-
therapy has been established. Less is known about the predictive value of a meta-
bolic response during radical (chemo-)RT, but the limited available data show a 
correlation with survival. The FDG response after radical treatment is of proven 
prognostic significance. A time interval of 70 days after the end of treatment is rec-
ommended for metabolic response assessment on basis of the EORTC criteria. 
An FDG-PET scan in the follow-up after combined modality therapy can detect pro-
gression amenable for radical retreatment in a limited number of patients.  
Tracers other than FDG are promising for treatment response assessment, but more 
research is needed before they can be clinically implemented. 
9.4 Small cell lung cancer (SCLC) 
SCLC is a tumour with a poor prognosis, characterized by a rapid growth rate. Tradi-
tionally, staging of those patients has been limited to the distinction between lim-
ited (LD) and extensive disease (ED) 142. Approximately 25% of patients present with 
limited-disease (LD), defined as disease confined to one hemithorax, including the 
mediastinum and bilateral supraclavicular fossae 143-145. Even in this patient group, 
surgery is rarely an option because of the advanced stage of locoregional disease. 
Concurrent chemo-radiation is currently the first choice treatment. Literature is 
sparse on the role of PET in LD-SCLC. The available literature suggests that FDG-PET 
has additional value above standard staging procedures in SCLC 146-153, with a re-
ported sensitivity and specificity up to 100% and 95% 154. Staging with PET can posi-
tively influence the outcome of chemoradiotherapy for LD-SCLC patients by means 
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of stage migration. Upstaging from LD to ED by FDG-PET scanning occurs in 6-33% 
146-148, 155-158 and downstaging in 3-40% 147, 148, 155, 157 of patients.  
9.4.1 Definition of the tumour volume to be treated 
Primary tumour 
In order to define the tumour volume, PET should be assessed for its ability to dis-
tinguish malignant from surrounding normal tissue. Studies addressing this issue are 
focussed on NSCLC 11-14. The same holds true for correlation studies with pathology 
24, 26, 27, 43, 44. Therefore, we can only assume that similar caveats apply as described 
above for NSCLC. In short, a major limitation of PET is the low spatial resolution. 
Hence, the major gain is to be expected in regions where anatomical imaging tech-
niques lack the capacity to discriminate malignant from normal tissue, e.g. in areas 
with atelectasis. Another question refers to which method should be applied for 
PET-based tumour delineation. Again, comparison and validation of different meth-
ods has exclusively been performed in NSCLC 22, 25. No conclusions can be drawn 
regarding which method is to be preferred, except that adaptive techniques are 
likely to be more accurate than the use of an absolute or relative SUV-based thresh-
old 20, 21. Obviously, blurring effects due to motion do hinder exact tumour delinea-
tion. Respiration correlated imaging techniques have the potential to include indi-
vidual tumour motion in the treatment volume, in conjunction with optimal image 
quality, as blurring effects are significantly reduced 40, 41. 
Microscopic disease extension 
As described previously, the only way to define microscopic disease extension be-
yond the tumour border visible on imaging is to correlate imaging with pathology. 
There are no data on image correlation with pathology available for SCLC.  
Lymph nodes 
The available data suggest that an FDG-PET scan can identify metastases to regional 
lymph nodes in 14-25% of patients whose mediastinal CT scan is negative 146, 150, 157. 
With the high sensitivity and specificity of PET in SCLC, it is likely that the use of PET 
scans improves the coverage of mediastinal lymph node areas in LD-SCLC. 
Until recently, only few prospective data concerning selective nodal irradiation (SNI) 
in SCLC were available. A report from the International Atomic Energy Agency (IAEA) 
meeting emphasized the need for prospective clinical evidence regarding SNI in 
SCLC 159. CT-based SNI resulted in an unacceptable amount (11%) of isolated nodal 
failures outside the treatment volume 160. These findings imply that results on the 
safety of SNI in NSCLC cannot straightforwardly be extrapolated to SCLC. 
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Since the publication of the IASLC report, two studies have become available evalu-
ating FDG-PET based SNI in SCLC. In a planning study, a difference in the treatment 
plan resulting from PET- and CT-based SNI was found in 24% of patients 161. Radia-
tion fields increased in 10% and decreased in 14% of patients, respectively. No sig-
nificant changes in the radiation exposure of the normal tissue were observed. In 
the subsequent prospective study, 3% of the patients experienced an isolated nodal 
failure after a minimal follow-up of 18 months, comparable to results in NSCLC. A 
remarkably low percentage (12%) of grade III esophagitis was found, while this oc-
curs in about 30% of patients receiving elective nodal irradiation or CT based SNI 160, 
162. This finding deserves further investigation. The low rate of isolated nodal fail-
ures and toxicity thus supports the use of PET-based SNI in LD-SCLC.  
 
A few points of caution should be taken into consideration. First, incidental irradia-
tion of surrounding nodal stations might partially explain the low rates of isolated 
nodal failures with SNI. Therefore, results should be re-evaluated with the applica-
tion of more conformal techniques (SBRT, IMRT, particle therapy). A second point of 
attention consists of the methods for target volume definition. In the available 
study, the mediastinal nodal regions involved on PET were included in the treat-
ment field 163. As our literature search did not yield any study evaluating autocon-
touring methods for lymph node delineation in SCLC, we recommend SNI of the 
whole mediastinal nodal station involved on PET.  
Clinical implications and future perspectives 
As in most cases, the bulk of disease in SCLC is located in the hilar and mediastinal 
regions, reduction of the treatment volume can mainly be reached by omitting elec-
tive nodal irradiation. As mentioned above, the first study with PET-based SNI 
showed a remarkably low rate of oesophageal toxicity 163. If this finding holds true, 
PET based SNI indeed provides opportunities for treatment intensification. With 
regard to RT planning, another point of consideration is the concept of subboosting 
areas of supposed radioresistance. FDG-PET, as well as PET with other tracers, could 
help to identify those regions within the tumour. Although this concept is readily 
evolving in NSCLC, no such trend is observed until now in SCLC. Although it is rea-
sonable to assume that characteristics associated with radioresistance are also het-
erogeneous in SCLC 29-31, the disease load in NSCLC is different from SCLC, as most of 
the tumour load is accounted for by nodal stations. Studies on the evolution and 
stability of regions with high FDG-uptake in NSCLC are entirely focussed on the pri-
mary tumour, and no such information is available with respect to lymph nodes. 
These issues should be addressed when heterogeneous dose escalation is taken into 
consideration in SCLC.  
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Conclusion 
There are no data available on the role of FDG-PET in defining the borders of the 
primary tumour. In contrast with CT-based SNI, first results indicate that selective 
irradiation of FDG-PET positive nodal stations appears to be safe and results in re-
markably limited toxicity. With the increased use of more conformal radiation tech-
niques, the safety of PET-based SNI should be re-evaluated. It is recommended to 
encompass the whole anatomical mediastinal region containing FDG-positive nodes 
in the treatment volume. 
9.4.2 Outcome prediction on basis of PET before or early after the start of 
treatment, and the prognostic value of PET after therapy 
The majority of SCLC patients still shows disease progression short after the comple-
tion of chemoradiotherapy, with over 30% having an isolated local recurrence as 
their first site of progression 162. Furthermore, the treatment is associated with 
considerable toxicity, with grade 3 esophagitis in up to 27% of patients 111, 164-166. 
Therefore, the ability to predict the benefit from treatment would be of great clini-
cal value, hereby avoiding ineffective treatment in the patient group in which bene-
fit is less likely. Recent data have made clear that the traditional staging system with 
two categories (limited and extensive disease) is on its own not an adequate predic-
tor of survival and is not sufficient to stratify patients for the most optimal therapy 
167, 168. Since recently, it is recommended to use the TNM staging for SCLC, as it has 
proven to result in a better stratification of patients in prognostic subgroups 169, 170. 
FDG uptake on PET before, during or after therapy could have a role as additional 
prognostic and predictive marker in SCLC. 
Prognostic value of pre-treatment PET 
Evidence concerning the prognostic value of FDG-uptake before treatment in SCLC is 
scarce. One study was identified that addressed this subject 171. The majority of 
patients had LD and were treated with concurrent chemoradiotherapy. Overall, as 
well as for the subgroup with LD, patients with a high SUVmax (i.e., higher than the 
median) had a significantly worse overall survival than patients with a low SUVmax 
(LD: 20.1 vs. 35.3 months). Three prognostic subgroups could be defined on basis of 
FDG-uptake and disease stage. Those results imply that different treatment strate-
gies are required for LD with low and high SUVmax. Randomized clinical studies are 
warranted to answer whether FDG-uptake in combination with anatomical staging 
is predictive of outcome and can be used to select the appropriate therapy for each 
patient group.  
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Outcome prediction on basis of early PET response during combined modality 
treatment 
The predictive ability of an FDG response early after the start of chemotherapy has 
been evaluated in 2 studies, both after one cycle of chemotherapy 172, 173. However, 
patients with both LD and ED were investigated. Therefore, the results reflect the 
predictive value of an FDG response early during palliative chemotherapy or radical 
chemoradiotherapy. Furthermore, both studies used CT response after completion 
of therapy as a reference, and not survival. Both studies concluded that the meta-
bolic response was correlated with the response according to RECIST.  
 
A couple of important questions need to be addressed in future studies to make 
early response assessment with PET during treatment a valuable clinical tool. Those 
questions include the type of measurement, the definition for response, and the 
most optimal time interval for the measurement of early response. Regarding re-
sponse criteria, the use of the EORTC recommendations 104, a 20% threshold, as well 
as the criteria for visual response assessment by MacManus are valid 109: Fischer et 
al. compared the visual method with the EORTC criteria in SCLC response evaluation 
after one cycle of chemotherapy and found no significant difference 172. Regarding 
the type of measurement and the time interval, no separate data on SCLC are avail-
able. As long as no such data are available, the most practical alternative is to ad-
here to the NSCLC recommendations. Those are the use of relatively simple semi-
quantitative measurements such as SUVmax 
90-92, and a time interval of 1 to 3 cycles 
of chemotherapy 90-92.  
 
Caution is warranted, however, when projecting results obtained in NSCLC at SCLC. 
As mentioned before, those are two distinct types of disease with different clinical 
behaviour. SCLC is characterized by a rapid response to chemo- and radiotherapy. 
Therefore, a response to therapy could be more rapidly visible on CT than it is in 
NSCLC, which might restrict the beneficial effect of PET. This hypothesis is sup-
ported by the study of Fischer et al., who found that early response assessment 
after one cycle of chemotherapy with CT and PET showed a comparable correlation 
with the final evaluation on basis of RECIST 172.  
Added value of PET after combined modality treatment 
Two retrospective studies evaluated the prognostic value of PET after treatment in 
SCLC patients 151, 174, with one specifically aimed at LD 174. The first study included 
both LD and ED, and both treated and untreated patients, with treated LD patients 
representing 50% of the study population. It is hard to draw separate conclusions on 
this group, but overall, there was a significant negative correlation between PET 
positivity or SUVmax and overall survival 
151.  
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The study evaluating exclusively LD patients has some limitations: only 73% was 
treated with chemoradiotherapy, the remaining patients with palliative chemother-
apy 174. Furthermore, the time interval between the end of treatment and PET-
scanning was variable (3-125 days). Finally, the definition of PET positivity was 
rather broad. With those limitations in mind, the study showed a significant differ-
ence in progression free survival between PET positive and -negative patients, with 
a trend for overall survival.  
A prerequisite for PET in the follow-up to have a positive impact on the final out-
come is that progression should be detected at a time that radical retreatment is 
still an option. The rapid growth rate and early dissemination make it less likely for 
progression to be detected in a “curable” stage in SCLC than in NSCLC. Although no 
studies have addressed the role of FDG-PET in the follow-up of SCLC, it can there-
fore be questioned whether PET scanning is advantageous with respect to outcome.  
Clinical implications and future perspectives 
It is obvious that the currently available data are insufficient to modify or adapt 
treatment on basis of pre-treatment FDG uptake or an early metabolic response in 
SCLC patients. Research in the field of early response assessment is of particular 
importance to define the additional benefit of PET above CT given the rapid re-
sponse of SCLC to chemo- and radiotherapy.  
Finally, the role of PET after combined modality therapy of LD-SCLC should be ad-
dressed. Given the early dissemination of SCLC, most benefit is to be expected with 
a tracer that allows response evaluation early after treatment. Given the high up-
take in inflammatory regions, FDG might not be ideal for this purpose. Therefore, 
other tracers should be evaluated.  
Conclusion 
Studies evaluating the prognostic value of PET, its ability to predict response to 
combined modality treatment and the added value of PET after treatment in SCLC 
are scarce. Available results mainly come from studies in patients with both limited 
and extensive disease. Overall, results do show some predictive value of an FDG 
response before and during therapy, as well as prognostic value of FDG uptake after 
treatment. No studies have evaluated the impact of PET in the follow-up of SCLC.  
9.5  General conclusions 
Molecular imaging with PET, using different tracers, has the potential to distinguish 
between vital tumour and non-malignant tissue and to identify intra-tumour charac-
teristics. The additional value of FDG-PET in defining the primary tumour volume 
has been established, mainly in regions with atelectasis or post-treatment effects. 
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Three dimensional models that correlate imaging findings with pathology are being 
developed for NSCLC, which could allow validation of different thresholds for SUV-
based contouring, evaluation of microscopic spread and intra-tumour heterogene-
ity. FDG-PET has the ability to identify regions within the tumour that are associated 
with radioresistance, and for NSCLC, it has been proved that these regions remain 
stable during a radiotherapy course. Therefore, boosting of radioresistant areas 
identified with FDG-PET appears to be feasible and is subject of current research. 
Selective irradiation of FDG-PET positive nodal stations in NSCLC is safe and leads to 
decreased normal tissue exposure, providing opportunities for dose escalation. For 
this reason, it is the preferred treatment in NSCLC. First results in SCLC suggest that 
the same holds true for SCLC. Data on the predictive value of pre-treatment FDG-
uptake and an early metabolic response during combined modality treatment are 
conflicting and limited, respectively. The FDG response after radical treatment is of 
prognostic significance. A time interval of 70 days between end of treatment and 
PET scanning is recommended for response evaluation in NSCLC. A PET scan in the 
follow-up of NSCLC potentially improves survival through the detection of progres-
sion with radical treatment options. Data on its value in the follow-up of SCLC are 
lacking.  
Tracers other than 18FDG are promising for treatment response assessment and the 
visualization of intra-tumour heterogeneity, but more research is needed before 
they can be clinically implemented.  
T H E R A P E U T I C  I M P L I C A T I O N S  O F  P E T  I N  L U N G  C A N C E R  
 163 
9.6 References 
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-
49. 
2. Janssen-Heijnen ML, Coebergh JW. Trends in incidence and prognosis of the histological subtypes of 
lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer 2001;31:123-37. 
3. Hoekstra CJ, Stroobants SG, Hoekstra OS, et al. The value of [18F]fluoro-2-deoxy-D-glucose positron 
emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for 
combined modality treatment. Lung Cancer 2003;39:151-7. 
4. Mac Manus MP, Hicks RJ, Ball DL, et al. F-18 fluorodeoxyglucose positron emission tomography 
staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation 
with survival and high impact on treatment. Cancer 2001;92:886-95. 
5. Mac Manus MP, Wong K, Hicks RJ, Matthews JP, Wirth A, Ball DL. Early mortality after radical radio-
therapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts 
treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys 2002;52:351-61. 
6. Hicks RJ, Kalff V, MacManus MP, et al. (18)F-FDG PET provides high-impact and powerful prognostic 
stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001;42:1596-604. 
7. MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metasta-
ses by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. 
Int J Radiat Oncol Biol Phys 2001;50:287-93. 
8. Nestle U, Weber W, Hentschel M, Grosu AL. Biological imaging in radiation therapy: role of positron 
emission tomography. Phys Med Biol 2009;54:R1-25. 
9. Van de Steene J, Linthout N, de Mey J, et al. Definition of gross tumor volume in lung cancer: inter-
observer variability. Radiother Oncol 2002;62:37-49. 
10. Steenbakkers RJ, Duppen JC, Fitton I, et al. Observer variation in target volume delineation of lung 
cancer related to radiation oncologist-computer interaction: a 'Big Brother' evaluation. Radiother 
Oncol 2005;77:182-90. 
11. Mah K, Caldwell CB, Ung YC, et al. The impact of (18)FDG-PET on target and critical organs in CT-
based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospec-
tive study. Int J Radiat Oncol Biol Phys 2002;52:339-50. 
12. Steenbakkers RJ, Duppen JC, Fitton I, et al. Reduction of observer variation using matched CT-PET for 
lung cancer delineation: a three-dimensional analysis. Int J Radiat Oncol Biol Phys 2006;64:435-48. 
13. Ashamalla H, Rafla S, Parikh K, et al. The contribution of integrated PET/CT to the evolving definition 
of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys 
2005;63:1016-23. 
14. Fox JL, Rengan R, O'Meara W, et al. Does registration of PET and planning CT images decrease in-
terobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer? 
Int J Radiat Oncol Biol Phys 2005;62:70-5. 
15. Bradley J, Thorstad WL, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in 
non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;59:78-86. 
16. Nestle U, Walter K, Schmidt S, et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for 
the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat On-
col Biol Phys 1999;44:593-7. 
17. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in 
lung nodules. J Clin Oncol 1998;16:1075-84. 
18. Nestle U, Kremp S, Grosu AL. Practical integration of [18F]-FDG-PET and PET-CT in the planning of 
radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, prob-
lems, perspectives. Radiother Oncol 2006;81:209-25. 
19. Geets X, Lee JA, Bol A, Lonneux M, Gregoire V. A gradient-based method for segmenting FDG-PET 
images: methodology and validation. Eur J Nucl Med Mol Imaging 2007;34:1427-38. 
Chapter9
C H A P T E R  9  
 164 
20. Black QC, Grills IS, Kestin LL, et al. Defining a radiotherapy target with positron emission tomography. 
Int J Radiat Oncol Biol Phys 2004;60:1272-82. 
21. Daisne JF, Sibomana M, Bol A, Doumont T, Lonneux M, Gregoire V. Tri-dimensional automatic seg-
mentation of PET volumes based on measured source-to-background ratios: influence of reconstruc-
tion algorithms. Radiother Oncol 2003;69:247-50. 
22. Nestle U, Kremp S, Schaefer-Schuler A, et al. Comparison of different methods for delineation of 18F-
FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell 
lung cancer. J Nucl Med 2005;46:1342-8. 
23. Wu K, Ung YC, Hornby J, et al. PET CT Thresholds for Radiotherapy Target Definition in Non-Small-Cell 
Lung Cancer: How Close Are We to the Pathologic Findings? Int J Radiat Oncol Biol Phys 2009. 
24. Yu HM, Liu YF, Hou M, Liu J, Li XN, Yu JM. Evaluation of gross tumor size using CT, 18F-FDG PET, 
integrated 18F-FDG PET/CT and pathological analysis in non-small cell lung cancer. Eur J Radiol 
2009;72:104-13. 
25. van Baardwijk A, Bosmans G, Boersma L, et al. PET-CT-based auto-contouring in non-small-cell lung 
cancer correlates with pathology and reduces interobserver variability in the delineation of the pri-
mary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys 2007;68:771-8. 
26. Dahele M, Hwang D, Peressotti C, et al. Developing a methodology for three-dimensional correlation 
of PET-CT images and whole-mount histopathology in non-small-cell lung cancer. Curr Oncol 
2008;15:62-9. 
27. Stroom J, Blaauwgeers H, van Baardwijk A, et al. Feasibility of pathology-correlated lung imaging for 
accurate target definition of lung tumors. Int J Radiat Oncol Biol Phys 2007;69:267-75. 
28. Siedschlag C, van Loon J, van Baardwijk A, et al. Analysis of the relative deformation of lung lobes 
before and after surgery in patients with NSCLC. Phys Med Biol 2009;54:5483-92. 
29. Cooper RA, Carrington BM, Loncaster JA, et al. Tumour oxygenation levels correlate with dynamic 
contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother 
Oncol 2000;57:53-9. 
30. Foo SS, Abbott DF, Lawrentschuk N, Scott AM. Functional imaging of intratumoral hypoxia. Mol 
Imaging Biol 2004;6:291-305. 
31. Zhao S, Kuge Y, Mochizuki T, et al. Biologic correlates of intratumoral heterogeneity in 18F-FDG 
distribution with regional expression of glucose transporters and hexokinase-II in experimental tu-
mor. J Nucl Med 2005;46:675-82. 
32. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 
2005;6:112-7. 
33. Bentzen SM. Dose painting and theragnostic imaging: towards the prescription, planning and deliv-
ery of biologically targeted dose distributions in external beam radiation oncology. Cancer Treat Res 
2008;139:41-62. 
34. Galvin JM, De Neve W. Intensity modulating and other radiation therapy devices for dose painting. J 
Clin Oncol 2007;25:924-30. 
35. Das SK, Miften MM, Zhou S, et al. Feasibility of optimizing the dose distribution in lung tumors using 
fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission com-
puted tomography guided dose prescriptions. Med Phys 2004;31:1452-61. 
36. Aerts HJ, van Baardwijk AA, Petit SF, et al. Identification of residual metabolic-active areas within 
individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother 
Oncol 2009;91:386-92. 
37. Abramyuk A, Tokalov S, Zophel K, et al. Is pre-therapeutical FDG-PET/CT capable to detect high risk 
tumor subvolumes responsible for local failure in non-small cell lung cancer? Radiother Oncol 
2009;91:399-404. 
38. Aerts HJ, Bosmans G, van Baardwijk AA, et al. Stability of 18F-deoxyglucose uptake locations within 
tumor during radiotherapy for NSCLC: a prospective study. Int J Radiat Oncol Biol Phys 
2008;71:1402-7. 
T H E R A P E U T I C  I M P L I C A T I O N S  O F  P E T  I N  L U N G  C A N C E R  
 165 
39. Caldwell CB, Mah K, Skinner M, Danjoux CE. Can PET provide the 3D extent of tumor motion for 
individualized internal target volumes? A phantom study of the limitations of CT and the promise of 
PET. Int J Radiat Oncol Biol Phys 2003;55:1381-93. 
40. Nehmeh SA, Erdi YE. Respiratory motion in positron emission tomography/computed tomography: a 
review. Semin Nucl Med 2008;38:167-76. 
41. Grgic A, Nestle U, Schaefer-Schuler A, Kremp S, Kirsch CM, Hellwig D. FDG-PET-based radiotherapy 
planning in lung cancer: optimum breathing protocol and patient positioning--an intraindividual 
comparison. Int J Radiat Oncol Biol Phys 2009;73:103-11. 
42. Chan R, He Y, Haque A, Zwischenberger J. Computed tomographic-pathologic correlation of gross 
tumor volume and clinical target volume in non-small cell lung cancer: a pilot experience. Arch 
Pathol Lab Med 2001;125:1469-72. 
43. Giraud P, Antoine M, Larrouy A, et al. Evaluation of microscopic tumor extension in non-small-cell 
lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 
2000;48:1015-24. 
44. Grills IS, Fitch DL, Goldstein NS, et al. Clinicopathologic analysis of microscopic extension in lung 
adenocarcinoma: defining clinical target volume for radiotherapy. Int J Radiat Oncol Biol Phys 
2007;69:334-41. 
45. Belderbos JS, Kepka L, Spring Kong FM, Martel MK, Videtic GM, Jeremic B. Report from the Interna-
tional Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: 
non-small-Cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2008;72:335-42. 
46. Senan S, De Ruysscher D, Giraud P, Mirimanoff R, Budach V. Literature-based recommendations for 
treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 
2004;71:139-46. 
47. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and 
computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-
analysis. Ann Intern Med 2003;139:879-92. 
48. Senan S, Burgers S, Samson MJ, et al. Can elective nodal irradiation be omitted in stage III non-small-
cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-
field radiotherapy. Int J Radiat Oncol Biol Phys 2002;54:999-1006. 
49. Belderbos JS, Heemsbergen WD, De Jaeger K, Baas P, Lebesque JV. Final results of a Phase I/II dose 
escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J 
Radiat Oncol Biol Phys 2006;66:126-34. 
50. De Ruysscher D, Wanders S, van Haren E, et al. Selective mediastinal node irradiation based on FDG-
PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat 
Oncol Biol Phys 2005;62:988-94. 
51. Sulman EP, Komaki R, Klopp AH, Cox JD, Chang JY. Exclusion of elective nodal irradiation is associated 
with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol 2009;4:5. 
52. Sura S, Greco C, Gelblum D, Yorke ED, Jackson A, Rosenzweig KE. (18)F-fluorodeoxyglucose positron 
emission tomography-based assessment of local failure patterns in non-small-cell lung cancer 
treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:1397-402. 
53. De Ruysscher D, Wanders S, Minken A, et al. Effects of radiotherapy planning with a dedicated com-
bined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues 
and radiation dose-escalation: a planning study. Radiother Oncol 2005;77:5-10. 
54. van Der Wel A, Nijsten S, Hochstenbag M, et al. Increased therapeutic ratio by 18FDG-PET CT plan-
ning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. Int J 
Radiat Oncol Biol Phys 2005;61:649-55. 
55. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al. The impact of (18)F-fluoro-2-deoxy-D-glucose 
positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in 
patients with non-small cell lung cancer. Radiother Oncol 2000;55:317-24. 
Chapter9
C H A P T E R  9  
 166 
56. Gomez-Caro A, Garcia S, Reguart N, et al. Incidence of occult mediastinal node involvement in CN0 
non-small-cell lung cancer patients after negative uptake of positron emission tomogra-
phy/computer tomography scan. Eur J Cardiothorac Surg. 
57. Zhao L, Chen M, Ten Haken R, et al. Three-dimensional conformal radiation may deliver considerable 
dose of incidental nodal irradiation in patients with early stage node-negative non-small cell lung 
cancer when the tumor is large and centrally located. Radiother Oncol 2007;82:153-9. 
58. Nestle U, Schaefer-Schuler A, Kremp S, et al. Target volume definition for 18F-FDG PET-positive 
lymph nodes in radiotherapy of patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 
2007;34:453-62. 
59. Thomas JG, Kashani R, Balter JM, Tatro D, Kong FM, Pan CC. Intra and interfraction mediastinal nodal 
region motion: implications for internal target volume expansions. Med Dosim 2009;34:133-9. 
60. Bosmans G, van Baardwijk A, Dekker A, et al. Time trends in nodal volumes and motion during radio-
therapy for patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 
2008;71:139-44. 
61. Pantarotto JR, Piet AH, Vincent A, van Sornsen de Koste JR, Senan S. Motion analysis of 100 medi-
astinal lymph nodes: potential pitfalls in treatment planning and adaptive strategies. Int J Radiat On-
col Biol Phys 2009;74:1092-9. 
62. van Baardwijk A, Bosmans G, Boersma L, et al. Individualized radical radiotherapy of non-small-cell 
lung cancer based on normal tissue dose constraints: a feasibility study. Int J Radiat Oncol Biol Phys 
2008;71:1394-401. 
63. van Baardwijk A, Wanders S, Boersma L, et al. Mature Results of an Individualized Radiation Dose 
Prescription Study Based on Normal Tissue Constraints in Stages I to III Non-Small-Cell Lung Cancer. J 
Clin Oncol. 
64. Feng M, Kong FM, Gross M, Fernando S, Hayman JA, Ten Haken RK. Using fluorodeoxyglucose posi-
tron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung can-
cer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol 
Biol Phys 2009;73:1228-34. 
65. Gillham C, Zips D, Ponisch F, et al. Additional PET/CT in week 5-6 of radiotherapy for patients with 
stage III non-small cell lung cancer as a means of dose escalation planning? Radiother Oncol 
2008;88:335-41. 
66. Petit SF, Aerts HJ, van Loon JG, et al. Metabolic control probability in tumour subvolumes or how to 
guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study. 
Radiother Oncol 2009;91:393-8. 
67. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron 
emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat On-
col Biol Phys 1996;36:417-28. 
68. Thorwarth D, Eschmann SM, Scheiderbauer J, Paulsen F, Alber M. Kinetic analysis of dynamic 18F-
fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC 
Cancer 2005;5:152. 
69. Mees G, Dierckx R, Vangestel C, Van de Wiele C. Molecular imaging of hypoxia with radiolabelled 
agents. Eur J Nucl Med Mol Imaging 2009;36:1674-86. 
70. Sovik A, Malinen E, Skogmo HK, Bentzen SM, Bruland OS, Olsen DR. Radiotherapy adapted to spatial 
and temporal variability in tumor hypoxia. Int J Radiat Oncol Biol Phys 2007;68:1496-504. 
71. Everitt S, Hicks RJ, Ball D, et al. Imaging cellular proliferation during chemo-radiotherapy: a pilot 
study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-
cell lung cancer. Int J Radiat Oncol Biol Phys 2009;75:1098-104. 
72. Ataman OU, Barrett A, Filleron T, Kramar A. Optimization of follow-up timing from study of patterns 
of first failure after primary treatment. An example from patients with NSCLC: a study of the REACT 
working group of ESTRO. Radiother Oncol 2006;78:95-100. 
T H E R A P E U T I C  I M P L I C A T I O N S  O F  P E T  I N  L U N G  C A N C E R  
 167 
73. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic 
radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-
small-cell lung cancer. J Clin Oncol 1999;17:2692-9. 
74. Mac Manus MP, Hicks RJ, Matthews JP, Wirth A, Rischin D, Ball DL. Metabolic (FDG-PET) response 
after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns 
of failure. Lung Cancer 2005;49:95-108. 
75. Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with 
cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung 
Cancer 2004;46:87-98. 
76. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy 
compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: 
Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 
95-01 Study. J Clin Oncol 2005;23:5910-7. 
77. Korst RJ, Gold HT, Kent MS, Port JL, Lee PC, Altorki NK. Surveillance computed tomography after 
complete resection for non-small cell lung cancer: results and costs. J Thorac Cardiovasc Surg 
2005;129:652-60. 
78. Korst RJ, Kansler AL, Port JL, Lee PC, Altorki NK. Accuracy of surveillance computed tomography in 
detecting recurrent or new primary lung cancer in patients with completely resected lung cancer. 
Ann Thorac Surg 2006;82:1009-15; discussion 15. 
79. Higashi K, Ueda Y, Ayabe K, et al. FDG PET in the evaluation of the aggressiveness of pulmonary 
adenocarcinoma: correlation with histopathological features. Nucl Med Commun 2000;21:707-14. 
80. Higashi K, Ueda Y, Yagishita M, et al. FDG PET measurement of the proliferative potential of non-
small cell lung cancer. J Nucl Med 2000;41:85-92. 
81. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-
18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837-44. 
82. Berghmans T, Dusart M, Paesmans M, et al. Primary tumor standardized uptake value (SUVmax) 
measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for 
survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the 
European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 
2008;3:6-12. 
83. Ichiya Y, Kuwabara Y, Sasaki M, et al. A clinical evaluation of FDG-PET to assess the response in 
radiation therapy for bronchogenic carcinoma. Ann Nucl Med 1996;10:193-200. 
84. Eschmann SM, Friedel G, Paulsen F, et al. Is standardised (18)F-FDG uptake value an outcome predic-
tor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging 2006;33:263-9. 
85. Borst GR, Belderbos JS, Boellaard R, et al. Standardised FDG uptake: a prognostic factor for inoper-
able non-small cell lung cancer. Eur J Cancer 2005;41:1533-41. 
86. Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, 2nd, Patz EF, Jr. Prognostic value of 
fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-
stage non-small-cell lung carcinoma. J Clin Oncol 2008;26:1459-64. 
87. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? 
In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 
1993;34:414-9. 
88. van Baardwijk A, Dooms C, van Suylen RJ, et al. The maximum uptake of (18)F-deoxyglucose on 
positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and 
GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007;43:1392-8. 
89. Nahmias C, Hanna WT, Wahl LM, Long MJ, Hubner KF, Townsend DW. Time course of early response 
to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. J Nucl Med 
2007;48:744-51. 
90. Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-
fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-
cell lung cancer. J Clin Oncol 2005;23:8362-70. 
Chapter9
C H A P T E R  9  
 168 
91. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung 
cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin 
Oncol 2003;21:2651-7. 
92. de Geus-Oei LF, van der Heijden HF, Visser EP, et al. Chemotherapy response evaluation with 18F-
FDG PET in patients with non-small cell lung cancer. J Nucl Med 2007;48:1592-8. 
93. Decoster L, Schallier D, Everaert H, et al. Complete metabolic tumour response, assessed by 18-
fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy 
predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). 
Lung Cancer 2008;62:55-61. 
94. Eschmann SM, Friedel G, Paulsen F, et al. 18F-FDG PET for assessment of therapy response and 
preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung 
cancer. Eur J Nucl Med Mol Imaging 2007;34:463-71. 
95. Hellwig D, Graeter TP, Ukena D, Georg T, Kirsch CM, Schafers HJ. Value of F-18-fluorodeoxyglucose 
positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. 
J Thorac Cardiovasc Surg 2004;128:892-9. 
96. Pottgen C, Levegrun S, Theegarten D, et al. Value of 18F-fluoro-2-deoxy-D-glucose-positron emissi-
on tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic 
response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006;12:97-
106. 
97. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET 
response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S-50S. 
98. Tanvetyanon T, Eikman EA, Sommers E, Robinson L, Boulware D, Bepler G. Computed tomography 
response, but not positron emission tomography scan response, predicts survival after neoadjuvant 
chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol 2008;26:4610-6. 
99. Zhang HQ, Yu JM, Meng X, Yue JB, Feng R, Ma L. Prognostic value of serial [(18)F]fluorode-
oxyglucose PET-CT uptake in stage III patients with non-small cell lung cancer treated by concurrent 
chemoradiotherapy. Eur J Radiol 2009. 
100. van Baardwijk A, Bosmans G, Dekker A, et al. Time trends in the maximal uptake of FDG on PET scan 
during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer 
(NSCLC) patients. Radiother Oncol 2007;82:145-52. 
101. Krak NC, Boellaard R, Hoekstra OS, Twisk JW, Hoekstra CJ, Lammertsma AA. Effects of ROI definition 
and reconstruction method on quantitative outcome and applicability in a response monitoring tri-
al. Eur J Nucl Med Mol Imaging 2005;32:294-301. 
102. Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer: reproducibility of quantitative measurements 
for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 1995;196:167-73. 
103. Nakamoto Y, Zasadny KR, Minn H, Wahl RL. Reproducibility of common semi-quantitative parame-
ters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-
deoxy-2-[18F]fluoro-D-glucose. Mol Imaging Biol 2002;4:171-8. 
104. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response 
using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC re-
commendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study 
Group. Eur J Cancer 1999;35:1773-82. 
105. Bruzzi JF, Munden RF. PET/CT imaging of lung cancer. J Thorac Imaging 2006;21:123-36. 
106. Hicks RJ, Kalff V, MacManus MP, et al. The utility of (18)F-FDG PET for suspected recurrent non-
small cell lung cancer after potentially curative therapy: impact on management and prognostic 
stratification. J Nucl Med 2001;42:1605-13. 
107. Rubins J, Unger M, Colice GL. Follow-up and surveillance of the lung cancer patient following curati-
ve intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 
2007;132:355S-67S. 
T H E R A P E U T I C  I M P L I C A T I O N S  O F  P E T  I N  L U N G  C A N C E R  
 169 
108. Duhaylongsod FG, Lowe VJ, Patz EF, Jr., Vaughn AL, Coleman RE, Wolfe WG. Detection of primary 
and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography 
(FDG PET). J Thorac Cardiovasc Surg 1995;110:130-9; discussion 9-40. 
109. Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to compu-
ted tomography scanning for response-assessment after radical radiotherapy or chemoradiothera-
py in patients with non-small-cell lung cancer. J Clin Oncol 2003;21:1285-92. 
110. Patz EF, Jr., Lowe VJ, Hoffman JM, Paine SS, Harris LK, Goodman PC. Persistent or recurrent bron-
chogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 1994;191:379-
82. 
111. Choi NC, Herndon JE, 2nd, Rosenman J, et al. Phase I study to determine the maximum-tolerated 
dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedu-
les with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 
1998;16:3528-36. 
112. Hebert ME, Lowe VJ, Hoffman JM, Patz EF, Anscher MS. Positron emission tomography in the 
pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiothe-
rapy: preliminary findings. Am J Clin Oncol 1996;19:416-21. 
113. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ. FDG-PET in staging and restaging non-small cell 
lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 
2002;35:179-87. 
114. Keidar Z, Haim N, Guralnik L, et al. PET/CT using 18F-FDG in suspected lung cancer recurrence: 
diagnostic value and impact on patient management. J Nucl Med 2004;45:1640-6. 
115. Hicks RJ, Mac Manus MP, Matthews JP, et al. Early FDG-PET imaging after radical radiotherapy for 
non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response 
and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 2004;60:412-8. 
116. Henderson MA, Hoopes DJ, Fletcher JW, et al. A pilot trial of serial 18F-fluorodeoxyglucose positron 
emission tomography in patients with medically inoperable stage I non-small-cell lung cancer trea-
ted with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys;76:789-95. 
117. Ishimori T, Saga T, Nagata Y, et al. 18F-FDG and 11C-methionine PET for evaluation of treatment 
response of lung cancer after stereotactic radiotherapy. Ann Nucl Med 2004;18:669-74. 
118. Benamore R, Shepherd FA, Leighl N, et al. Does intensive follow-up alter outcome in patients with 
advanced lung cancer? J Thorac Oncol 2007;2:273-81. 
119. Edelman MJ, Schuetz J. Follow-up of local (stage I and stage II) non-small-cell lung cancer after 
surgical resection. Curr Treat Options Oncol 2002;3:67-73. 
120. Walsh GL, O'Connor M, Willis KM, et al. Is follow-up of lung cancer patients after resection medi-
cally indicated and cost-effective? Ann Thorac Surg 1995;60:1563-70; discussion 70-2. 
121. Patz EF, Jr., Connolly J, Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for 
non-small cell lung cancer. AJR Am J Roentgenol 2000;174:769-74. 
122. Ahuja V, Coleman RE, Herndon J, Patz EF, Jr. The prognostic significance of fluorodeoxyglucose 
positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 
1998;83:918-24. 
123. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission 
tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin 
Oncol 2004;22:3255-60. 
124. Kased N, Erasmus JJ, Komaki R, Cox JD. Prognostic value of posttreatment [18F] fluorodeoxyglucose 
uptake of primary non-small cell lung carcinoma treated with radiation therapy with or without 
chemotherapy: a brief review. J Thorac Oncol 2008;3:534-8. 
125. van Loon J, Grutters J, Wanders R, et al. Follow-up with 18FDG-PET-CT after radical radiotherapy 
with or without chemotherapy allows the detection of potentially curable progressive disease in 
non-small cell lung cancer patients: a prospective study. Eur J Cancer 2009;45:588-95. 
Chapter9
C H A P T E R  9  
 170 
126. van Loon J, Grutters JP, Wanders R, et al. 18FDG-PET-CT in the follow-up of non-small cell lung 
cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation. 
Eur J Cancer;46:110-9. 
127. Apisarnthanarax S, Alauddin MM, Mourtada F, et al. Early detection of chemoradioresponse in 
esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Clin Can-
cer Res 2006;12:4590-7. 
128. Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with PET: 18F-FLT 
versus 18F-FDG. J Nucl Med 2003;44:1426-31. 
129. Muzi M, Vesselle H, Grierson JR, et al. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: 
validation studies in patients with lung cancer. J Nucl Med 2005;46:274-82. 
130. Wagner M, Seitz U, Buck A, et al. 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission 
tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human 
disease. Cancer Res 2003;63:2681-7. 
131. Yamamoto Y, Nishiyama Y, Ishikawa S, et al. Correlation of 18F-FLT and 18F-FDG uptake on PET with 
Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 
2007;34:1610-6. 
132. Yap CS, Czernin J, Fishbein MC, et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 
18F-fluorodeoxyglucose-positron emission tomography. Chest 2006;129:393-401. 
133. Pan MH, Huang SC, Liao YP, et al. FLT-PET imaging of radiation responses in murine tumors. Mol 
Imaging Biol 2008;10:325-34. 
134. Roels S, Slagmolen P, Nuyts J, et al. Biological image-guided radiotherapy in rectal cancer: is there a 
role for FMISO or FLT, next to FDG? Acta Oncol 2008;47:1237-48. 
135. Wieder HA, Geinitz H, Rosenberg R, et al. PET imaging with [18F]3'-deoxy-3'-fluorothymidine for 
prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol 
Imaging 2007;34:878-83. 
136. Kubota R, Kubota K, Yamada S, et al. Methionine uptake by tumor tissue: a microautoradiographic 
comparison with FDG. J Nucl Med 1995;36:484-92. 
137. Nettelbladt OS, Sundin AE, Valind SO, et al. Combined fluorine-18-FDG and carbon-11-methionine 
PET for diagnosis of tumors in lung and mediastinum. J Nucl Med 1998;39:640-7. 
138. Tsuyuguchi N, Sunada I, Ohata K, et al. Evaluation of treatment effects in brain abscess with posi-
tron emission tomography: comparison of fluorine-18-fluorodeoxyglucose and carbon-11-
methionine. Ann Nucl Med 2003;17:47-51. 
139. van Waarde A, Jager PL, Ishiwata K, Dierckx RA, Elsinga PH. Comparison of sigma-ligands and meta-
bolic PET tracers for differentiating tumor from inflammation. J Nucl Med 2006;47:150-4. 
140. Murayama C, Harada N, Kakiuchi T, et al. Evaluation of D-18F-FMT, 18F-FDG, L-11C-MET, and 18F-
FLT for monitoring the response of tumors to radiotherapy in mice. J Nucl Med 2009;50:290-5. 
141. Yamaura G, Yoshioka T, Fukuda H, et al. O-[18F]fluoromethyl-L-tyrosine is a potential tracer for 
monitoring tumour response to chemotherapy using PET: an initial comparative in vivo study with 
deoxyglucose and thymidine. Eur J Nucl Med Mol Imaging 2006;33:1134-9. 
142. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973;4:31-
42. 
143. de Jong WK, Schaapveld M, Blaauwgeers JL, Groen HJ. Pulmonary tumours in the Netherlands: focus 
on temporal trends in histology and stage and on rare tumours. Thorax 2008;63:1096-102. 
144. Bunn PA, Jr., Carney DN. Overview of chemotherapy for small cell lung cancer. Semin Oncol 
1997;24:S7-69-S7-74. 
145. Ihde DC. Small cell lung cancer. State-of-the-art therapy 1994. Chest 1995;107:243S-8S. 
146. Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA. Positron emission tomo-
graphy in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004;22:3248-54. 
147. Brink I, Schumacher T, Mix M, et al. Impact of [18F]FDG-PET on the primary staging of small-cell 
lung cancer. Eur J Nucl Med Mol Imaging 2004;31:1614-20. 
T H E R A P E U T I C  I M P L I C A T I O N S  O F  P E T  I N  L U N G  C A N C E R  
 171 
148. Chin R, Jr., McCain TW, Miller AA, et al. Whole body FDG-PET for the evaluation and staging of small 
cell lung cancer: a preliminary study. Lung Cancer 2002;37:1-6. 
149. Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-
cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 
2007;18:338-45. 
150. Niho S, Fujii H, Murakami K, et al. Detection of unsuspected distant metastases and/or regional 
nodes by FDG-PET in LD-SCLC scan in apparent limited-disease small-cell lung cancer. Lung Cancer 
2007;57:328-33. 
151. Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [18F]FDG-PET imaging in small cell lung 
cancer. Eur J Nucl Med Mol Imaging 2003;30:78-84. 
152. Shen YY, Shiau YC, Wang JJ, Ho ST, Kao CH. Whole-body 18F-2-deoxyglucose positron emission 
tomography in primary staging small cell lung cancer. Anticancer Res 2002;22:1257-64. 
153. Vinjamuri M, Craig M, Campbell-Fontaine A, Almubarak M, Gupta N, Rogers JS. Can positron emissi-
on tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer 2008;9:30-4. 
154. Ung YC, Maziak DE, Vanderveen JA, et al. 18Fluorodeoxyglucose positron emission tomography in 
the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst 2007;99:1753-67. 
155. Azad A, Chionh F, Scott AM, et al. High Impact of (18)F-FDG-PET on Management and Prognostic 
Stratification of Newly Diagnosed Small Cell Lung Cancer. Mol Imaging Biol 2009. 
156. Blum R, MacManus MP, Rischin D, Michael M, Ball D, Hicks RJ. Impact of positron emission tomo-
graphy on the management of patients with small-cell lung cancer: preliminary experience. Am J 
Clin Oncol 2004;27:164-71. 
157. Kamel EM, Zwahlen D, Wyss MT, Stumpe KD, von Schulthess GK, Steinert HC. Whole-body (18)F-
FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 
2003;44:1911-7. 
158. Schumacher T, Brink I, Mix M, et al. FDG-PET imaging for the staging and follow-up of small cell lung 
cancer. Eur J Nucl Med 2001;28:483-8. 
159. Videtic GM, Belderbos JS, Spring Kong FM, Kepka L, Martel MK, Jeremic B. Report from the Interna-
tional Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung can-
cer: small-cell lung cancer (SCLC). Int J Radiat Oncol Biol Phys 2008;72:327-34. 
160. De Ruysscher D, Bremer RH, Koppe F, et al. Omission of elective node irradiation on basis of CT-
scans in patients with limited disease small cell lung cancer: a phase II trial. Radiother Oncol 
2006;80:307-12. 
161. van Loon J, Offermann C, Bosmans G, et al. 18FDG-PET based radiation planning of mediastinal 
lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study. 
Radiother Oncol 2008;87:49-54. 
162. Turrisi AT, 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in 
limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 
1999;340:265-71. 
163. van Loon J, De Ruysscher D, Wanders R, et al. Selective Nodal Irradiation on Basis of (18)FDG-PET 
Scans in Limited-Disease Small-Cell Lung Cancer: A Prospective Study. Int J Radiat Oncol Biol Phys 
2009. 
164. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemothera-
py and the last day of chest radiation is the most important predictor of survival in limited-disease 
small-cell lung cancer. J Clin Oncol 2006;24:1057-63. 
165. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P. Systematic 
review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in pa-
tients with limited-stage, small-cell lung cancer. Ann Oncol 2006;17:543-52. 
166. Pijls-Johannesma MC, De Ruysscher D, Lambin P, Rutten I, Vansteenkiste JF. Early versus late chest 
radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev 2005:CD004700. 
Chapter9
C H A P T E R  9  
 172 
167. Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treat-
ment of patients with extensive disease small-cell lung cancer: A randomized study. J Clin Oncol 
1999;17:2092-9. 
168. Shepherd FA, Ginsberg RJ, Haddad R, et al. Importance of clinical staging in limited small-cell lung 
cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Onco-
logy Group. J Clin Oncol 1993;11:1592-7. 
169. Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung 
Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer 
in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J 
Thorac Oncol 2007;2:1067-77. 
170. Vallieres E, Shepherd FA, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals regar-
ding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming 
(seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009;4:1049-59. 
171. Lee YJ, Cho A, Cho BC, et al. High tumor metabolic activity as measured by fluorodeoxyglucose 
positron emission tomography is associated with poor prognosis in limited and extensive stage 
small-cell lung cancer. Clin Cancer Res 2009;15:2426-32. 
172. Fischer BM, Mortensen J, Langer SW, et al. PET/CT imaging in response evaluation of patients with 
small cell lung cancer. Lung Cancer 2006;54:41-9. 
173. Yamamoto Y, Kameyama R, Murota M, Bandoh S, Ishii T, Nishiyama Y. Early assessment of thera-
peutic response using FDG PET in small cell lung cancer. Mol Imaging Biol 2009;11:467-72. 
174. Onitilo AA, Engel JM, Demos JM, Mukesh B. Prognostic significance of 18 F-fluorodeoxyglucose - 
positron emission tomography after treatment in patients with limited stage small cell lung cancer. 
Clin Med Res 2008;6:72-7. 
  173 
 
CHAPTER 10 
General Discussion and Future 
Perspectives 
 
 
 
 
 
 
 
C H A P T E R  1 0  
 174 
 
 
 
 
 
 
 
 
 
 
 
 
G E N E R A L  D I S C U S S I O N  A N D  F U T U R E  P E R S P E C T I V E S  
 175 
Combined modality treatment with chemotherapy and radiotherapy (RT) is the 
treatment of choice for the approximately one third of lung cancer patients present-
ing with locally advanced disease. Although survival has improved significantly with 
combined modality therapy, the prognosis remains very poor. The objective of this 
thesis was to address the potential of molecular imaging with PET to optimize com-
bined modality treatment in lung cancer. In this chapter, the main findings are 
summarized and discussed in view of the currently available evidence. Future per-
spectives to further improve outcome in locally advanced lung cancer are provided. 
10.1 FDG-PET-CT based target volume definition to optimize 
radiotherapy for locally advanced lung cancer 
Microscopic disease extension  
In RT planning, a margin of surrounding tissue is added to the gross tumour volume 
(GTV) to ensure coverage of potential microscopic spread, resulting in the clinical 
target volume (CTV) 1.  
Microscopic spread beyond the tumour border visible on imaging can only be quan-
tified by correlating imaging with the findings at pathologic examination. Population 
statistics in NSCLC report an average distance of microscopic spread ranging from 
1.5 mm to 8 mm 2-5. These ranges are probably underestimated as tissue deforma-
tions occur between in-vivo imaging and ex-vivo pathology. This underestimation 
may arise up to a factor of 2 6, 7, suggesting that currently applied margins, usually 
around 5 mm, are probably too small to allow delivery of the full radiotherapy dose 
to areas with microscopic disease. The dose required to eradicate microscopic dis-
ease, however, is expected to be lower than the dose for macroscopic tumour 8, 9. 
Furthermore, not all lung tumours do show microscopic disease spread 3, 7. In this 
thesis, a prediction model for the presence of microscopic spread in NSCLC was 
developed on the basis of risk factors on pre-treatment PET-CT (Chapter 2). Mean 
tumour density on CT and tumour volume on CT were predictive for the presence of 
microscopic disease. After validation in an independent patient cohort, finally, these 
factors could allow an individual adaptation of the dose to the tissue surrounding 
the GTV according to subgroups of patients, thus optimizing the balance between 
local control and toxicity in the individual patient.  
FDG-PET based selective nodal irradiation 
Routine elective nodal irradiation is no longer recommended in NSCLC 10, 11. FDG-
PET scan is more accurate for the detection of lymph node involvement than CT in 
both NSCLC and SCLC 12-16. In NSCLC, the sensitivity and specificity of PET compared 
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to CT are 83% vs. 56% and 89% vs. 81%, respectively. Although in SCLC, no clinical 
trials are available that directly assess the diagnostic performance for lymph node 
staging, the available data report a sensitivity and specificity of 89-100% and 78-95% 
in the overall staging of SCLC. This suggests that the diagnostic accuracy for lymph 
node staging of PET is higher than CT in SCLC as well 16. 
 
Both PET- and CT-based selective nodal irradiation (SNI) of involved lymph nodes 
has proven its safety in NSCLC, with an isolated nodal failure rate of less than 5% 17-
20. In NSCLC, SNI is not only safe, but also results in a reduction of radiation fields 
based on CT, and even further based on FDG-PET 21, providing opportunities for 
radiation dose-escalation through decreased radiation exposure of the lungs and 
the esophagus 21, 22.  
 
In SCLC, data on the applicability of SNI are scarce 23. CT-based SNI cannot be con-
sidered safe, as it resulted in an amount of 11% of isolated nodal failures 24. We 
confirmed in a planning study that differences in the treatment plan resulting from 
PET- and CT-based SNI occur, which was the case in 24% of patients (Chapter 3). The 
subsequent prospective study indicated that FDG-PET-based SNI is safe, with 3% of 
the patients experiencing an isolated nodal failure (Chapter 4). The treatment re-
sulted in a remarkably low percentage (12%) of grade III esophagitis. Anticipating 
that further intensification of the combined modality treatment regimen results in 
improved outcome in SCLC patients as well 25, two intensified RT schedules are cur-
rently compared to the standard treatment schedule (45 Gy twice daily) in a ran-
domized phase III trial 26. The low rate of isolated nodal failures and toxicity sup-
ports the use of PET-based SNI in future intensified treatment schedules for stage I-
III SCLC. 
 
Caution is warranted with the application of more conformal RT technologies, such 
as stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT) 
and particle therapy, as they are associated with altered penumbra characteristics.  
10.2 Value of FDG-PET-CT in the follow-up of locally advanced lung 
cancer 
The most effective follow-up strategy for lung cancer patients treated with curative 
intent therapy is still not established. This uncertainty is reflected in the large het-
erogeneity in recommendations from the different cancer societies, diverging from 
no imaging at all to repeated imaging with chest CT scans 27. The added value of 
chest X-rays and/or chest CT has not been confirmed in any prospective study. The 
most recent study comparing intensive follow-up with repeated CT-imaging to less 
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intensive radiologic follow-up showed no significant improvement of survival 28. A 
main reason for this is the fact that progression or recurrence is mostly detected at 
a stage that no more radical treatment options exist, and hence, no survival benefit 
can be expected 29. The poor discriminating capacity of CT and chest X-ray between 
residual tumour and post-treatment changes 30, 31 causes a delay as progression is 
often only confirmed after repeated imaging.  
 
FDG-PET-CT is more accurate than CT in the evaluation of response to treatment as 
well as in outcome prediction 32-40. This formed the rationale for the hypothesis that 
PET-CT may have additional benefit. We report in this thesis the results of a pro-
spective study in 100 NSCLC patients treated with chemo-radiotherapy or RT alone 
with curative intent. This study confirms that an FDG-PET-CT 3 months after therapy 
can detect progression amenable for treatment with curative intent, and hereby, 
possibly lead to an increase in survival. This was, however, only the case in a small 
proportion of patients (2%), and only in the subgroup that was asymptomatic at the 
time of scanning (Chapter 5). Based on these results, an economic evaluation was 
subsequently performed comparing PET-CT based follow-up with usual follow-up 
with either a CT scan or repeated chest X-rays. A PET-CT scan 3 months after 
(chemo-)radiotherapy turned out to be potentially cost-effective, and was more 
cost-effective than CT alone. As the advantage was confined to the asymptomatic 
patients, representing 55% of the total population, performing a PET-CT in this 
group only is probably as effective and more cost-effective (Chapter 6).  
 
Hence, we suggest that on basis of the currently available evidence, if any imaging is 
wished to be performed for treatment evaluation in NSCLC, an FDG- PET-CT scan 3 
months after therapy is to be preferred above CT alone. The uncertainty surround-
ing the decision whether to implement PET-CT in the follow-up makes it worthwhile 
to perform additional research. This uncertainty is caused for a major part by the 
relatively small patient population in the prospective study. In this respect, a direct 
comparison between conventional, CT based and PET-CT based follow-up in a ran-
domized trial, including a prospective evaluation of the associated costs, would add 
significantly to the final decision regarding which strategy to implement in routine 
clinical practice. 
A multicentre phase III trial in NSCLC patients after curative resection is currently 
ongoing in France which should give a definitive answer regarding the value of CT 
based follow-up 41. Unfortunately, however, PET-CT scans are not included in this 
trial.  
 
No studies have addressed the role of FDG-PET in the follow-up of SCLC. Because of 
the rapid growth rate and early dissemination of SCLC, it is less likely that an FDG-
PET scan 3 months after therapy detects progression in a stage that is still curable. 
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As earlier response evaluation with FDG is limited by its uptake in inflammatory 
areas, other tracers, such as proliferation markers that are described below, may be 
better suitable for this purpose.  
10.3 Novel PET tracers for the non invasive imaging of tumour 
characteristics 
The supplementary role of FDG-PET in the diagnosis, staging and treatment of lung 
cancer is beyond doubt. The correlation between high FDG uptake and worse over-
all survival has been shown in multiple studies 42-45, and was confirmed in a meta-
analysis, with a combined HR for survival of 2.27 36. Nevertheless, the inherent 
properties of FDG limit its value in certain areas. Furthermore, the development and 
introduction of new therapeutic strategies specifically targeted at tumour cell char-
acteristics provide novel opportunities for molecular imaging to specifically visualize 
one of these characteristics. This makes it worthwhile to investigate whether alter-
native tracers can complement FDG. 
 
The limited ability of FDG to discriminate between tumour activity and inflamma-
tory effects due to therapy, has forced the search for more specific markers of tu-
mour cell proliferation. Two groups of proliferation markers have been evaluated 
for their ability to image proliferation during (chemo-)radiotherapy. Thymidine 
analogues, markers of DNA synthesis, of which 18F-fluorothymidine (18F-FLT) is most 
extensively applied, has been correlated with tumour proliferative activity in lung 
cancer 46-49 and has the feasibility to image proliferation during chemoradiotherapy 
50. In head and neck cancer patients, however, FLT has been shown to accumulate 
as well in reactive B-lymphocytes, which forms a potential drawback for is use in 
early response assessment 51. 
The second group of proliferation markers consists of amino-acid tracers, such as 
11C-methionine (11C-Met) and 18F-fluoromethyltyrosine (18F-FMT). Data on their 
usefulness in evaluating treatment response are scarce 52-55, but preclinical studies 
with 18F-FMT did show a rapid response to antitumour therapy with little accumula-
tion in inflammatory cells 56, 57.  
 
Tumour hypoxia is an important marker of cancer prognosis, being associated with 
aggressive growth, metastasis, and resistance to anticancer therapy 58. Non-invasive 
PET imaging allowing detection and quantification of hypoxia could select patients 
who may benefit from hypoxic radio-sensitizers or dose-escalation. Although the 
uptake of glucose, and thus FDG, is increased by hypoxia, many other factors includ-
ing proliferation and cell density also increase cellular glucose influx 59. Clinical stud-
ies in NSCLC regarding the correlation between FDG uptake and the degree of hy-
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poxia within the tumour have shown contradictory results 39, 60-63. Therefore, spe-
cific hypoxia targeted tracers are required to image hypoxia in lung cancer.  
 
[18F]HX4, a recently developed hypoxia marker of the 2-nitroimidazole family, has in 
preclinical models proven to be a good tracer for the detection and evaluation of 
tumour hypoxia. [18F]HX4 was cleared faster from normal tissues and better re-
flected tumour heterogeneity compared to commonly used hypoxia markers such as 
[18F]FMISO and [18F]FAZA, suggesting that [18F]HX4 may be a better alternative than 
these known hypoxia markers 64. We demonstrated in a phase I trial that PET imag-
ing with [18F]HX4 is safe (Chapter 7). The median tumour to muscle ratio (TMR) at 
120 minutes post-injection was 1.40 (range: 0.63-1.98). No imaging at later time 
points was performed to limit the burden for the patients, all suffering from end 
stage disease. Future trials are needed to determine optimal imaging parameters, as 
preclinical data suggest 240 minutes post-injection as the most optimal time-point 
of scanning, with a maximum tumour to blood ratio of 7.6 64. 
 
Another area where non-invasive PET imaging could have additional clinical benefit 
is in the imaging of tumour expression of receptors that are targets for specific anti-
cancer agents. One of these targets is the epidermal growth factor receptor (EGFR). 
Expression of this receptor has been correlated with tumour aggressiveness and 
treatment resistance 65. EGFR inhibitors, such as the monoclonal antibody cetuxi-
mab, are increasingly used in combination with RT and/or chemotherapy to improve 
treatment outcome compared to RT alone 66, 67. The expression of EGFR, however, is 
heterogeneous throughout the tumour, and can alter under the influence of anti-
cancer treatment 68. Therefore, non invasive imaging of cetuximab binding to cancer 
cells before and during combined modality therapy could help to select the patients 
with the highest probability to benefit from treatment and would provide insight in 
intra-tumour characteristics associated with treatment resistance. Zirconium-89 
(89Zr) labelled cetuximab has been tested in pre-clinical animal models with excel-
lent results (Figure 10.1) 69. 
Safety results of the phase I trial in this thesis form the basis for future patient stud-
ies to evaluate its potential clinical efficacy (Chapter 8). In this study, the maximal 
tumour to blood ratio for cetuximab uptake was 1.6. Future clinical studies are 
planned in patients before the start of any antitumour therapy, to allow correlation 
of EGFR expression at histology with imaging results. These studies will include ki-
netic imaging to enable the measurement of tumour perfusion. Optimal imaging 
conditions, including the appropriate loading dose of unlabelled cetuximab, are to 
be defined.  
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Figure 10.1 Time series of representative small-animal PET images at indicated time points after injec-
tion of 89Zr-cetuximab into HT-29 tumour bearing mouse 
Grey arrows indicate tumours. Uptake levels plateaued from 72 h after injection onward. To allow com-
parison between different time points, images are shown at mid-plane cross-section through tumour. 
Images are corrected for injected dose and decay and represented as %ID/mL 
10.4 Future perspectives 
Future developments to further improve outcome of the combined modality treat-
ment of locally advanced lung cancer should adhere to the following principle: Im-
proving tumour control whilst keeping normal tissue toxicity at a constant level.  
Molecular imaging provides several opportunities to contribute to this goal in the 
future, which will be discussed below. 
 
Accurate target volume definition is a prerequisite for the further improvement of 
conformal radiotherapy. PET-CT could optimize different aspects with regard to this 
subject: delineation of macroscopic tumour and lymph nodes encompassing the 
GTV, definition of the CTV margin to cover microscopic spread, and finally, the ap-
plication of a PTV-margin appropriate to cover inaccuracies due to delineation un-
certainty, set-up errors and tumour movement 1. Ideally, validation of the deline-
ated tumour volume on PET AND CT should be obtained by correlating it with the 
tumour volume at pathologic examination, being the gold standard. Data that are 
currently available are only based on two-dimensional correlations in early stage 
disease 70-72. Three-dimensional models correlating PET and CT findings with pathol-
ogy are under development, and results in large patient cohorts are pending 6, 7, 73.  
Individually adapted CTV and PTV margins could contribute significantly to personal-
ized optimization of therapy. This thesis proved the feasibility to predict the pres-
ence of microscopic spread on basis of the pre-treatment PET/CT scan. Validation of 
the model is to be awaited, with the final aim to implement the use of individually 
adapted CTV margins.  
 
The limitations of PET to define the exact tumour extent should be kept in mind. 
Blurring of the tumour edges does occur due to the poor resolution and motion 
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artefacts associated with the long acquisition time of PET 74. The long acquisition 
time is, however, advantageous with respect to determining the extent of tumour 
motion. In a phantom study, PET-based treatment volumes resulted in an adequate 
coverage of the tumour during the whole respiratory cycle, while CT-based volumes 
harboured the risk of a geographical miss 75. So-called four dimensional (4D) imag-
ing techniques add respiration movements as a fourth dimension to conventional 
3D CT and PET. It allows the incorporation of information on the extent of tumour 
motion, while optimizing image quality and quantification through reduction of the 
blurring effect. This provides the opportunity to apply personalized PTV margins 
depending on the extent of tumour motion. These techniques are presently being 
evaluated in clinical studies 76, 77. 
 
The incorporation of PET in RT planning has already shown the potential for dose 
escalation through a reduction of the radiation fields 21, 22, 78. Further optimization 
could be reached with the prescription of an individually determined maximal toler-
able dose instead of applying the same radiation dose in all patients. The concept of 
individualized radiation dose escalation based on normal tissue constraints has 
recently been introduced in the clinic. This technique is an ultimate example of 
individualized treatment intensification at an acceptable toxicity rate. Survival rates 
of patients treated on basis of this concept with sequential chemo-radiation had 
survival rates comparable to results with concurrent chemo-radiation schedules, 
while less toxicity was observed 79. These results suggest that individual dose escala-
tion with PET-based RT planning can ultimately lead to higher cure rates, which 
should be the subject of future randomized prospective studies. 
 
Recently, the concept of intratumoral radiation dose distribution has been estab-
lished as a counterpart to homogeneous irradiation. The rationale behinds this con-
cept is that characteristics associated with radioresistance, such as hypoxia, cell 
density and proliferation, are heterogeneous across the tumour 80-82. Therefore, it is 
anticipated that selective boosting of these radioresistant areas, whilst decreasing 
the dose to the less resistant zones, would result in higher tumour control with 
similar side effects 83-86. FDG is at present the most reasonable tracer to identify 
therapy-resistant areas within the tumour. Certain key issues before initiating a 
clinical trial on FDG-PET based dose redistribution have recently been addressed. 
First, it has been demonstrated that regions with high FDG uptake prior to radio-
therapy correspond well with the location of recurrent or persistent tumour after 
sequential chemo-radiotherapy or radiotherapy alone 69, 87. Furthermore, it has 
been shown that those regions remain stable during a course of RT 88. Thus, selec-
tive boosting of areas of assumed radioresistance identified with FDG-PET before 
the start of RT appears to be feasible. A multicentre prospective trial has recently 
been started to evaluate whether selective boosting leads to better treatment out-
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come. On basis of the currently available evidence and the wide availability of FDG 
as a tracer, FDG represents the most appropriate tracer for boosting subvolumes. 
Other tracers that are more specific to hypoxia (18F-FMISO, [18F]HX4) or proliferation 
(18F-FLT), however, could be used complimentary to FDG 50, 89-92, and deserve further 
investigation for this purpose.  
The ultimate method to guide tumour dose distribution would be the development 
of a voxel control probability map on the basis of tumour characteristics identified 
on CT and PET with different tracers. For this purpose, pathology correlation studies 
are underway to examine the relation between the pre-treatment PET/CT charac-
teristics of a voxel and the underlying histopathology (tumour cell density, hypoxia, 
proliferation). The resulting probability map could be used for dose distribution with 
the application of a dose modifying factor to each voxel depending on the relative 
radioresistance, resulting in an optimal “voxel control probability”.  
 
Until now, the majority of patients still suffer from disease progression short after 
the completion of treatment 33, 93-96. In order to avoid ineffective treatment with the 
associated toxicity, extensive efforts have been made to select these patients be-
fore or early during treatment, enabling alternative therapy or treatment modifica-
tion in cases where the expected benefit of the proposed treatment is insufficient. 
Different methodologies have been developed in the search for predictive factors of 
treatment outcome, such as genomics, cytomics, proteomics and identification of 
predictive imaging features. It remains a challenge to effectively select those pa-
rameters that are of up most predictive value. So-called “Computer assisted ther-
anostics” (CAT) provide a method to incorporate different predictive parameters to 
determine the expected benefit of a particular treatment for each individual pa-
tient. Obviously, data obtained with molecular imaging should be included in CAT. 
Although in the overall patient group with NSCLC, pre-treatment FDG-uptake has 
prognostic value 36, results in advanced stage disease are conflicting, with the most 
recent study in the largest patient cohort not showing a significant correlation with 
survival 42, 43, 97. Data in SCLC are scarce, but indicate that pre-treatment SUVmax has 
prognostic value 98. The predictive value of an early metabolic response during in-
duction chemotherapy has been established 99, 100. With respect to the predictive 
value of a metabolic response during radical (chemo-)RT itself, the limited available 
data show a correlation with survival 101, 102. Also in this regard, other tracers are 
worthwhile to be investigated. Especially proliferation markers, that are less suscep-
tible to uptake in inflammatory tissue, are supposed to have additional value above 
FDG in response evaluation during and after treatment 50.  
 
A potential drawback of PET is its associated costs in comparison to anatomic imag-
ing modalities. Health care costs put an increasing burden on the overall economy. 
In the Netherlands, in 2008, 80 billion Euro was spent on health care, representing 
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13% of the gross domestic product 103. At present, cancer care accounts for ap-
proximately 5% of the total health care costs, and this proportion is expected to 
increase 104. Different countries increasingly request for evidence regarding the 
cost-effectiveness of novel therapeutic strategies in order to support its reim-
bursement, as only finite resources are available. In this light, the costs associated 
with the introduction of PET in different aspects of the combined modality treat-
ment of lung cancer have to be weighed against its benefits. Information regarding 
cost-effectiveness can be obtained by an economic evaluation in which different 
treatment strategies including diagnostics can be compared with respect to both 
their costs and consequences on the basis of the currently available evidence 105.  
10.5 Conclusions 
The aim of this thesis was to address the potential of molecular imaging with PET to 
optimize combined modality treatment in lung cancer.  
FDG-PET improves target volume definition both with respect to the primary tu-
mour and lymph nodes. The only way to accurately assess the extent of microscopic 
spread is by means of pathology correlation studies. This thesis proved the feasibil-
ity to predict the presence of microscopic spread on basis of the pre-treatment 
PET/CT scan. Finally, adapted CTV margins may be applied for low and high risk 
patients, resulting in an individually optimized sparing of normal tissue and im-
proved coverage of all microscopic disease. 
Selective nodal irradiation (SNI) of FDG-PET positive nodal stations has already been 
established as the preferred treatment in NSCLC. Results from this thesis suggest 
that FDG-PET based SNI is also safe in SCLC and is associated with a low toxicity rate, 
which may provide opportunities for dose escalation.  
With regard to the role of PET scanning in the follow-up of lung cancer, it has been 
shown that an FDG-PET scan 3 months after combined modality therapy for NSCLC 
potentially improves survival through the detection of progression in a stage that 
radical treatment is still an option.  
Tracers other than 18FDG offer potential to select patients with the highest probabil-
ity to benefit from treatment with hypoxic radio-sensitizers or anticancer agents 
targeted at receptors on the surface of cancer cells. Furthermore, these tracers 
could have additional value for treatment response assessment and the visualiza-
tion of intra-tumour heterogeneity, but more research is needed before they can be 
clinically implemented.  
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Lung carcinoma is the third common malignancy in Europe and forms the major 
cause of cancer death. On basis of its histology, it is broadly divided in two main 
categories: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).  
Combined modality treatment with radiotherapy (RT) and chemotherapy is the 
treatment of choice for locally advanced NSCLC patients and for SCLC patients with-
out distant metastases. Traditionally, anatomical imaging modalities are applied for 
the diagnosis and staging, as well as in the follow-up of lung cancer patients. Ana-
tomical imaging with computed tomography (CT) is very accurate with respect to 
anatomical information in lung cancer, but it has limitations in certain other areas, 
such as the distinction between vital tumour and non-malignant tissue. Recently, 
molecular imaging techniques have been developed, which allow the visualization 
of molecular processes inside tumour and normal tissues in a non-invasive manner.  
In this thesis, different aspects of the potential of molecular imaging with positron 
emission tomography (PET) to optimize the combined modality treatment of lung 
cancer are assessed. Chapter 1 provides a general introduction to the epidemiology 
and treatment of lung cancer, and the imaging modalities that are used. Further-
more, the outline of the thesis is described. The thesis consists of 3 main parts, 
which are summarized below.  
Part I: FDG-PET-CT based target volume definition to optimize 
radiotherapy for locally advanced lung cancer 
In RT planning, a margin of tissue surrounding the macroscopic tumour is added in 
all patients to ensure that the area with potential microscopic tumour spread is 
covered by the radiation field. Microscopic disease spread, however, does not occur 
in all patients with NSCLC. In chapter 2, risk factors for the presence of microscopic 
disease spread were identified on pre-treatment PET-CT. The pathological speci-
mens of 34 NSCLC patients who underwent lobectomy were examined microscopi-
cally for microscopic disease extension outside the macroscopic tumour. Image 
based risk factors for microscopic disease were identified and a prediction model 
was developed based on these factors. Mean tumour density on CT and tumour 
volume on CT were predictive for the presence of microscopic disease. Finally, these 
risk factors could allow tumour tailored adaptation of the dose to the tissue sur-
rounding the macroscopic tumour. In this way, the balance between local tumour 
control and sparing of normal tissue in individual patients can be optimised. 
 
In chapter 3 and 4, selective irradiation of FDG-PET positive mediastinal lymph 
nodes in SCLC was evaluated. Traditionally, all mediastinal nodal areas are irradiated 
prophylactically, resulting in large treatment volumes. Selective nodal irradiation 
(SNI) on basis of CT has previously shown to result in an unacceptable amount (11%) 
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of isolated nodal failures in SCLC. On basis of the hypothesis that fluorodeoxyglu-
cose (FDG)-PET based SNI would improve the coverage of involved lymph nodes, a 
planning study (chapter 3) was performed. Two conformal treatment plans were 
made with selective irradiation of involved lymph nodes, based on CT and on PET, 
respectively. A difference in the treatment plan resulting from PET- and CT-based 
SNI was seen in 24% of patients. Results of the subsequent prospective study are 
reported in chapter 4, in which the safety of PET-based SNI in SCLC was evaluated in 
60 patients. Two patients (3%) experienced an isolated nodal failure. The median 
actuarial overall survival was 19 months. The treatment resulted in a remarkably 
low percentage (12%) of grade III or worse oesophageal toxicity. 
It was concluded that this low rate of isolated nodal failures and toxicity supports 
the use of PET-based SNI in stage I-III SCLC. Results should be re-evaluated, how-
ever, with the application of more conformal RT techniques because these are asso-
ciated with altered penumbra characteristics.  
Part II: Value of FDG-PET-CT in the follow-up of locally advanced 
lung cancer 
In the second part of this thesis, the added value of FDG-PET-CT after curative intent 
therapy for locally advanced NSCLC was evaluated. In chapter 5, we prospectively 
evaluated whether a PET-CT 3 months after therapy can detect potentially curable 
progression in 100 NSCLC patients treated with (chemo-)radiation. Progression 
amenable for retreatment with curative intent was detected in a small proportion of 
patients (2%), and only in the subgroup that did not have symptoms at the time of 
scanning. This progression was only detected with PET, not with CT alone.  
The results of this study formed the basis for the economic evaluation described in 
chapter 6. The long-term cost-effectiveness of a PET-CT based follow-up was com-
pared with the “usual” follow-up with either a CT scan or repeated chest X-rays. 
Cost-effectiveness of the different follow-up strategies was expressed in incre-
mental cost-effectiveness ratios (ICERs), calculating the incremental costs per qual-
ity adjusted life year (QALY) gained. A PET-CT scan 3 months after treatment turned 
out to be potentially cost-effective, costing € 69.086 per QALY gained compared to 
conventional follow-up. As the advantage was confined to the asymptomatic pa-
tients, performing a PET-CT in this group only is probably as effective and more cost-
effective (€ 42.265 per QALY gained). CT-based follow-up was only slightly more 
effective than conventional follow-up, resulting in an ICER of € 264.033 per QALY 
gained. 
This part of the thesis thus indicates that a PET-CT scan 3 months after 
(chemo)radiotherapy with curative intent is a potentially cost-effective follow-up 
method, and is more cost-effective than CT alone. On basis of the currently avail-
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able evidence, it is therefore suggested that an FDG-PET-CT scan 3 months after 
therapy is to be preferred above CT alone. It is worthwhile to perform additional 
research to reduce the uncertainty regarding the decision which imaging to perform 
in the follow-up of NSCLC. 
Part III: Novel PET tracers for the non invasive imaging of tumour 
characteristics 
Part III of this thesis consists of two trials evaluating the safety of new PET-tracers 
directed at two different biological characteristics of cancer cells. Chapter 7 reports 
the results of a phase I trial in incurable cancer patients evaluating [18F]HX4, a re-
cently developed hypoxia marker of the 2-nitroimidazole family. A two-dose step 
study design was used, with 3 patients included in each dose step. PET-CT images of 
the largest tumour site were acquired at 30, 60 and 120 minutes after injection. No 
toxicity was observed in any of the patients at either dose level. The median tumour 
to muscle ratio (TMR) at 120 minutes post-injection was 1.40 (range: 0.63-1.98). In 
conclusion, [18F]HX4 PET imaging is not associated with any toxicity. Trials are 
planned to determine the optimal time point of imaging, as in preclinical studies 
tumour to blood ratios up to 7.6 can be reached when imaging is performed at later 
time points post-injection.  
In chapter 8, the safety of Zirconium-89 (89Zr) labelled cetuximab, an antibody 
against the epidermal growth factor receptor, was evaluated in 7 patients with 
incurable cancer. The safety of two different dose schedules was tested. Labelled 
cetuximab administration was preceded by a standard loading dose of unlabelled 
cetuximab. PET-CT scans were acquired on day 4, 5 and 6 (step 1) and 5, 6, 7 (step 2) 
post injection. Five of six patients who completed the study experienced skin toxic-
ity, a known side-effect from cetuximab administration. No additional toxicity was 
reported. The maximal tumour to blood ratio (TBR) was 1.6 (range: 0.42-1.60). Fu-
ture trials are needed to define optimal imaging conditions, including the appropri-
ate loading dose of unlabelled cetuximab. In the end, visualization and quantifica-
tion of tumour uptake of cetuximab with PET before and during (chemo-
)radiotherapy would have major benefit in the appropriate selection of patients for 
cetuximab treatment. 
 
Finally, part IV of this thesis provides a discussion on the role of PET in the combined 
modality therapy of lung cancer. In chapter 9, the available literature regarding this 
subject is reviewed, while chapter 10 describes the major results of this thesis in the 
context of the currently existing evidence. Furthermore, perspectives for future 
research to further improve outcome in locally advanced lung cancer are high-
lighted.  
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In conclusion, FDG-PET provides several opportunities to improve the combined 
modality treatment of locally advanced lung cancer, both in the field of defining the 
volume to be treated with RT, and in the follow-up after treatment. Prospective 
randomized trials are encouraged in this field. Tracers other than 18FDG offer poten-
tial to select patients with the highest probability to benefit from treatment with 
hypoxic radio-sensitizers or anticancer agents targeted at receptors on the surface 
of cancer cells, but additional research is needed before these tracers can be im-
plemented in clinical practice.  
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Longkanker is de derde meest voorkomende maligniteit in Europa en is de belang-
rijkste oorzaak van kankersterfte. Op basis van de celkenmerken wordt longkanker 
ruwweg ingedeeld in 2 hoofdcategorieën: het niet-kleincellig longcarcinoom (non-
small cell lung carcinoma, NSCLC) en het kleincellig longcarcinoom (small cell lung 
carcinoma, SCLC).  
Gecombineerde behandeling met bestraling (radiotherapie, RT) en chemotherapie 
is de behandeling van keuze voor patiënten met lokaal gevorderd NSCLC of SCLC 
zonder uitzaaiingen op afstand. Van oudsher worden anatomische beeldvormings-
technieken gebruikt, zowel voor de diagnostiek en stadiëring van longkanker als 
voor de evaluatie na de behandeling. Anatomische beeldvorming met “computed 
tomography”, ofwel CT scans, is accuraat wat betreft anatomische informatie, maar 
kent beperkingen op andere gebieden, zoals het onderscheid tussen vitaal tumor-
weefsel en niet-kwaadaardig weefsel. Meer recent zijn moleculaire beeldvormings-
technieken ontwikkeld die het mogelijk maken moleculaire processen binnen de 
tumor en normale weefsels te visualiseren op een niet-invasieve manier. Positron 
emissie tomografie (PET) is een bekende moleculaire beeldvormingstechniek. PET 
maakt het mogelijk de verdeling van een radioactieve stof in het lichaam driedimen-
sionaal in beeld te brengen. Voor de beeldvorming van kanker wordt verreweg het 
meest gebruik gemaakt van radioactief gelabelde suiker (18F-fluorodeoxyglucose, 
FDG). Kankercellen gebruiken meer suiker dan de meeste niet-kwaadaardige cellen, 
en dit verschil in suikermetabolisme resulteert in een verhoogde opname van FDG 
ter plaatse van de tumor. Ook andere moleculen kunnen radioactief worden ge-
maakt door ze te binden aan een radioactieve tracer. Dit maakt het mogelijk om 
bepaalde eigenschappen van een tumor te visualiseren die geassocieerd zijn met de 
agressiviteit van de tumor en de te verwachten respons op antikankerbehandeling. 
In dit proefschrift werden verschillende mogelijkheden onderzocht om de gecombi-
neerde modaliteitsbehandeling van longkanker te optimaliseren door middel van 
moleculaire beeldvorming met PET. Hoofdstuk 1 geeft een algemene introductie in 
de epidemiologie en de behandeling van longkanker en de beeldvormingstechnie-
ken die worden gebruikt. Ook wordt een overzicht gegeven van de opbouw van het 
proefschrift. De drie hoofdonderdelen van het proefschrift worden hieronder sa-
mengevat.  
Deel 1: Definitie van het doelvolume op basis van FDG-PET-CT ter 
optimalisatie van de radiotherapie voor locaal uitgebreide 
longkanker  
Bij het plannen van de bestralingsbehandeling wordt altijd een marge weefsel 
rondom de macroscopisch zichtbare tumor meegenomen om te verzekeren dat het 
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gebied met mogelijk microscopische tumoruitbreiding wordt meebestraald. Micro-
scopische ziekte-uitbreiding is echter slechts in een deel van de patiënten met 
NSCLC aanwezig. In hoofdstuk 2 werden risicofactoren voor de aanwezigheid van 
microscopische tumoruitbreiding vastgesteld aan de hand van een PET-CT die voor 
de behandeling werd verricht bij 34 NSCLC patiënten die een lobectomie ondergin-
gen. De pathologische preparaten van deze patiënten werden microscopisch onder-
zocht op ziekte-uitbreiding buiten de macroscopische tumor. Risicofactoren op PET 
en/of CT werden geïdentificeerd en op basis van deze factoren werd een predictie-
model ontwikkeld. De gemiddelde tumordichtheid op CT en het tumorvolume op CT 
waren predictief voor de aanwezigheid van microscopische ziekte. Uiteindelijk zou-
den deze risicofactoren kunnen worden gebruikt om de bestralingsdosis op het 
weefsel rondom de macroscopische tumor per individu aan te passen. Op deze 
manier kan het evenwicht tussen lokale tumorcontrole en het sparen van het nor-
male weefsel in elke individuele patiënt worden geoptimaliseerd. 
 
In hoofdstuk 3 en 4 werden de resultaten geëvalueerd van selectieve klierbestraling 
van FDG-PET positieve mediastinale klieren in SCLC. Bij een conventionele bestraling 
worden alle mediastinale klierstations profylactisch bestraald, resulterend in grote 
bestralingsvolumes. In NSCLC is inmiddels aangetoond dat selectieve bestraling van 
klieren die positief zijn op CT of PET veilig is. Selectieve bestraling van CT-positieve 
klieren leidde in SCLC echter tot een onacceptabele hoeveelheid (11%) geïsoleerde 
klierrecidieven. Op basis van de hypothese dat FDG-PET betrouwbaarder is dan CT 
voor de detectie van positieve klieren in SCLC, werd in hoofdstuk 3 een planning 
studie uitgevoerd. Er werden twee conformele bestralingsplannen ontwikkeld, één 
voor selectieve bestraling van CT-positieve klieren, de andere voor PET-gebaseerde 
selectieve klierbestraling. In 24% van de patiënten werd een verschil gevonden 
tussen de bestralingsplannen voor PET- en CT gebaseerde klierbestraling. Vervol-
gens werd een prospectieve studie uitgevoerd welke beschreven wordt in hoofd-
stuk 4. In deze prospectieve studie werd de veiligheid van PET-gebaseerde selectie-
ve klierbestraling geëvalueerd in 60 SCLC patiënten. Twee van hen (3%) ontwikkel-
den een geïsoleerd klierrecidief. De mediane overleving bedroeg 19 maanden. De 
behandeling resulteerde in een opvallend laag percentage patiënten met een graad 
3 of hogere slokdarmtoxiciteit.  
Het lage aantal geïsoleerde klierrecidieven samen met een lage toxiciteit onder-
steunt de toepassing van PET-gebaseerde selectieve klierbestraling in stadium I-III 
SCLC. Indien in de toekomst meer conformele bestralingstechnieken worden toege-
past zullen resultaten opnieuw moeten worden geëvalueerd aangezien deze nieuwe 
technieken gepaard gaan met een andere dosisverdeling rondom het doelvolume 
van de radiotherapie.  
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Deel II: Waarde van FDG-PET in de evaluatie na behandeling van 
het lokaal uitgebreide longcarcinoom 
In het tweede deel van het proefschrift werd de toegevoegde waarde onderzocht 
van een FDG-PET-CT na curatieve behandeling van het lokaal uitgebreide longcarci-
noom. In hoofdstuk 5 werd bij 100 NSCLC patiënten prospectief beoordeeld of een 
PET-CT 3 maanden na de behandeling progressie kan detecteren die in aanmerking 
komt voor herbehandeling met curatieve opzet. In een klein aandeel (2%) van de 
patiënten werd progressie vastgesteld die in opzet curatief kon worden behandeld. 
Dit was alleen het geval bij de patiënten die asymptomatisch waren op het moment 
van de PET-CT scan. Progressie werd bij deze patiënten alleen gedetecteerd met 
PET, niet met uitsluitend de CT-scan.  
De resultaten van deze studie vormden de basis van de economische evaluatie die 
wordt beschreven in hoofdstuk 6. In deze studie werd de kosteneffectiviteit op de 
lange termijn vergeleken van verschillende follow-up strategieën: de PET-CT geba-
seerde follow-up, een follow-up met CT-scan, of een conventionele follow-up waar-
bij alleen een X-thorax wordt vervaardigd. De kosteneffectiviteit van de verschillen-
de strategieën werd uitgedrukt in zogenaamde incrementele kosteneffectiveitsra-
tio’s (ICER’s). Deze ratio geeft de additionele kosten aan per gewonnen levensjaar 
gecorrigeerd voor de kwaliteit van leven gedurende dit jaar (quality adjusted lifeye-
ar, QALY). Uit deze analyse kon worden afgeleid dat een PET-CT scan 3 maanden na 
behandeling een potentieel kosteneffectieve methode is vergeleken met conventi-
onele follow-up, resulterend in een ICER van € 69.086 per gewonnen QALY. Aange-
zien het voordeel beperkt was tot de groep asymptomatische patiënten, is het 
waarschijnlijk even effectief en meer kosteneffectief om alleen een PET-CT te ver-
richten in deze patiëntengroep (€ 42.265 per QALY). CT-gebaseerde follow-up was 
in geringe mate effectiever dan conventionele follow-up, resulterend in een ICER 
van € 264.033 per QALY.  
Concluderend geeft deel II van dit proefschrift aan dat een PET-CT 3 maanden na 
curatieve (chemo)radiotherapie een potentieel kosteneffectieve methode is voor de 
evaluatie na behandeling, en meer kosteneffectief is dan alleen een CT-scan. Op 
basis van het beschikbare bewijs is daarom een FDG-PET-CT te prefereren boven 
alleen een CT-scan 3 maanden na behandeling. Aanvullend onderzoek is zinvol ter 
reductie van de onzekerheid in de besluitvorming rond beeldvorming in de follow-
up. 
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Deel III: Nieuwe PET-tracers voor de niet-invasieve beeldvorming 
van tumoreigenschappen 
Deel III van dit proefschrift bestaat uit 2 studies die de veiligheid van nieuwe PET-
tracers evalueren, beide gericht op specifieke biologische eigenschappen van kan-
kercellen. Hoofdstuk 7 beschrijft de resultaten van een fase I studie met 18F-HX4 in 
incurabele kankerpatiënten. 18F-HX4 is een recent ontwikkelde radioactieve merk-
stof voor cellen met zuurstoftekort (hypoxie), behorend tot de familie van 2-
nitroimidazolen. Er werd een studieopzet met 2 dosisstappen gebruikt. In elke stap 
werden 3 patiënten geïncludeerd. PET-CT beelden van de grootste tumorlokalisatie 
werden verkregen op 30, 60 en 120 minuten na injectie van 18F-HX4. In geen van de 
geïncludeerde patiënten werd toxiciteit geobserveerd. De mediane tumor-spier 
ratio 120 minuten na injectie was 1.40 (range: 0.63-1.98). Uit deze studie kan wor-
den geconcludeerd dat PET met 18F-HX4 niet gepaard gaat met toxiciteit. Momen-
teel worden studies opgezet met als doel het optimale tijdstip voor de PET scan te 
bepalen. In preklinische studies met proefdieren zijn tumor-bloed ratio’s tot een 
waarde van 7.6 gedetecteerd indien op latere tijdstippen na injectie werd gescand. 
In hoofdstuk 8 wordt de veiligheid geëvalueerd van cetuximab gelabeld met de 
radioactieve tracer Zirconium-89 (89Zr). Cetuximab is een antilichaam gericht tegen 
de epidermale groeifactor receptor (EGFR). Activatie en overexpressie van EGFR in 
kankercellen is geassocieerd met de ontwikkeling van resistentie voor radiotherapie 
en chemotherapie. De toxiciteit van twee verschillende doseringsschema’s van 89Zr-
cetuximab werd onderzocht. In beide schema’s werd de dosering van het gelabelde 
cetuximab voorafgegaan door een standaard “laaddosis”ongelabeld cetuximab. Op 
dag 4, 5 en 6 (stap 1), of dag 5, 6 en 7 (stap 2) na injectie werden PET-CT beelden 
verkregen. Vijf van de zes patiënten ontwikkelden huidtoxiciteit, een bekende bij-
werking van cetuximab. Additionele toxiciteit ten gevolge van de toediening van het 
gelabelde cetuximab werd niet geobserveerd. De maximale tumor-bloedratio was 
1.6 (range: 0.42-1.60). Toekomstige studies zijn nodig om de optimale beeldvor-
mingsomstandigheden te definiëren, waaronder de optimale laaddosis ongelabeld 
cetuximab. Uiteindelijk kan de visualisatie en de kwantificatie van cetuximabopna-
me door de tumor met PET voor en tijdens (chemo)radiotherapie een belangrijke 
invloed hebben op een juiste selectie van patiënten voor behandeling met cetuxi-
mab.  
 
Tenslotte wordt in deel IV van dit proefschrift de rol van PET in de gecombineerde 
modaliteitsbehandeling van longkanker bediscussieerd. Hoofdstuk 9 bestaat uit een 
review van de beschikbare literatuur over dit onderwerp. Hoofdstuk 10 beschrijft 
de belangrijkste resultaten van het proefschrift in het licht van het momenteel be-
schikbare bewijs. Hiernaast worden toekomstperspectieven beschreven ten aanzien 
van verder wetenschappelijk onderzoek.  
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Concluderend biedt FDG-PET verschillende mogelijkheden om de gecombineerde 
modaliteitsbehandeling van het lokaal gevorderde longcarcinoom te verbeteren. Dit 
geldt zowel op het gebied van het definiëren van het doelgebied voor radiotherapie, 
als voor de evaluatie na de behandeling. Prospectieve gerandomiseerde studies op 
dit gebied worden aanbevolen. Andere tracers dan 18FDG bieden de mogelijkheid 
om patiënten te selecteren met de hoogste kans op baat van behandeling met ra-
diosensitizers gericht op hypoxie of middelen gericht tegen receptoren op het op-
pervlak van kankercellen. Aanvullend wetenschappelijk onderzoek is echter noodza-
kelijk voordat deze tracers in de klinische praktijk kunnen worden geïntroduceerd.  
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Terugkijkend op 3 jaar onderzoek moet ik toch echt concluderen dat de tijd is om-
gevlogen. Dit wil natuurlijk niet zeggen dat alle onderzoeksresultaten zonder slag of 
stoot tot stand zijn gekomen. Ik wil dan ook iedereen bedanken die direct of indirect 
hieraan heeft bijgedragen.  
 
In de eerste plaats de patiënten, in het bijzonder zij die hebben deelgenomen aan 
de studies uit het derde deel van het proefschrift. In hun verlangen een bijdrage te 
leveren aan de strijd tegen longkanker bezochten ze ondanks hun slechte prognose 
herhaaldelijk het ziekenhuis voor injecties, scans of bloedafnames in het kader van 
wetenschappelijk onderzoek.  
 
De leden van de beoordelingscommissie, prof. dr. E. Wouters, dr. B. Brans, prof. dr. 
Y. Lievens en prof. dr. J. van Meerbeeck, wil ik hartelijk danken voor het beoordelen 
van dit proefschrift en de bereidheid plaats te nemen in de promotiecommissie.  
 
Dan de 3 teamleden die me de afgelopen jaren heel wat kneepjes van het weten-
schapsvak hebben bijgebracht: promotoren prof dr. De Ruysscher en prof. dr. Lam-
bin, en copromotor dr. Boersma. Dirk, er zijn tig redenen te noemen waarom ik me 
gelukkig mag prijzen je eerste “promovenda” te zijn. De belangrijkste is natuurlijk je 
ongebreidelde enthousiasme voor onderzoek, gepaard gaande met een voor het 
oor en oog onuitputtelijke literatuurkennis (“de winst in die studie was ergens in de 
orde van 8.63%..”) en ideeën. Daarnaast heb ik veel baat gehad bij onze synchroon 
afgestemde biologische klok, waardoor ik je ook in de latere “kantoor”uren nog wel 
te pakken kreeg om de meer of minder ingewikkelde vraagstelling te bespreken.  
Philippe, een kort treffen in de wandelgang binnen Maastro, op een congres of 
tijdens een personeelsuitje was meestal al voldoende om weer vooruit te kunnen 
met een vervolgonderzoek of compleet nieuw studieonderwerp. Dank voor de ge-
boden mogelijkheid mijn specialisatie te onderbreken voor het verrichten van pro-
motieonderzoek.  
Liesbeth, superbedankt dat je me hebt gestrikt voor de KWF-studie! Niet alleen 
omdat het me een ontzettend interessant project heeft opgeleverd, maar temeer 
omdat ik jou als leermeester erbij kreeg. Ondanks je volle agenda wist je bij vragen 
altijd wel ergens een plekje te creëren. Je “down to earth” benadering van elk pro-
bleem leidde er altijd toe dat ik met een concreet stappenplan en vol goede moed 
de deur uitliep. Je constructieve commentaar op menig manuscript, vaak uitgedrukt 
in een prikkelende vraag, was bijna zonder uitzondering terecht.  
 
De radiotherapeut-oncologen wil ik bedanken voor hun interesse en bemoedigende 
woorden bij de koffieautomaat. Angela, bedankt voor je vertouwen in mij als jouw 
“opvolger”. Ik heb veel gehad aan je praktische tips in elke fase van het promotie-
traject, van het schrijven van m’n eerste abstract tot advies over de hapjes bij de 
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receptie! Jos de Jong: “Het belangrijkste wat je leert tijdens een promotietraject is 
nee zeggen.” Ik heb me destijds niet gerealiseerd dat deze opmerking zo waar zou 
blijken. Rinus, jouw vrolijke noot was erg welkom tijdens de eenzame dagen achter 
de computer. Jos Jager, de herhaaldelijke vraag over wanneer ik weer terugkwam in 
de kliniek stelde je uit gemis, niet vanuit opleidingstechnisch oogpunt toch? 
 
Datamanagement: ik daag jullie uit één overeenkomst te vinden tussen jullie geor-
ganiseerde bureaus en het mijne. Chantal, dank voor je toewijding bij het ontwikke-
len, verzamelen en bewaken van de CRF’s! Madelon, mijn statussen mogen nu echt 
terug naar het archief! Cary, dank voor het delen van je knoppenkennis in SPSS. 
Ruud, bewonderenswaardig hoe je elk “statistiekvraagje” weer op een doorzichtige 
wijze weet te doorgronden.  
 
(Research)Laboranten, Marije, Daisy, dank voor jullie hulp bij het intekenen. Clau-
dia, je spoorzoektocht naar verdwenen PET-CT’s in de wirwar van digitale archieven 
was geweldig. “Groep CT-PET”, jullie zagen me liever gaan dan komen het afgelopen 
jaar! Bedankt voor jullie flexibiliteit en de goede zorgen voor mijn studiepatiënten! 
 
Het is een (niet overbodige) luxe een rij klinisch fysici op kruipafstand van je werk-
kamer te hebben. Geert en Lars, jullie onderwijscapaciteiten maken het erg verlei-
delijk even binnen te lopen voor een lesje fysica voor dummies. Geert, je mapje 
“promotie_info” is inmiddels een wijd verbreid begrip. Michel, ook jouw deur had 
een lage drempel met betrekking tot 4D-scans en zirconium, maar ook voor luchti-
gere onderwerpen. Ik zie uit naar het volgende hooikoortsseizoen!  
 
De vruchtbare meetings van de researchgroep thorax waren een welkome afleiding 
op de dinsdagmiddag. Steven en Hugo, ik denk dat de kruisbestuiving kliniek-fysica 
haar vruchten wel heeft afgeworpen. Volgens mij kunnen jullie die longtumor nu 
ook zonder mijn hulp vinden! Wouter, kom gerust wat vaker langswandelen als het 
saai wordt op de derde verdieping. Marco TrueD, hoe vind je de plaatjes?? Nooit 
geweten dat een man zoveel kennis kan hebben van kleurencombinaties, in het 
bijzonder magenta en rainbowscale! Ludwig, bedankt voor je snelle en bruikbare 
bijdrage vanuit het Maastro-lab. Bart, de spaarzame minuten freetime op Flims 
waren erg gezellig! Bedankt dat je me hebt betrokken bij de PET-cursus.  
 
Janneke, HTA, KEA, QALY, ICER, CEAC, EVPI (ik prefereer nog altijd de uitspraak efpi) 
waren tot 2 jaar geleden zo goed als abracadabra voor me. Bedankt voor de manier 
waarop je me in afzienbare tijd wegwijs heb gemaakt in de wereld die health eco-
nomics heet. Je enthousiasme heeft me aangestoken, kom gerust een keertje langs 
straks in Londen!  
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Brigitte, Tineke en Hannie, verbeeldde ik het me of trokken jullie echt wit weg als ik 
binnenkwam? Laten we zeggen dat het niet alleen mijn schuld was dat het inplan-
nen van die afspraken zo lang duurde (hoe heette dat systeem ook alweer?). DA’s, 
in het bijzonder Félice en Lizette, dank dat jullie met gevaar voor eigen leven alle 
bloedbuisjes veilig hebben verzameld en afgeleverd. Rianne, bedankt voor de on-
dersteuning bij het verzamelen en verzenden van alle benodigde correspondentie!  
 
Verschillende afdelingen van het MUMC+ hebben een belangrijke rol gespeeld in het 
realiseren van de verschillende studies. Ten eerste de afdeling longziekten: Anne-
Marie Dingemans, Monique Hochstenbag, Arne van Belle en de onco-verpleeg-
kundigen, dank dat jullie tussen de bedrijven door er toch aan dachten patiënten te 
selecteren voor mijn onderzoek. Anne-Marie, ook dank voor je bijdrage aan vrijwel 
alle manuscripten in dit proefschrift. Longchirurgen, dankzij het accuraat plakken 
van dé gele sticker kwam elk preparaat veilig aan op de pathologie.  
Erik Vegt, Boudewijn Brans en Pascal Kempers van nucleaire geneeskunde, dank 
voor jullie inzet bij de opzet, uitvoering en beoordeling van de verschillende studies, 
en de hulp bij het verzamelen van “mooie plaatjes”. 
Robert-Jan van Suylen, ik denk dat het niet ondanks, maar dankzij de bedwelmende 
gaslucht en sterke verhalen is geweest dat we zo’n onbeschrijflijke berg werk heb-
ben verzet. Die longpathologie is zowaar bijna net zo interessant als je wijnkelder! 
Roy Lalisang, dank voor je inclusie van patiënten voor deel III van dit proefschrift!  
 
Longartsen van de IKL-regio, dank voor de prettige samenwerking en de interesse in 
de onderzoeksresultaten. Nucleaire geneeskunde van het Atrium, bedankt voor 
jullie inzet bij het doorsturen van alle scans.  
 
Co-investigators van “de KWF-studie”: Christian Siedschlag, Kenneth Gilhuijs, Joep 
Stroom, Maddalena Rossi van het NKI-AvL en Hans Blaauwgeers van het OLVG, er is 
wat creativiteit voor nodig om duizenden coupes tussen randstad en Maastricht te 
vervoeren, maar we mogen trots zijn op het eindresultaat!  
 
Dank aan de collega’s in het VU medisch centrum, Guus van Dongen, Danielle Vugts, 
Bert Windhorst en Ronald Boellaard, voor hun onmisbare bijdrage aan de fase-I 
studies. Guus, bedankt voor je kritische en snelle beoordeling van de manuscripten. 
 
Mijn kamergenoten, AIOS! Er was geen betere plek te bedenken om me elke och-
tend (geen grappen aub) achter m’n compu te nestelen dan tussen jullie gekakel. De 
positieve correlatie tussen het aantal geproduceerde decibellen en mijn productivi-
teit staat onomstotelijk vast. Jeroen, Angela en Véronique, dank voor het delen van 
jullie ervaring als doorgewinterde assistent. Myrte, ik zal je woonplaats hier niet 
uitspellen, maar de afstand tot Mestreech vormt gelukkig geen barrière voor onze 
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vriendschap. Bart en Torsten, testosteron en Duitse humor hebben me regelmatig 
tot tranen toe laten lachen. Gelukkig is jullie wijnleverancier in het zuiden blijven 
plakken! Inge, David (onze enige haan), Kitty, Maaike, Patricia en Ada, thanks voor 
het delen van alledaagse beslommeringen uit de kliniek. Succes met het veroveren 
van mijn privilegeplekje aan het raam. Ik zie uit naar februari! 
H&H, Haike en Hiske, er zijn evenveel overeenkomsten als verschillen in onze karak-
ters, maar toch staan onze neuzen altijd dezelfde kant op, net zoals vandaag! Haike, 
je bent in alles net zo fanatiek als op het hockeyveld, en dat maakt je zowel een 
topcollega als -vriendin! His, jouw neus werkt bovengemiddeld voor de detectie van 
geur, maar ook voor mijn humeur! Thanks voor je relativerende woorden. 
 
De boog kan niet altijd gespannen zijn, en gelukkig zijn er veel mensen buiten het 
werk die me daaraan herinneren. Nyneve, ik stond na mijn bestuursjaar al met één 
been in het ziekenhuis toen jullie me vroegen mede-oprichter te worden van ons 
genootschap. Ik heb nooit spijt gehad dat ik hier volmondig ja op heb gezegd. 
Thanks voor jullie blijvende interesse in de nyneve-oma. Nu alle afstudeerborrels 
achter de rug zijn wordt het tijd voor andere redenen tot feest. Gelukkig zijn we 
goed op weg! Tine, mede dankzij jou ben ik ook lichamelijk in conditie gebleven.  
 
De geneeskundeclan, Geertje, Lilian, Leonie en Milou, de spinazie-met-spekjes (hoe-
veel gram?)-pasta heeft plaatsgemaakt voor hoogculinaire gerechten danwel pogin-
gen ertoe, en ook de AH-huiswijn is omgeruild voor iets beters, denken we tenmin-
ste. Gelukkig blijven de gespreksonderwerpen opvallend dezelfde en nemen we 
geen blad voor onze mond!  
 
Anna, het letterlijk midden in de nacht elkaars studentenkamer binnenvallen is 
omgezet in een figuurlijk dag en nacht er voor elkaar zijn. Super! 
 
Pap en mam, “words cannot express…”. Wat ik wel kan zeggen is dat ik dolblij ben 
jullie dochter te zijn! Jullie vertrouwen en de geboden veiligheid en vrijheid maken 
dat ik de stappen kan zetten die ik zet. Tijs en Marjolein, jullie rust is als een oase 
voor me! Hanne, je bent nu al m’n superheldin. PimMel (!), je bent en blijft m’n 
kleine broertje, maar wel een van wie ik heel veel kan leren!  
Cilia, bedankt voor je interesse en de gezellige bezoekjes aan Eijsden! Theo en Ine, 
een weekendje bij jullie voelt als een weekendje thuis! 
 
Andor…, jouw levensvreugde straalt uit je hele doen en laten. Just what I need! Ik 
ben er supertrots op dat ik met de enige professionele Bourgondiër mag samenle-
ven. Je weet het, ik vergeet het vaak te zeggen maar de liefste ben jij (GM 2009). 
Thanks voor dat je bent wie je bent!  
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